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Abstract 
The highly polymorphic human leukocyte antigens are an important player in the 
immune response against pathogens. However, the variability can also cause problems 
to patients, clinicians and drug manufacturers due to the phenomenon of 
immunologically based adverse drug reactions (ADRs) where the interaction between 
the drug and antigen presenting proteins can interfere with the body’s ability to 
recognise host cells leading the immune system to mount a response against the host. 
The underlying mechanisms by which this is brought about are not fully understood. 
Over recent years a number of studies have reported HLA alleles are associated with 
adverse drug reactions where this number is growing. This has made research into the 
field increasingly challenging as relevant data has become spread across the literature. 
 
To address this issue, a centralised and searchable web database (HLA-ADR) was 
constructed which was populated with data extracted from a literature review 
investigating HLA alleles that have been associated with ADRs. The HLA-ADR 
database was then used to investigate a question that arose when analysing the data; 
there was an apparent trend whereby it seems that patients of Asian descent were more 
prone to ADRs compared to other populations. The analysis in this thesis found no 
evidence to support this hypothesis and instead revealed potential reporting bias and 
issues with the poor replication of findings in the literature. 
 
Finally, HISTO SPOT, a new HLA typing method that aims to type patients with high 
turnaround and at low cost where it highlights patients carrying one or more of a panel 
of HLA alleles known to be associated with immune mediated ADRs was investigated. 
The method is able to accurately type patients with 100% concordance with currently 
implemented HLA sequence based typing. Alongside this, a clinical decision support 
tool was developed to provide clinicians with a means to interpret the HISTO SPOT 
results by providing expert knowledge.  
 
In conclusion, the bioinformatical tools developed in this thesis provide a potential 
framework by which to aid research and clinical decision making. The tools will 
hopefully advance the field and provide a stepping stone towards the goal of 
personalised medicine. 
 1 
 
Chapter 1. General Introduction 
1.1. Adverse drug reactions 
One of the biggest issues faced by clinicians and pharmaceutical companies is the risk 
that patients might experience adverse drug reactions (ADRs) upon exposure to a drug 
treatment. In the United Kingdom, between 6 and 12% of hospital admissions are 
attributed to ADRs. [1, 2] Approximately 3-5% of approved drugs in Europe and North 
America (approved between 2002-2011 and 1990-2009 respectively) were withdrawn 
from the market for safety reasons with hepatotoxicity being the second most 
commonly cited reason for both Europe and North America. It is worth noting that 
hepatotoxicity is not always caused by immune mediated ADRs. Cardiovascular 
events was the most common reason for drug withdrawal. [3, 4] 
 
1.1.1. Definition and classification of adverse drug reactions 
An ADR is defined by the World Health Organisation as ‘a response to a drug that is 
noxious, unintended and occurs at doses normally used as part of standard treatment’. 
[5] ADRs have been categorised into six subdivisions by Rawlins and Thompson based 
on the differences of their general responses to the drug. [6] These classifications are 
defined in Table 1.1. The main focus of this thesis revolves around Type B reactions 
whilst the mainstream definition for Type B reactions describes these responses as 
unpredictable. There have been some that argue that due to the implication of 
particular human leukocyte antigen alleles as risk factors (described in section 1.1.4) 
the ‘unpredictable’ description should be removed from the definition. [7, 8] 
 
1.1.2. Clinical manifestations of ADRs 
Immune mediated ADRs have been reported to induce a wide variety of phenotypes 
which can affect any organ with the most common being skin and liver. The severity 
of cutaneous reactions varies greatly from mild skin rashes to Stevens–Johnson 
syndrome / toxic epidermal necrolysis (SJS/TEN) – symptoms include but are not 
limited to extreme blistering and skin detachment and possible mortality. [9]  
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Table 1.1: Classification of ADRs by Rawlins and Thompson  
Type Definition 
A ‘Augmented’ - The most common variant, also known as ‘on target’ ADRs. 
These are the result of the drug’s known pharmacology and toxic effects 
which are part of the desired pharmacological action. 
B ‘Bizarre’ – Also known as ‘off target’ or ‘idiosyncratic’. These reactions 
have no relation to the known pharmacological effects of the drug and are 
not dose dependent. These reactions are often referred to as immune 
mediated and are thought to be unpredictable. 
C ‘Continuing’ – Reactions that are the related to the cumulative dose of the 
drug. 
D ‘Delayed’ – Usually related to the dose and are reactions that occur after a 
significant amount of time has passed (from drug administration). 
E ‘End-of-use’ – Reactions that observed after drug treatment has stopped 
(withdrawal). 
F ‘Failure’ – usually caused by drug-drug interactions. 
 
 
Maculopapular exanthema (MPE) is the most common type of cutaneous ADR 
accounting for more than 90% of drug induced ADRs and the time of onset is usually 
after 1-2 weeks after the start of treatment. [10] SJS/TEN is the most severe type of 
cutaneous skin reaction and has an approximate mortality rate of 30% SJS and TEN 
are considered to be the same condition with the difference defined as the extent of 
skin detachment (< 10% for SJS; 10-30% for SJS-TEN overlap and >30% for TEN). 
[11]  
 
As mentioned at the start of this chapter, drug induced liver injury (DILI) is one of the 
leading causes of drug withdrawal. It is a probable site for adverse drug reactions as 
the organ is key for drug metabolism where many of the drug’s metabolites are formed. 
DILI has two major forms where the alanine aminotransferase (ALT) and alkaline 
phosphatase (ALP) levels change dramatically relative to the upper limit of normal 
(ULN). Hepatocellular liver injury is the most common form of DILI and is 
characterised by a dramatic increase of ALT (≥ 3 times ULN) and the ALT/ALP ratio 
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(≥5 times ULN) - the time of onset is typically 1-3 months. The other major form, 
cholestatic DILI, is characterised by ALP ≥2 times ULN and ALT/ALP ratio of ≤2 
times ULN. [10, 12] It has been reported that hepatocellular DILI is exhibited in a higher 
portion of women and tends to occur in younger patients compared to cholestatic DILI 
where older age and higher male : female ratio has been reported. [13, 14] 
 
Table 1.2 shows a list of well-known ADR phenotypes that have been reported in the 
literature. The table also demonstrates that different patients on the same drug may 
exhibit different ADR phenotypes. 
 
Table 1.2: Examples of different drug induced ADR phenotypes 
Drug class Drug ADR phenotype 
Antiretroviral 
abacavir drug-induced hypersensitivity syndrome (DIHS) [15] 
nevirapine DILI [16] 
Anticonvulsant 
carbamazepine SJS/TEN [17] 
DIHS [18, 19] 
phenytoin SJS/TEN [20] 
lamotrigine maculopapular exanthema (MPE) [21] 
SJS/TEN [22] 
Antigout allopurinol drug-induced skin reaction (DISI) [23] 
Antibiotic 
flucloxacillin DILI [24] 
amoxicillin-
clavulanate 
DILI [25] 
Antirheumatics 
and NSAIDs 
aspirin aspirin-intolerant asthma (AIA) [26] 
aspirin-induced urticaria (AIU) [27] 
Anticancer lapatinib DILI [28] 
 
1.1.2.1. Alternative names for ADR phenotypes 
The multitude of ADR phenotypes may also have interchangeable terms used 
throughout the literature. This thesis may use some of the terms interchangeably 
however, the term in the left column of Table 1.3 will be the preferred term. These 
alternative terms were identified using medical subject headings (MeSH). The MeSH 
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terms are controlled by the United States’ National Library of Medicine and acts as a 
thesaurus for interchangeably used medical terms. [29]  
 
Table 1.3: Interchangeable terms referring to certain ADR phenotypes 
Term used in this thesis Alternative term(s) 
drug-induced hypersensitivity 
syndrome (DIHS) 
Hypersensitivity syndrome (HSS) 
drug rash with eosinophilia and systemic 
symptoms (DRESS) 
drug-induced skin reaction (DISI) 
cutaneous adverse drug reactions (cADR) 
severe cutaneous adverse drug reaction 
(SCAR) 
maculopapular exanthema (MPE) 
mild maculopapular eruption (MPE) 
exanthema 
skin rash 
Stevens-Johnson syndrome (SJS) / 
toxic epidermal necrolysis (TEN) 
erythema multiforme exudativum 
erythema multiforme major 
bullosum  
drug induced liver injury (DILI) 
hepatotoxicity 
gout 
hyperuricemia  
 
1.1.3. Current understanding of immune mediated adverse drug 
reactions 
Type B reactions are regarded as being immune mediated that whilst rare (20% of all 
ADRs), can potentially cause severe morbidity and possibly death. [30, 31] In many 
cases, human leukocyte antigens have been implicated as risk factors for ADR events. 
[19, 24, 27, 32-36] The exact mechanisms by which the drug interacts with the HLA system 
is not fully understood however, probable mechanisms of action have been proposed. 
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All of these mechanisms involve interference between the HLA antigen and T-cell 
interaction that enables the immune system to identify self and non-self cells. 
 
1.1.3.1. Hapten hypothesis 
A hapten is a small molecule (< 1,000 Daltons) that on its own is too small to become 
antigenic (elicit the production of antibodies) but can covalently bind to a large carrier 
(e.g. a protein) whereby the modified carrier induces an immune response via T-cell 
activation. Different haptens can be produced depending on the hapten agent and 
modified carrier. For example, derivatives of penicillin were shown to bind covalently 
to lysine residues of serum albumin and that anti-penicillin T-cells are present in the 
blood of patients hypersensitive to penicillin. [10, 37] This is a possible explanation as 
to why the different drug-MHC allele combinations may induce different ADR 
phenotypes.  
 
In the hapten hypothesis model (see Figure 1.1), the drug (or a metabolite) covalently 
bonds with a protein. The drug-protein hybrid is taken up by a cell and hydrolysed and 
the peptide fragment containing the bound drug is processed for antigen presenting on 
the cell surface via the MHC molecules. The modified antigen is recognised by the 
interacting T-cell as non-self, which then triggers a cascade to induce an immune 
response. A study by Ortmann et al., 1992 demonstrated that hapten modified antigens 
were able to induce T-cell responses. [38]   
 
1.1.3.2. Pharmacological interaction concept 
The pharmacological interaction (p-i) concept was proposed as an alternative 
hypothesis as it was noted that clones of T-cells obtained from ADR patients would 
proliferate in the presence of the drug that caused the ADR but outside of any 
metabolic activity that would generate the drug’s reactive metabolite. [39] The theory 
proposed (see Figure 1.2) that the drug binds noncovalently and reversibly to the T-
cell receptors or to the antigen itself, which would interfere with the normal antigen 
presentation and T-cell interaction and therefore the T-cell would trigger the cascade 
leading to an immune response as if it had encountered a non-self antigen. [40, 41] 
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Figure 1.1: Model of hapten hypothesis 
Adapted from Uetrecht, 2007 [42] 
 
1.1.3.3. Danger hypothesis 
The danger hypothesis was proposed as an alternative as it argued that one signal was 
insufficient for T-cell activation – i.e. it would need at least one more signal in addition 
to the altered interaction between antigen and T-cell to trigger the immune response. 
[43] An individual expresses certain proteins much later in life which are required for 
development. These proteins are ones that the body would not have previously been 
exposed to – e.g. hormones released during puberty or pregnancy. The individual’s 
immune system would be unfamiliar with antigens produced from the breakdown of 
these time/event specific proteins and yet they do not induce an immune response. The 
theory goes on to add that cellular damage (e.g. caused by a pathogen) would release 
a so called “danger” signal that combined with the non-self antigen signal will trigger 
the immune response. Without the danger signal, the result is immune tolerance (see 
Figure 1.3 showing both the danger and tolerance pathways). 
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Figure 1.2: Model of p-i concept 
Adapted from Uetrecht, 2007 [42] 
 
Despite investigations, the identification of these damage signals has been difficult 
although suggestions have been offered including: heat shock proteins, interferon-α, 
interleukin-1 β, uric acid. [44, 45] Although the danger hypothesis is its own separate 
model, it can hypothetically be additive to the other models discussed in this section. 
 
1.1.3.4. Altered peptide repertoire hypothesis 
The altered peptide repertoire model was developed from the discovery of the 
mechanism of abacavir induced hypersensitivity. Illing et al. demonstrated using 
protein crystallography that unmodified abacavir binds noncovalently inside the F-
pocket of the antigen binding cleft of the HLA-B*57:01 MHC molecule. [46] There is 
exquisite specificity in this interaction that the group was also able to show that this 
binding does not occur with the HLA-B*57:03 protein which only differs from the 
first allele by the substitution of two amino acid residues. The result of this binding 
alters the shape of the antigen binding cleft and therefore the antigen repertoire of the 
MHC molecule. This means that a different peptide fragment is instead presented 
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resulting in a T-cell recognising the antigen as non-self and triggering an immune 
reaction. 
 
 
Figure 1.3: Model of danger hypothesis 
Adapted from Uetrecht, 2007 [42] 
 
The specificity was further demonstrated when Hughes et al. showed that populations 
with higher carriage of the HLA-B*57:02, HLA-B*58:01 and the above-mentioned 
HLA-B*57:03 alleles had a lower incidence rate of abacavir hypersensitivity 
compared to populations where HLA-B*57:01 is higher. [47] 
Although the exact model of abacavir hypersensitivity has been demonstrated, the 
positive predictive value for patients carrying HLA-B*57:01, being treated with 
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abacavir and developing an immune mediated ADR is 47.9% indicating that other 
factors are likely involved. [48] 
 
1.1.4. Current clinical guidelines and future perspectives 
As the evidence supporting immune-mediated ADRs is increasing, the 
recommendations for drug usage to clinicians has altered to reflect this knowledge. 
The warning labels for abacavir have been changed in the regions regulated by the 
United States Food and Drugs Administration (FDA), European Medicines Agency 
(EMA) and the Canadian HC-SC bodies to recommend screening for the carriage of 
HLA-B*57:01 in patients about to undergo abacavir treatment. [49, 50] Genetic 
screening for HLA-B*15:02 in patients of Asian ancestry is also recommended when 
considering carbamazepine and the structurally related compounds: oxcarbazepine 
and phenytoin. [51-53] Other drug allele combinations associated with immune mediated 
ADRs, have not been recommended for routine genetic screening prior to the start of 
the treatment. [54] 
 
Monoclonal antibodies that supress the immune response have been used to treat 
autoimmune diseases for a number of years. [55] However, advances in 
immunotherapy, allow the generation of antibodies that respond against tumour cells, 
thereby allowing the individual to mount an immune response against the tumour cells. 
[56] This has become an important tool in cancer therapy. Very recently, evidence has 
emerged that a patient’s HLA class I genotype can influence how T-cells recognise 
tumour peptides and how it responds to checkpoint inhibitor immunotherapies. The 
findings indicate that maximal Class I HLA heterozygosity improved patient survival 
chances compared to HLA homozygosity for at least one HLA locus.  In addition, 
somatic loss of heterozygosity was associated with poor outcome in two melanoma 
cohorts. [57] It is likely that increased research into this phenomenon will play an 
important avenue in the field of oncology. Heterozygosity and homozygosity describe 
the degree of similarity between alleles for a locus within the genome. As explained 
in section 1.2.2, the HLA region is very polymorphic. “Maximal heterozygosity” as 
used earlier describes that the loci of the Class I HLA genes have a very low degree 
of similarity meaning that the two alleles of the diploid loci confer different protein 
products. 
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1.2. Human leukocyte antigens 
Human leukocyte antigens (HLAs) are part of the major histocompatibility complex 
(MHC) region. This region is approximately 4,000 kilobases in length and contains a 
group of >200 related genes located on the short arm of chromosome 6 (specifically 
Chr 6p21). The genes within the MHC region are subdivided into three classes based 
on functionally related but distinct proteins. [58] The focus of this thesis will around 
classical HLA class I and class II genes. A diagrammatic representation of the MHC 
region in the context of the chromosome can be viewed in Figure 1.4 below). 
 
Figure 1.4: Diagram of MHC region located on chromosome 6 
Adapted from Westover et al., 2011 [59] 
 
1.2.1. Primary function of classical HLA genes 
MHC class I (also HLA class I) genes/proteins present antigens that are generated 
from the proteolysis of cytosolic proteins, which are then bound to the membrane of 
the cell. The host organism’s own proteins are cleaved and bound to the presenting 
HLA protein. The antigenic peptide is presented to cytotoxic T-cells (CD8+) which 
will recognise the peptide fragment (and therefore the cell as a whole) as an antigen 
belonging to a host cell due to previous exposure to the same antigenic peptide. In the 
case of bacterial or viral infections, proteins from the invading cell are 
processed/broken down and exported to the surface of the human cell. In these cases, 
the presenting antigen is recognised as non-self, inducing cytotoxic T-cells to kill the 
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cell that is presenting the foreign peptide. Class I proteins are represented in yellow in 
Figure 1.4. Additionally, see section 1.2.2 for list of genes belonging to this class. 
 
Class II HLA proteins present extra-cellular peptides to T-lymphocytes, which in turn 
induce the production of T-helper cells (CD4+). For antigens recognised as foreign, 
the T-helper cells will initiate B-cells to produce antibodies that are specific to that 
antigen whilst for antigens recognised as host, suppressor T-cells prevent the 
production of antibodies that are specific to host antigens. Class II proteins are 
encoded in pairs of genes (producing the α and β chains) and are represented in Figure 
1.4 as pale blue and dark blue). Both class I and class II molecules are involved with 
the adaptive immunity. 
 
Conversely, Class III MHC genes are associated with the complement system in 
relation to immunity and carry out a variety of different functions including the 
inflammation response as well as the tumour-necrosis factor alpha (TNF) gene, 
lymphotoxin alpha (LTA), heat shock proteins and also contain an assortment of non-
immune related genes.  
 
Non-classical HLA molecules differ from their classical counterparts by their relative 
lack of allele diversity. The role of these is not as well defined however, there have 
been suggestions that these non-classical HLA molecules play a role in mediating the 
activation of natural killer cells. [60, 61] The classical genes are made up of HLA-A, 
HLA-B and HLA C for MHC class I loci whilst for class II the classical alleles are 
HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1 and HLA-DRB1. The other 
genes that are featured in Table 1.4 and Table 1.5 (see section 1.2.2) are non-classical.  
 
1.2.2. Highly polymorphic characteristic of HLA genes 
As of October 2017, there are 17,331 known HLA alleles (see Table 1.4 and Table 
1.5), which makes these genes one of the most polymorphic within the human genome. 
[62] The high levels of polymorphisms, particularly with the classical loci, means that 
probability that an individual is homozygous for each HLA gene is extremely low with 
the exception of consanguineous parentage. This high level of MHC heterozygosity 
maximises the adaptive immunity against infections and disease. [58] Pathogens have 
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evolved to try and evade the immune system by constantly altering the sequence of 
their antigen binding peptides with the primary aim of fooling the immune cells into 
recognising them as host cells. 
 
The extreme diversity found within human population (seen even despite the out of 
Africa migratory bottleneck limiting  genetic diversity in general) has been built from 
the infectious agents encountered during the course of human evolution and aims to 
prevent a single pathogen from displaying antigens which are structurally similar to 
human host antigens for all individuals. This provides a greater chance that at least a 
subset of the human population will be immune to the emergence of a new pathogen 
capable of spreading rapidly. In addition to this, the role of self-recognition by the 
HLA genes is also an important factor in terms of organ transplantation. For a 
successful transplant to occur, the donor organ needs to present antigens which can be 
recognised as self by the recipient’s immune system.  
 
1.2.3. Structure of HLA molecules 
The high levels of polymorphisms generally occur in the antigen presenting region of 
the molecule allowing for variation in the presented peptide antigen – for MHC class 
I, this region (also referred to as the α1 and α2 domains) is encoded by exons 2 and 3 
of the gene. The other regions of the protein molecule must be conserved in order to 
maintain their function. Exon 1 encodes the leader peptide (or signal peptide), exon 4 
encodes the α3 domain, exon 5 encodes the transmembrane domain and the 
cytoplasmic tail being encoded by exons 6 and 7. [63] For MHC class II molecules, the 
final peptide is encoded by a pair of genes which produce the α and β subunits. The 
exons that produce the domains for each subunit are listed in Table 1.6 below. [64] A 
diagram showing the arrangement of the MHC class I and class II molecules is shown 
in Figure 1.5. Both MHC class I and class II polypeptide molecules are heterodimeric 
proteins. The class I molecule is comprised of a single α chain that is paired with a β2-
microglobulin protein (β2m). β2m is not involved with antigen presentation. The 
bulges in the α1 and α2 domains represent regions that are genetically conserved to 
allow for T-cell interaction. Similarly in class II, the bulges for the α1 and β1 domains 
are also conserved for the same reason.  
  
 
1
3 
Table 1.4: Number of class I HLA alleles, protein products and null alleles that are currently known (as of October 2017) for each gene 
HLA Class I 
Gene A B C E F G 
Alleles 3,997 4,859 3,605 26 26 56 
Proteins 2,792 3,518 2,497 8 5 18 
Nulls 186 147 131 1 0 2 
 
Table 1.5: Number of class II HLA alleles, protein products and null alleles that are currently known (as of October 2017) for each gene 
HLA Class II 
Gene DRA DRB DQA1 DQB1 DPA1 DPA2 DPB1 DPB2 DMA DMB DOA DOB 
Alleles 7 2,395 92 1,152 56 5 942 6 7 13 12 13 
Proteins 2 1,751 35 779 26 0 655 0 4 7 3 5 
Nulls 0 66 3 31 0 0 22 0 0 0 1 0 
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Table 1.6: HLA class II exons that encode each of the peptide domains  
Peptide domain α chain β chain 
Leader peptide Exon 1 Exon 1 
Antigen presenting domain Exon 2 & Exon 3 Exon 2 & Exon 3 
Transmembrane domain 
Exon 4 
Exon 4 
Cytoplasmic tail Exon 5 
 
 
 
Figure 1.5: MHC molecule structure for class I and class II proteins. 
Modified from Lyczak, 2004 [58] and The-Crankshaft Publishing, 2012 [65] 
 
1.2.4. Variation in peptide binding 
The MHC/HLA molecules are not limited to presenting a single peptide fragment, 
instead the HLA molecule is capable of presenting several distinct antigens to the T-
cells. The HLA protein typically accommodates a peptide fragment of 9 amino acid 
residues in length. [58] For class I MHC molecules, the N and C termini of the fragment 
are used for anchoring to the MHC molecule and the middle bulges slightly. With class 
II HLA molecules the fragments are not anchored and so longer fragments are possible 
although 9 residues still appears to be the norm. Peptide fragments of length between 
8 to 15 residues have been observed with increased bulging in the middle.  [66] There 
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have been several computational models built to predict binding affinity of peptide 
fragments to the MHC molecules. [67-74] Many of these work by analysing the peptide 
binding groove of the MHC molecule and statistically determining the most likely 
residues that can be accommodated within that particular area of 3D space. Aspects 
including, but not limited to residue charge, residue size, bond types (e.g. van der 
Waals, hydrogen etc.) are taken into account with the software prediction algorithms. 
 
1.2.5. Nomenclature system of HLA alleles 
This immensely high allelic variation has led to the nomenclature for the HLA gene 
products to be reformed on multiple occasions. The original nomenclature system, 
from the 1960s, was based on serotype - utilising antigens raised as a result of the 
rejection of transplanted organs. There were originally 15 identified antigens HL-A1 
to HL-A15.  It was later observed that this set could be divided into two groups as it 
was only possible to identify 2 members of these groups in any individual. As a result, 
the new A series comprised of the original HL-A1, 2, 3, 9, 10, 11 types and the newly 
formed series B list contained HL- A5, A7, A8, A12, A13, A14, A15 which were 
renamed as B5, B7, B8, B12, B13, B14 and B15 respectively. The example of B1 and 
others were never used as a serotype identifiers to allow for the transition from the 
original system to this version. Thereby, explaining the lack of a B1 or conversely, an 
A7 serotype, which also prevails in the current nomenclature system. Over the years, 
additional groups were identified.  
 
From the 1970s onwards, methods for serotyping began to be implemented across the 
world for transplantation; however, in certain cases the serotype did not provide 
enough resolution to give reliable prediction. For example, in some cases patients who 
were typed and verified to accept organs from a B5 donor could still reject the 
transplant. Gradually, techniques were improved allowing for the discovery of new 
serotypes which could specify a smaller, subset of antigens with a higher degree of 
precision meant that broad antigen groups such as B5 were sub-divided into split 
antigens (B51 and B52) however; rejection was still a significant risk.  
 
The advent of molecular genetics led to the formal discovery of the C series and also 
the D group which later became the class II gene sub-family – which is why all of the 
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class II genes start with a D prefix. With molecular sequencing, the nomenclature 
system was changed to so that 4 numbers followed the gene letter. The new names 
were based on the serotype information (e.g. B*5101, B5102 and B5103) are all 
distinct protein sequences within the B51 serotype. [75] This was later reformed into 
the current system (through intermediary steps) so that a colon would separate a level 
of resolution to a maximum of 4 levels, referred to as fields (e.g. A*01:01:01:01). [76] 
The first level/field denotes the allele group, which is based on the historical serotype 
(A1) although this does not always apply. The second field allows for differentiation 
between distinct proteins by the detection of non-synonymous mutations. The 3rd field 
reports synonymous mutations i.e. HLA-A*01:01:01 produces the same protein as 
HLA-A*01:01:02. The final level shows the differences in non-coding regions of the 
gene (see Figure 1.6). 
 
Occasionally a suffix letter is also included which provides additional information. 
Null alleles are given the suffix ‘N’ to report this status. Other suffixes include ‘L’ for 
low surface expression (relative to normal levels), ‘S’ to indicate alleles that are 
expressed as secreted soluble molecules and ‘Q’ if the expression of the allele is 
questionable. [77] 
 
 
Figure 1.6: Nomenclature system for HLA alleles 
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The HLA informatics group maintains an internationally recognised IMGT/HLA 
database, [78] which provides the official repository for HLA sequences for the World 
Health Organization Nomenclature Committee. For new HLA alleles to be submitted 
into the IMGT/HLA database, the minimum requirement is to provide the genetic 
sequences for the exons that encode the antigen presenting domain. Although, 
complete gene sequence data is preferred. 
 
1.3. HLA typing methods 
1.3.1. Serological assay typing 
The first method that was employed for classifying MHC/HLA proteins looked at the 
observed response of the cell samples against specific antibodies that were able to 
distinguish these proteins based on epitope expression. These antibodies are able to 
distinguish HLA protein down to gene/loci and the allele group (explained in 1.2.5) 
meaning that relative to the standardised nomenclature system, HLA proteins can be 
classified to 1st field resolution using this method. [58] 
 
The tests are performed on patient’s lymphocytes using a method known as a 
complement-dependent cytotoxicity (CDC) test. This involves exposing the patient 
lymphocytes to a panel of anti-HLA antibodies that are known to react against 
particular HLA types. These anti-HLA antibodies are usually derived from cell lines 
or donors where the HLA type is known and are arranged in a plate (or typing tray) 
within individual wells. The lymphocytes of the individual to be typed is then 
introduced and distributed across the wells where the cross-reactivity reactions are 
evaluated based on the uptake of a reporter dye – usually trypan blue or eosin red. The 
cross-reactivity of the anti-HLA antibodies against the HLA molecules (antibody-
antigen complexes) will cause the cells to become permeable and therefore take up the 
dye and appear that reporter dye’s colour when observed visually. The percentage of 
lysed/stained cells is then measured against a scoring system (see Table 1.7) where a 
score of >6 (high cytotoxicity) is classed as a positive hit. The antibody belonging to 
these wells where high cytotoxicity occurred is read as the patient’s HLA type. Due to 
the subjective nature of the interpretation, tests require at least 2 independent 
technicians to agree before the final HLA type is recorded. [79] 
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Table 1.7: Interpretation of complement-dependent cytotoxicity (CDC) results  
% of lysed (stained) cells Score Interpretation 
 0 unreadable 
0-10 1 Negative 
11-20 2 Doubtful negative 
21-50 4 Weak positive 
51-80 6 Positive 
81-100 8 Strong positive 
 
1.3.2. Sequence-specific primer assay 
The HLA-SSP typing method works by using (as the name suggests) primers that are 
complementary to specific HLA alleles or group of similar alleles, i.e. 1st field and 2nd 
field resolution respectively. These primers are designed so that the polymorphisms in 
the allele’s genetic sequence is identified at the 3′ terminus of the primer. This means 
that perfect matches to the primer (i.e. the specific allele containing the sequence) will 
be extended by the Taq DNA polymerase during the PCR step. Once the HLA-SSPs 
are created, they are distributed within microtiter plate where they are then stored 
frozen or freeze dried and stored at approx. 4˚C. For HLA typing an individual’s DNA 
sample, the sample’s extracted DNA is mixed with dNTPs and Taq DNA polymerase 
which is then aliquoted into the microtiter trays that contain the SSP sets and the DNA 
is amplified by PCR. Modern primer sets have been designed so that all of these primer 
sets require the same PCR conditions. The amplified (or not) PCR product can be then 
detected by electrophoresis through agarose gel and intercalating with ethidium 
bromide to allow the presence of DNA (i.e. the PCR product) to be revealed under 
exposure of ultra violet light. HLA alleles that correlate to these amplified primers are 
assigned to the sample’s HLA typing status. [80] 
 
1.3.3. Sequence-specific oligonucleotide assay 
HLA-SSO typing involves the extracted and PCR amplified DNA samples to be 
exposed to DNA primers that are known to be specific to all alleles for a particular 
HLA locus. These SSO typing primers are focused to specific exons: primers targeting 
exons 2 and 3 for HLA class I genes and exon 2 for HLA class II genes (explained in 
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section 1.2.3 as the region that confers functional variability). The amplified DNA is 
then blotted onto a positively charged nylon membrane, one for each oligonucleotide 
probe, allowing for hybridisation of complementary DNA-oligonucleotide sequences 
to occur. Stringency washes remove any unbound oligonucleotide probes. The SSO 
probes are designed such that the allele specific polymorphism is located at the middle 
of the oligonucleotide sequence, if there are partially bound probes then there is an 
increased chance of the probe being washed away by the stringent buffer. Hybridised 
molecules can then be detected using chemiluminescent or colour-metric reactions 
where pattern of the positive reactions can be used to determine the HLA type. [80] 
 
1.3.4. Typing with SNP tags 
SNP tagging is used commonly to type the HLA status of patients and involves 
amplifying sample DNA with DNA probes that are specific to an allele’s single point 
polymorphism that is known to be in complete (or very high) linkage with the allele 
and detecting these variations with for example, fluorescently labelled probes or 
restriction length fragment polymorphism (RFLP) where the amplified DNA 
containing the different alleles of the SNP can (or can’t) be digested with a restriction 
enzyme. The SNP tag acts as a proxy marker to detect for the presence of an allele of 
interest. 
 
SNP tagging methods are commonly used as a rapid and cost-effective method for 
sequencing which detect for the presence or absence of individual and specific alleles 
– e.g. detect for the presence or absence of HLA-B*57:01. For the SNP tagging 
methods, the SNP’s location can be found either inside or outside the gene/allele of 
interest. If the SNP is found outside, then the allele must be shown to be in complete 
(or very strong) linkage disequilibrium with the tagged allele. Not all SNPs can be 
designed to be within the gene due to the above mentioned difficulties in designing 
probes. A paper published by de Bakker et al. lists SNPs that can be used as a proxy 
for many common HLA alleles. [81] 
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1.3.5. Sequencing based typing  
1.3.5.1. Sanger sequencing 
Sanger sequencing is a technique where the DNA sample that is to be sequenced (after 
being amplified) is mixed with a DNA primer (tailored for the region to be sequenced) 
and a DNA polymerase enzyme and a mixture of deoxynucleosidetriphosphates 
(dNTPs) and modified di-deoxynucleosidetriphosphates (ddNTPs). The modification 
of the ddNTPs render the nucleotide chain to be unable to be extended by the DNA 
polymerase enzyme and the ddNTPs are also labelled (fluorescent or radiolabelled). 
The sample DNA is separated into four individual sequencing reactions/lanes (A, C, 
G, T) which also contain dNTPs, one of the four ddNTPs at a 100-fold lower 
concentration relative to the dNTPs and the DNA primer that is bound to the sample 
DNA. The procedure allows several copies of the same region to be made which are 
of different length due to the terminating ddNTP. The fragments are then separated by 
size (e.g. gel electrophoresis) and the radio/fluorescent labels are measured. The 
differences in fragment size allow the sequence to be built using the terminating 
ddNTP labelled base residue. In the case of HLA, the Sanger sequencing procedure is 
performed using the same exons as SSO typing (exons 2 and 3 for class I HLA genes 
and exon 2 for class II). [82] 
 
1.3.5.2. Next generation sequencing 
The technology for next generation sequencing (NGS) has come a long way in recent 
years to overcome some of the challenges faced with typing HLA using this method 
(see section 1.3.6 below). Many different NGS technologies exist and the process 
differs from all other sequencing methods discussed in this section as the method looks 
to sequence across the entire gene (including all exons, the untranslated terminals, 
introns, and also some upstream and downstream regions beyond the gene itself). This 
means that the process can be described as “ultra-high resolution” where fourth field 
resolution can be achieved (see section 1.2.5 on HLA nomenclature) i.e. resolution of 
polymorphisms in intergenic regions, as well as exonic. 
 
The NGS process works by sequencing the PCR amplified DNA across long regions 
where the DNA primers, that enable DNA extensions, overlap so multi-fold coverage 
of the sequence is obtained. The overlapping fragment sequences/scaffolds allow the 
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entire gene to be sequenced using the NGS machines included software as the 
overlapping sequences are pieced together to form a single contiguous sequence. 
 
1.3.6. Comparison of the typing methods 
Serological typing methods typically do not offer typing resolution beyond the first 
field. Even then, there have been reports of some HLA class I specificities which have 
been called inaccurately where in one study 18.5% of HLA-A and 25.4% of HLA-B 
typing showed discrepancies with some of the causes were reported as antigen mis-
assignment or missed antigens. [83] This study was conducted using a black patient 
cohort meaning that serological testing needs to take into account patient ethnicity. 
Another study reported a mis-assignment of HLA-B antigens by serological methods 
to be 22.5%. [84] Although serological HLA typing has been largely supplanted by 
DNA based typing methods, the process is still sometimes used in conjunction with 
DNA based typing methods as a means of determining whether the allele is expressed 
on the cell surface; many null alleles have been identified this way. [85] 
 
SSO typing is very proficient at processing a large number of samples in a single run. 
This makes it ideal for HLA typing laboratories, which need to perform these tests 
routinely where, with the inclusion of control samples, approx. 90 samples can be run 
in a single microtitre tray. The system is also adaptable and additional membranes 
containing new oligonucleotides can be added to detect new alleles or resolve 
ambiguities. The most significant disadvantage to the SSO based typing is that it is 
unable to distinguish between cis and trans polymorphism whilst SSP typing 
implements a system of using both forward and reverse primers allowing it to detect 
cis and trans polymorphisms that are located between the forward and reverse primer 
binding sites allowing it to resolve some of the ambiguities that would disadvantage 
SSO typing allele calls. Current SSO typing methods take approximately 2 days from 
the PCR step before the full result of the typing can be assigned. Whilst not quick, the 
above mentioned high throughput enables efficient typing of many samples in a cost 
effective manner. The SSO primers are also designed to select from a non-variable 
part of the gene meaning that as long as the polymorphism does not exist in this region 
and is covered in the region covered by SSO typing, SSO typing is better at detecting 
new, previously unknown alleles compared to SSP as it will appear as a new pattern 
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that does not correspond to the reference of known alleles. Both SSO and SSP typing 
methods are only able to detect polymorphisms that occur within exon 2 (and in some 
cases, exon 3). It is generally accepted that only polymorphisms in this region confer 
peptide binding specificity [86] - i.e. functional changes which is the region that is 
covered with the hypothesised ADR models detailed in Chapter 1.1.3.  
 
Although SNP tagging provides a very quick and cheap method of HLA typing, it is 
impractical to type for a large range of alleles due to the need for a labelled 
probe/restriction enzyme for each allele (Chapter 1 discusses the thousands of known 
alleles). It can however, test for the presence/absence of specific alleles which means 
that in very particular cases (e.g. testing for HLA-B*57:01 prior to abacavir treatment) 
the method could be used to detect for that particular allele – the method has been 
recommended for pharmacogenetic screening (see example featured in Chapter 2.2.3), 
however this would require different SNPs in populations of different ancestry. 
Additionally, an absence result won’t tell the user what the allele actually is so 
negative results only offer very limited HLA typing information depending on how 
much information is desired. This limitation may still provide adequate information in 
some circumstances. For example, in the context of ADRs, a clinician may only need 
to know if a patient carries a risk allele, if not then the allele is insignificant 
information. 
 
Whilst these limitations exist in current SNP tagging methods, advances have been 
made whereby HLA alleles can be imputed using multiple SNP positions – for 
example HIBAG. [87] SNP imputing algorithms that were designed previous to this are 
limited as they require extremely large ethnic controlled cohorts (>1,000) as training 
data in order to make predictions with sufficient accuracy. These forms of training 
data sets are not readily on hand resulting in increased difficulty in accurately calling 
alleles that are rare in these populations. [88] With newer imputing algorithms, such as 
the above mentioned HIBAG, the limitation of controlling for sample ethnicity can be 
overcome due to the use of multiple data points to analyse, greatly increase the call 
accuracy. However, further analysis and scrutiny of the newer approach method is 
required before it can be readily implemented. 
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Sanger sequencing is a more established method of sequence based typing compared 
to NGS. It is able to obtain the sequence over exon 2 (and also exon 3 for class I genes) 
and therefore providing more information, in terms of raw data points – i.e. more of 
the gene sequence, compared to SSO, SSP and SNP tagging methods. However, the 
above mentioned ambiguities brought about by limiting sequencing to exons 2 and 3 
apply with Sanger sequencing. It has been reported that this ambiguity can affect 
around 66% of HLA-A, 71% of HLA-B and 58% of HLA-C allele calls using 
traditional Sanger sequencing although the study also reported on an in-house Sanger 
sequencing technique with 4.4%, 4.4% and 0% ambiguity for HLA-A, HLA-B and 
HLA-C respectively – note that these ambiguities do not necessarily translate to an 
incorrect call as SNP tags and other known polymorphisms in high linkage along with 
ethnicity/population data can be factored in to statistically infer the most probable 
allele. [82] 
 
Although the genomic HLA region is highly polymorphic, it also shows a high degree 
of sequence similarity across the different loci which makes it very challenging to 
design primers/probes to amplify/detect the alleles. Consequently, sequence based 
typing methods of HLA alleles to high resolution is expensive, time consuming and 
laborious procedure. This issue is less problematic in the rest of the genome where the 
technology is widely accessible. This meant that at the turn of the millennium, 
although DNA based methods such as SSO and SSP typing were available, serological 
typing was still the primary typing method and it took many years after that before 
DNA based typing methods became the de facto method. However, more recently, the 
technology for next generation sequencing has improved to overcome many of the 
issues faced. Previously, due to the high sequence similarity in some areas of the MHC 
region, it was difficult to form overlapping contiguous sequences using earlier forms 
of NGS technology. However, with newer technological advances, massive 
parallelisation, high throughput and longer reads can be achieved at more affordable 
costs allowing for not only sequencing of entire individual HLA genes, but the 
possibility of phasing the entire MHC region. [89] The ability to phase the MHC region 
allows for haplotype information to be obtained and the ability to analyse the non-
coding regions of the gene that could affect expression. The other methods which limit 
themselves to just exons 2 and 3 (e.g. SSO, SSP etc) have some inherent ambiguity 
with the final called allele, for example, the combined exons 2 and 3 sequence for 
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HLA-A*02:01:01 is identical to 21 other HLA-A*02 alleles. [82] The biggest drawback 
for all forms of NGS methods is that the turnaround time is still relatively long which 
negatively impacts its suitability in clinical scenarios where expedient results are 
required.  
 
1.4. General database design 
Over recent years, as computational power has increased and become more 
widespread, the usage within biology has similarly expanded. There are many aspects 
to employing computational approaches to solving biological problems, too many to 
detail in this thesis. This thesis makes particular use of websites and databases - which 
will be discussed in this section.   
 
1.4.1. Relational databases 
Databases are used to store and allow for easy retrieval of information in a centralised 
manner, this makes them ideal for websites which require a collection of large amounts 
of data. Relational Database Management Systems (RDBMS) are one of the most 
common ways that, as indicated in the name, a database is managed by system 
administrators. On top of the basic functionality described above (easy storage and 
retrieval), an RDBMS also provides some levels of security (i.e. permissions and user 
access), data integrity and other administrative actions (e.g. performance monitoring, 
data backup and recovery). The security aspect is of great importance as it allows 
system administrators with user credentials that grant them full read, write and modify 
access of not just the data within but also for the database schema (an example is 
described in Chapter 3.2.2) whilst also restricting end users to only view data within 
the confines of their permitted access rights, in most cases the end user will only be 
able to view information from a select set of the overall data. These restrictions based 
on user access provides the database administrators with the ability to effectively 
maintain and manage the database whilst preventing end users from accidently or 
maliciously altering the data or accessing restricted parts of the data. 
 
Relational databases contain one or more tables to house the data. Each row of the 
table represents one record with each column representing a field. Table 1.8 below 
shows a simple example based on a fictitious student course registration database 
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displaying students and the subjects they are taking along with their teachers. In this 
example, each student is a record within the table which consists of several fields to 
represent a component of the record, in this case, the student’s name, subjects/courses 
they are enrolled on, the classroom where they are taught and the staff member who 
teaches the subject. This system of records and fields allows for efficient storage of 
information that needs to be kept in a rigid and organised structure. Efficiency can be 
further increased using a concept known as “database normalisation” to spread the 
data across multiple tables in order to reduce data redundancy and ensure data that has 
dependencies are stored logically (see 0). 
 
Table 1.8:  Fictitious example of a basic database table structure using a class 
enrolment scenario. Columns represent a field or aspect and rows represent a 
record. 
student_id first_name last_name courses room teacher 
58001 Laurits Anderson 
Biology, 
Computing 
103, 105 Woodward, James 
58002 Amy Jones 
Biology, 
Maths 
103, 104 Woodward, Shaw 
58003 Manpreet Kaur 
Biology, 
Chemistry 
103, 102 Woodward 
58004 John Smith 
Computing, 
Maths 
105, 104 James, Shaw 
 
1.4.2. Database table normalisation 
The process of database normalisation aims to decompose tables in order to reduce 
data redundancy that can occur between records. There are a minimum of 3 levels of 
normalisations that are typically employed, 1st normal form, 2nd normal form and 3rd 
normal form (1NF, 2NF and 3NF respectively), higher levels do exist but are not 
typically implemented unless using extremely complex relationships. [90] Although 
database normalisation initially changes the data layout to a more complex structure 
(compared to a single 2 dimensional table of simply rows and columns), from a 
computational point of view, database normalisation allows for easier data 
maintenance and updating in situations with larger and/or complex databases 
containing more information. [91] Using the above Table 1.8 as an example, there are 
some unnecessary data redundancy so this section will describe each forms of 
normalisation. 
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The first normal form requires that each column only contain one attribute where all 
entries in that column must be of the same type and that each row must be unique. [92] 
With regards to Table 1.8, the rule that each column only contain one attribute has 
been violated, whilst the other aspects of the first normal form are true – student IDs 
column only contains their unique identifying number, the first name and surname 
columns only contain “name” information for the student, the courses column only 
contains the subjects the students are enrolled on with their rooms column containing 
the room numbers and the teachers’ names in the teacher column. In order for the table 
to meet the requirements of the 1st normal form the individual items within the courses, 
room and teachers column to have separate records/rows as shown in Table 1.9.  
 
The 2nd normal form (2NF) requires that the database conforms to 1NF and that each 
column can only exist in the table where it is either the primary key or the column is 
dependent of the entire primary key for its existence; a primary key is a column or 
columns which can uniquely identify that particular row. In this context, the 
“student_id” column represents a primary key for the individual however, classroom 
number and the teacher is dependent on the course/subject, not the individual’s student 
ID which therefore violates 2NF. In order to conform to 2NF, the table will need to be 
separated; one table will describe the students whilst the other depicts the course 
characteristics. This reduces data redundancy as the teacher and room information are 
not needlessly duplicated for each student. It also makes input errors or mistypes when 
entering the information easier to identify as the mistake will affect all records 
associated with that key rather than a specific record as editing a single record is more 
efficient than editing the same mistake/type for multiple records (see Table 1.10). 
 
A junction table (c) is required to show the relationship between the students and 
courses because the enrolment information was lost in the process to achieve 2nd 
normal form.  In comparison to Table 1.9 the data redundancy has been reduced where 
the student details have not been duplicated on a per enrolled course basis. 
 
  
 
2
7 
Table 1.9: Showing the information displayed in Table 1.8 which conforms to the standards of the 1st normal form (1NF; for database 
normalisation).  
 
student_id first_name last_name course room teacher 
58001 Laurits Anderson Biology 103 Woodward 
58001 Laurits Anderson Computing 105 James 
58002 Amy Jones Biology 103 Woodward 
58002 Amy Jones Maths 104 Shaw 
58003 Manpreet Kaur Biology 103 Woodward 
58003 Manpreet Kaur Chemistry 102 Woodward 
58004 John Smith Computing 105 James 
58004 John Smith Maths 104 Shaw 
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Table 1.10: a, b and c Showing the information from Table 1.8 which conforms to 
both 1st normal form and 2nd normal form (1NF and 2NF respectively)  
a) 
student_id first_name last_name 
58001 Laurits Anderson 
58002 Amy Jones 
58003 Manpreet Kaur 
58004 John Smith 
 
 c) 
course room teacher 
Chemistry 102 Woodward 
Biology 103 Woodward 
Maths 104 Shaw 
Computing 105 James 
 
b) 
student_id course 
58001 Biology 
58001 Computing 
58002 Biology 
58002 Maths 
58003 Biology 
58003 Chemistry 
58004 Computing 
58004 Maths 
 
 
The next stage in the process of database normalisation is 3rd normal form (3NF) which 
requires, in addition to conforming to 1NF and 2NF, that each of the columns in a 
table must be either the primary key or dependent only on the contents of the primary 
key and no other column. In the previous example in Table 1.10 the conditions for 
3NF were violated as the information for the teacher in Table 1.10b was dependent on 
the course information but did not require the room number for its existence. 
Therefore, the course and teacher information required its own table.  
 
Although higher forms of normalisation exist to take the process beyond 3NF, the 
other forms are rarely implemented unless the information has very complex 
relationships. The database described in this chapter was only decomposed to conform 
to the standards of 3NF. A common mnemonic that is used to remember the order of 
database normalisation and over simplistic description to the process is a phrase 
whereby the non-key fields/columns in a table must be “dependent on the key (1NF), 
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the whole key (2NF) and nothing but the key (3NF), so help me Codd” where Codd 
refers to the author who proposed the process of database normalisation. [93, 94] 
 
It is also worth noting that, decomposing the data such that it is spread over multiple 
tables must then rely on relationships between keys and non-key fields in order to 
maintain the integrity of the information. Using the example in Table 1.11, although 
the student and course information are kept in separate tables, the junction Table 1.11c 
provides a link to relate the other 3 tables together such that all of the information can 
be accessed when using the correct query (see Chapter 1.4.3.2). 
 
1.4.3. Database considerations 
1.4.3.1. Available relational database management systems (RDBMS) 
There are many developers that supply RDBMSs. Accurate numbers for database 
management systems that are based on usage are difficult to obtain. However, DB-
Engines provides rankings based on web metrics and lists the major providers for the 
various database management systems. [95] Table 1.12 shows the top 20 database 
management systems based on DB-Engines’ scoring system. By far the most prevalent 
type of database model used is the relational database management system which has 
been described previously in Chapter 1.4.1. For this chapter, an RDBMS was chosen 
as the strict, logical structure requirements enforces good data handling practice, the 
data lends itself quite well for this logically enforced model and the prevalence of 
RDBMS models provides the database, that will underlie the clinical decision support 
tool, with great flexibility in terms of deployment as a greater number of hosting 
servers will be able to support RDBMS allowing for greater choice for server 
deployment. Specifically, the database was built using MySQL as this provides the 
greatest level of flexibility for RDBMSs as the language itself is directly supported by 
Oracle. The differences between Oracle’s RDBMS and MySQL is that the latter is the 
community supported/open source implementation based on Oracle. Additional 
RDBMSs such as MariaDB (ranked 18th in Table 1.12) are based upon, as a fork of, 
MySQL which allows MariaDB to support code written in MySQL, however, this 
cross-compatibility could eventually be lost depending on the direction of the 
fork/divergence. Overall, writing SQL queries with MySQL provides the greatest level 
of flexibility overall for database deployment.  
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Table 1.11: a, b, c and d Showing the information from Table 1.8 but now conforms 
to 1st normal form, 2nd normal form and 3rd normal form. 
a) 
student_id first_name last_name 
58001 Laurits Anderson 
58002 Amy Jones 
58003 Manpreet Kaur 
58004 John Smith 
 
b) 
course room 
Chemistry 102 
Biology 103 
Maths 104 
Computing 105 
 
 
c) 
student_id course 
58001 Biology 
58001 Computing 
58002 Biology 
58002 Maths 
58003 Biology 
58003 Chemistry 
58004 Computing 
58004 Maths 
 
d) 
course teacher 
Chemistry Woodward 
Biology Woodward 
Maths Shaw 
Computing James 
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Table 1.12: DB-Engines Ranking of database management systems based on their 
popularity.  
 
Rank Database Management 
System 
Database Model DB-Engines Score 
1 Oracle  RDBMS 1374.88 
2 MySQL  RDBMS 1349.11 
3 Microsoft SQL Server  RDBMS 1226 
4 PostgreSQL  RDBMS 369.44 
5 MongoDB  Document store 332.77 
6 DB2  RDBMS 191.25 
7 Microsoft Access RDBMS 126.13 
8 Cassandra  Wide column store 124.12 
9 Redis  Key-value store 121.51 
10 Elasticsearch Search engine 115.98 
11 SQLite RDBMS 113.86 
12 Teradata RDBMS 78.37 
13 SAP Adaptive Server RDBMS 66.91 
14 Solr Search engine 66.02 
15 HBase Wide column store 63.62 
16 Splunk Search engine 60.3 
17 FileMaker RDBMS 58.65 
18 MariaDB  RDBMS 54.36 
19 SAP HANA  RDBMS 47.94 
20 Hive  RDBMS 46.2 
Note: The method for calculating DB-Engines’ score is listed in full on their website 
(https://db-engines.com/en/ranking_definition) but in general, it is based on 
internet/social media metrics and job advertisements. The scores are current as of 
July 2017. 
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1.4.3.2. Structured Query Language (SQL) 
The SQL based RDBMS also enables for the retrieval of data from the database with 
specific commands to refine the search to specifics that the user desires. [96] This is 
achieved with the use of HTML elements embedded into webpages such as 
dropdowns/radio buttons etc. whereby users can chose from the available options. 
Once submitted, the webserver can generate the SQL code based on the selection. 
Effectively, the SQL code is already partially complete and just requires the user 
selected options to fill in the missing section. For example, using a simple scenario 
involving fruit as described in Table 1.13, the webserver already has the SQL code 
“SELECT column_fruit FROM table_fruits WHERE column_fruit = ‘<<user 
option>>’;”. Once the user selects an option the code is then completed and then 
executed; example “SELECT column FROM table_fruits WHERE column_fruit = 
‘gooseberry’;”. In this scenario the record for gooseberry is retrieved. 
 
Multiple entries can be retrieved as well; continuing with the fruits example, a user 
can search for all the berries if they wanted to by using “SELECT column_fruit FROM 
table_fruits WHERE fruit_type = ‘berry’;” which will return banana, gooseberry and 
blackcurrant.  
 
Table 1.13: Hypothetical table called “table_fruits” which is made of the columns 
(fields) of the identification number, the fruit names and the botanical category 
that fruit belongs to. 
id_fruit column_fruit fruit_type 
1 apple pome 
2 pear pome 
3 banana berry 
4 gooseberry berry 
5 blackcurrant berry 
6 blackberry aggregate fruit 
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1.5. Web development languages 
The server-side programming languages are used to generate interactive webpages, 
which allow the users to interact with the data stored on the database.  The webpages 
act both to limit the users’ access to the database by removing an interface with direct 
database access, this is due to the possibility of holding sensitive information such as 
user login credentials etc.). The webpages also act as a means of a friendly graphical 
user interface (GUI) so that the information can be provided in an aesthetically 
pleasing manner. 
 
It is difficult to obtain the full usage statistics for the various server-side programming 
languages available as this is not usually declared or automatically collected. 
However, the W3Techs website aims to specifically collect metrics regarding the 
server-side programming languages used by websites. [97] The methods by which they 
obtain the data is described within their FAQ page. An adapted bar chart showing the 
W3Techs data is shown in Figure 1.7. The usage statistics show that the PHP 
programming language dominates the market share and therefore would be highly 
likely to be installed by hosting server providers. Similarly to SQL based RDBMS 
solutions described earlier, developing a website with PHP served webpages will 
allow the website the greatest amount of flexibility for deployment.  
 
  
 
3
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Figure 1.7: Bar chart showing usage statistics of server-side programming languages that are used to serve webpages across the web. [97] 
Not all available languages are represented here. 
Note that websites may use more than one language to generate its webpages. 
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1.6. Aim of thesis 
The fields of pharmacogenomics and immune-mediated adverse drug reactions has 
been expanding at an immense rate. New HLA allele-drug combinations are being 
reported every year meaning it has become ever more important for clinicians and 
pharmaceutical companies to keep up to date with this growing field for reasons of 
patient health and the development of new medicines. It is therefore clear that the 
importance of research into ADRs has also developed alongside the growth in the 
literature.  
 
However, much of this research is dispersed amongst the published articles which 
makes the task of keeping track of this field ever more difficult. This thesis aims to 
address this by: 
 
1. Review the literature and collect information to gather an overall picture for 
the field of adverse drug reactions that have been associated with HLA allele 
carriage. 
 
2. Exploring computational methods that will enable researchers to interact with 
the collected data and enable new methods of conducting analyses for 
investigating immune mediated adverse drug reactions. 
 
3. Validate a new method of HLA typing that is designed to test patient DNA for 
the carriage of one or more HLA alleles in a panel of preselected HLA alleles 
that are known to cause adverse drug reactions 
 
4. In addition to the aim 3, develop a clinical decision support tool that will aid 
clinicians with interpreting the results from the HLA typing apparatus. 
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Chapter 2. A systematic review to examine the 
association between immune-mediated adverse drug 
reactions and patient HLA genotype 
 
2.1. Introduction 
Due to the great impact that ADRs can have on patient health as well the financial 
investments made by the pharmaceutical companies into drug development, research 
into this field of pharmacogenetics is vitally important to patients, clinicians and the 
pharmaceutical companies. However, one of the main obstacles that these groups face 
is that much of the research is dispersed amongst the literature. Several literature 
reviews regarding ADRs have been published covering specific drugs, drug classes or 
a broad range of drugs. [32, 33, 98] However, the field of pharmacogenetics is rapidly 
evolving with new ADR-inducing drugs becoming reported on a continuous basis. 
This presents great challenges for researchers attempting to keep up to date with the 
field and obtain an overall view of the field. 
 
2.1.1. Current resources available for researchers 
Researchers have several methods for obtaining published literature regarding ADRs 
and three major resources have been listed below.  
 
HuGE Navigator is a web-based tool which contains a database of published PubMed 
abstracts of studies relating to genetic associations with diseases. [99] The studies 
within the database are manually curated from the NCBI Medline/PubMed. This tool 
has the ability to allow for searches using MeSH terms (Medical Subject Headings 
available through- http://www.nlm.nih.gov/mesh/meshhome.html) which standardise 
alternative names of diseases giving them specific keywords. This allows many related 
terms to be searched using only one search term. 
 
MEDLINE is a web resource containing one of the largest repositories of citations and 
title/abstracts from peer reviewed published biomedical articles and is hosted by the 
(United States) National Library of Medicine. [100] PubMed is the web-browser based 
interface to retrieve abstracts from MEDLINE. Similarly, the Excerpta Medica 
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database (EMBASE) also offers bibliographic records with citations for biomedical 
and pharmacological peer-reviewed articles. [101] 
 
2.1.2. Aim and objective for systematic review 
The primary aim of this systematic review was to summarise the relevant data that 
examine the relationship of adverse drug reactions and patient HLA genetics. 
Specifically, what genetic factors of the HLA gene family are involved with immune-
mediated adverse drug reactions? 
 
2.2. Materials and methods 
2.2.1. Literature search 
To answer the question laid out in the aim for the systematic review, the first step was 
to retrieve peer-reviewed publications containing the case-control studies. This 
involved searches using the three major tools (see Table 2.1) that allow users to 
retrieve published studies involving immune-mediated ADRs. 
 
Table 2.1: Summary of the literature resources used to retrieve studies for this 
systematic review.  
The table also includes the search terms that were entered to create the search. 
Literature resource Search terms used 
PubMed / Medline 
Main search (papers published between the year 2000 until 
April 2014) – see Search strategy 2.2.6.1 MEDLINE  
Supplementary search (papers published up to April 2014) - 
“<<drug>> AND (hypersensitivity OR pharmacogenetics OR 
HLA)” 
Follow-up search (April 2014 – August 2015) and a second 
covering (August 2015 – October 2017) – see section 2.2.5 
Semi-automated literature mining 
EMBASE See Appendix Search Strategy 2.2.6.2 EMBASE 
HuGE Navigator “Drug Toxicity AND HLA”  
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The date range for the literature search started with the year 2000. This date was 
chosen based on an initial pilot search that was conducted using only the results from 
HuGE Navigator search (this was a curated set of data that has no initial start date). 
When looking at this data, it was noted that studies which featured high resolution 
typing (a requirement of the literature search that is described in greater detail in 
section 2.2.3) were published after 2000. Articles published before this date featured 
low resolution HLA typing. This was the basis as to why the main literature search 
used the year 2000 as the start for the date range. April 2014 was the selected end date 
as this was the time the search was conducted therefore, this provided the ability to 
select the end date that would provide the latest information available at the time of 
the search. 
 
With HuGE Navigator, ADRs come under the MeSH term “drug toxicity”. The tool 
also includes the alternative terms: “Erythema Multiforme”, “Drug Eruptions”, 
“Poisoning by medicaments NOS” and “Toxic Epidermal Necrolysis”. For this 
review, the search was limited to just HLA genes so as to remove other genes 
implicated with ADRs, for example,  cytochrome P450 genes. Therefore, the term 
“Drug Toxicity and HLA” was entered into the search. 
 
For both MEDLINE and EMBASE, a search strategy for each resource was developed 
(see section 0) and implemented. The search was constructed using keywords related 
to HLAs and drug hypersensitivity. The search also included a list of drugs which were 
featured in recent publications reviewing drug hypersensitivity. [31, 33, 102, 103] The list 
can be found on each search strategy (section 0 - identical in both) under entry 9. The 
list of drugs is designed to cast a wider net for the search. It allows to the search to 
include these drugs (prior knowledge) but does not function to restrict the search to 
these drugs. The list was also used to perform a supplementary search within PubMed. 
Here, the search term followed the format: “<<drug>> AND (hypersensitivity OR 
pharmacogenetics OR HLA)” where <<drug>> represents one of the entries from the 
drugs list e.g. “Abacavir AND (hypersensitivity OR pharmacogenetics OR HLA)” was 
then followed by “Allopurinol AND (hypersensitivity OR pharmacogenetics OR 
HLA)” until searches using all the drugs in the list were covered. This was achieved 
through using a computer script written in the Python computing language and used 
the e-utils module which allows for access and interaction with the Medline 
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application program interface (API). [104] The script would then collect the PMIDs 
from the results of each search and place the PMIDs into a basic text (.txt) file. 
 
The results from all of these searches were collected as a list of PubMed Identifiers 
(PMID) and then the individual PMID lists (HuGE Navigator, MEDLINE, PubMed 
and EMBASE) were merged into one super-list in which duplicates were removed, 
thereby representing published articles found by the literature search that will be 
considered for review. 
 
2.2.2. Literature screening 
Once the list of publications (as represented by their PMIDs) was composed, it was 
assessed to determine if it contained publications which featured data relevant to the 
systematic review. This process was divided into two stages of screening with the 
details of eligibility summarised in Table 2.2. For the first stage, the titles and abstracts 
were reviewed to identify potential studies of relevance and the second stage involved 
examining the entire study manuscript to fully assess whether the paper fulfilled the 
eligibility criteria. A second reviewer (Ana Alfirevic) also assessed these selected 
studies with discrepancies being resolved through discussion.  
 
2.2.3. Eligibility criteria 
For this review, only case-controlled studies or randomised controlled trials that 
investigated ADRs in patients were considered. These investigations were required to 
provide statistical evidence (e.g. number of study participants, p-values, and odds 
ratios with 95% confidence intervals) so that statistical analyses could be undertaken 
by users of the data (eventually made available in Chapters 3 and 4). Studies were also 
limited to those where the participants’ HLAs were genotyped to determine specific 
proteins (high resolution typing sometimes referred to as “4-digit resolution”). This 
was decided because, with the example of abacavir, it has been demonstrated that HLA 
proteins which are part of the same antigenic group and only differ by a few amino 
acids do not stimulate the same adverse response. [46] This means that protein specific 
resolution (> 4-digits) is required to distinguish between HLA alleles that are 
associated with ADRs and those that are not. Consequently, serotype or antigenic 
resolution alleles do not contribute much meaningful information. However, studies 
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were included in cases where they provided a mixture of high and low resolution 
typing. 
 
Table 2.2: Inclusion criteria for the systematic review. 
Studies were considered for data extraction if they included the following criteria. 
Population Patients with a hypersensitivity reaction to drugs administered 
as part of standard treatment 
Study design Retrospective and prospective case-controlled studies, 
randomised controlled trials 
Statistical 
evidence 
Provided statistical evidence (e.g. number of cases and 
controls, p-values, odds ratio with 95% confidence intervals) to 
determine the strength of the association. 
HLA typing 
Investigations where patient and control HLA status was 
determined to the protein level (high resolution typing 
sometimes referred to as “4-digit resolution”). 
 
Studies where the HLA allele were genotyped within the gene 
itself, i.e. not using proxy SNPs. 
Study date 
The formal systematic review was performed covering studies 
with the publication year between 2000 and the time of the 
search (April 2014). 
 
In addition to this, studies which are able to genotype the patient-control cohorts at 
high resolution with high confidence were considered for inclusion. As a result, studies 
which implemented a SNP-based proxy/tagging method (as described in Chapter 
1.3.4) were excluded. These SNP tags which are found outside of the relevant gene, 
elsewhere on the chromosome, have been shown to be limited when looking at 
different populations because the method relies on the tagged SNP to be in perfect 
linkage disequilibrium with the allele of interest. For example, hypersensitivity to 
abacavir has been linked to carriage of the HLA-B*57:01 allele. [15, 16, 105-110] A study 
conducted using a Mexican population reported that the SNP rs2395029 was in 
absolute linkage with HLA-B*57:01. [111] However, this is not observed across all 
populations, a study which investigated the rs2395029 SNP in an Italian population 
reported that the SNP and carriage of the HLA-B*57:01 allele were not in absolute 
linkage (r2 = 0.89) and recommended against using SNP tag alone as a proxy marker 
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for HLA-B*57:01. [112, 113] A study by de Bakker et al. investigated SNP tags for HLA 
alleles in 4 different populations: Yoruba people from Ibadan, Nigeria (YRI); Utah 
residents of European ancestry (CEU); Han Chinese individuals from Beijing, China 
(CHB); and Japanese residents from Tokyo, Japan (JPT). [81] The study reported that 
different SNP tags would be required for the same allele in different populations. For 
example; the tagged SNP for HLA-A*31:01 (for carbamazepine hypersensitivity) 
would require: rs1061235 in Caucasians; rs3823318 & rs1061235 in Chinese and 
rs1061235 & rs1150739 in Japanese populations. The multiple tag SNPs required to 
represent a single allele would limit the clinical relevance and would also restrict the 
ability to perform meta-analysis with the data when comparing different populations. 
Therefore, studies which typed patients using tagging SNPs were excluded. 
 
2.2.4. Data extraction 
Data were extracted from the studies brought forward by the literature search of the 
systematic review.  This was performed by 3 reviewers, with GG extracting data from 
50% of the papers identified for extraction and the remaining studies being mined for 
data by MHM (25%) and AS (25%). This was then checked by 2 reviewers, GG 
independently verified the data extracted by MHM and AS (GG did not verify own 
data extraction) whilst ES verified the data extraction performed by GG. A list of the 
types of data that were extracted from the selected studies are shown in Table 2.3Table 
2.3. 
 
Data were extracted to a spreadsheet document file where as much of the data was 
recorded as it appeared in the original study. Certain circumstances required 
interpreting the data in order to facilitate meta-analysis. For example, ADRs may use 
alternative terms (refer to section 0), these terms were standardised based on expert 
medical knowledge of Dr Ana Alfirevic and is described in Table 1.3 . Additionally, 
certain papers would report a significance of association (p-value) simply as 
“significant” or “not-significant”. In these cases the studies p-value threshold was used 
and the value was reported relative to the significance threshold (for statistically 
significant results after and correcting for multiple comparisons; “0.05” with a note 
stating it is less than the threshold or if the association is not-statistically significant, 
then the column was left blank and a note was included to explain this). As the 
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eligibility criteria required the number of cases and controls, the type of controls were 
divided into two distinct groups (recorded separately within the spreadsheet 
document) based on whether the controls were patients also exposed to the drug as 
part of their treatment or if these were population controls which were not patients 
being treated (i.e. not exposed to the drug) for disease/condition that the patient group 
were. 
 
Table 2.3: Types of data that were extracted from the studies identified during the 
literature search of the systematic review. 
Study details 
 
Bibliographic information 
PubMed ID – to provide link back to original 
manuscript 
Corresponding authors and email 
Disease (that patients were initially treated for) 
Drug administered 
Study cohort demographic 
Country 
City & province/state 
Group sizes (patients, controls) 
Ethnicity 
Association data 
Allele 
Induced phenotypes (ADRs) 
Frequency of allele within each sample group 
Odds ratio (with confidence intervals) 
P-values 
Statistical method used for analysis  
(including corrections for multiple comparisons) 
 
2.2.5. Semi-automated literature mining 
In order to speed up the process for future data collection, a computer script written in 
the Python scripting language was developed. The script utilised the e-utils module in 
order for the computer to interact with the Medline/PubMed database. The searches 
still required manual input to perform, and just repeated the procedure described in 
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2.2.1 Literature search (for Medline) with the dates adjusted to capture studies with a 
publication date starting from the point of the previous search to the time of the search. 
A copy of the script can be found in the accompanied CD / USB flash drive under the 
chapter 2 folder as “semi_automated_literature_miner.py” (can be opened in notepad 
if the reader does not have a specialised program for viewing script files). The file has 
been modified to include the date range for the last performed search (August 2015 to 
October 2017). This can be found on lines 73-78 of the script.  
 
The script was developed to automatically perform the first stage of screening 
(assessment of relevance for titles and abstracts). Using the list of unique PMIDs 
obtained from the search, the titles and abstracts were downloaded and scanned by the 
script to search for HLA alleles using regular expressions. The script was designed to 
compensate for the changes of the nomenclature system over the years i.e. the script 
understands the current nomenclature and also older formats of the nomenclature (as 
described in Chapter 1.2.5). If the title and/or abstract contained a reference to a named 
HLA allele then the PMID is placed into a new list (in a file called “filtered PMIDs”) 
as potential studies to be considered during the second stage of screening. The script 
also searched for terms relating to ADRs – a list of these terms is found in Table 
2.4Table 2.4 below. Additionally, many studies are present in Medline however, only 
contain the title and lack the abstract. In such cases the script scans the title and places 
any PMIDs for studies which contain references to HLA alleles and ADRs into a 
“forwarded titles” file, and rejected studies lacking an abstract were placed into a 
“rejected titles” list. Studies which contained a title and abstract and that were rejected 
by the script were placed into a “rejected” list. The second stage of screening and the 
data extraction was performed manually in the same manner as described previously. 
This manual review during the second stage of screening was required as the script is 
not able to understand the context of the title/abstract in the same way a human with 
the relevant expertise could achieve. 
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Table 2.4: List of ADR terms that were searched for by the computer script designed 
to perform the semi-automated literature search. 
Search term 
cutaneous adverse drug reaction 
cADR 
skin rash 
mild maculopapular eruption 
MPE 
drug rash with eosinophilia and systemic symptoms 
DRESS 
Stevens-Johnson syndrome 
Stevens-Johnsons syndrome 
SJS 
toxic epidermal necrolysis 
TEN 
severe cutaneous adverse drug reaction 
SCAR 
erythema multiforme major 
EMM 
drug-induced hypersensitivity syndrome 
DIHS 
drug-induced 
erythema exudativum multiforme 
EEM 
exanthema 
hepatotoxicity 
drug induced skin injury 
DISI 
drug induced liver injury 
DILI 
drug induced kidney injury 
DIKI 
immune mediated 
drug toxicity 
adverse drug reaction 
drug reactions 
drug hypersensitivity 
drug eruption 
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2.2.6. Search strategy 
2.2.6.1. MEDLINE 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and 
Ovid MEDLINE(R) <1946 to Present> 
 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     (drug induced or drug-induced).ti,ab. (27831) 
2     (adverse drug reaction$ or adverse reaction$).ti,ab. (30786) 
3     exp Drug Hypersensitivity Syndrome/ or exp Drug Hypersensitivity/ (37955) 
4     hypersensitivit$.ti,ab. (48656) 
5     exp Pharmacogenetics/ (9386) 
6     exp HLA Antigens/ (64053) 
7     (human leukocyte antigen$ or HLA).ti,ab. (81597) 
8     (pharmacogenetic$ or genetic$).ti,ab. (670906) 
9     (Abacavir or Allopurinol or Aminopenicillin or Aspirin or Carbamazepine or 
Clozapine or Co-amoxiclav or Co-trimoxazole or d-Penicillamine or Diclofenac or 
Feprazone or Flucloxacillin or Gold Sodium or Thiomalate or Hydralazine or 
Lapatinib or Levamisole or Lumiracoxib or Methazolamide or Nevirapine or 
Oxcarbazepine or Oxicam or Phenytoin or Sulphamethoxazole or Ticlopidine or 
Trichloroethylene or Ximelagatran).af. (146055) 
10     or/1-4 (133860) 
11     or/5-8 (758141) 
12     10 and 11 (5967) 
13     9 and 12 (772) 
14     (animals not (humans and animals)).sh. (3860455) 
15     13 not 14 (759) 
16     limit 15 to english language (696) 
 
*************************** 
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2.2.6.2. EMBASE 
Database: Embase <1974 to 2014 June 20> 
 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     (drug induced or drug-induced).ti,ab. (35493) 
2     (adverse drug reaction$ or adverse reaction$).ti,ab. (44767) 
3     exp drug hypersensitivity/ (49292) 
4     hypersensitivit$.ti,ab. (59577) 
5     exp pharmacogenetics/ (21416) 
6     exp HLA antigen/ (80485) 
7     (human leukocyte antigen$ or HLA).ti,ab. (103869) 
8     (pharmacogenetic$ or genetic$).ti,ab. (781699) 
9     (Abacavir or Allopurinol or Aminopenicillin or Aspirin or Carbamazepine or 
Clozapine or Co-amoxiclav or Co-trimoxazole or d-Penicillamine or Diclofenac or 
Feprazone or Flucloxacillin or Gold Sodium or Thiomalate or Hydralazine or 
Lapatinib or Levamisole or Lumiracoxib or Methazolamide or Nevirapine or 
Oxcarbazepine or Oxicam or Phenytoin or Sulphamethoxazole or Ticlopidine or 
Trichloroethylene or Ximelagatran).af. (336136) 
10     or/1-4 (174284) 
11     or/5-8 (902379) 
12     10 and 11 (8682) 
13     9 and 12 (1899) 
14     limit 13 to (human and english language) (1596) 
*************************** 
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2.2.6.3. List of keywords used in titles scan (for PubMed entries without abstracts) 
performed by computer script 
 
 cutaneous adverse drug reaction / cADR 
 skin rash 
 mild maculopapular eruption / MPE 
 drug rash with eosinophilia and systemic symptoms / DRESS 
 Stevens-Johnson syndrome / Stevens-Johnsons syndrome / SJS 
 toxic epidermal necrolysis / TEN 
 severe cutaneous adverse drug reaction / SCAR 
 erythema multiforme major / EMM 
 drug-induced hypersensitivity syndrome / DIHS 
 drug-induced 
 drug induced skin injury / DISI 
 drug induced liver injury / DILI 
 drug induced kidney injury / DIKI 
 erythema exudativum multiforme / EEM 
 exanthema 
 hepatotoxicity 
 immune mediated 
 drug toxicity 
 adverse drug reaction 
 drug reactions 
 drug hypersensitivity 
 drug eruption 
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2.3. Results 
2.3.1. Data 
The PRISMA flow diagram (Figure 2.1) shows the number of studies that were 
identified along with the source during each stage of the systematic review and 
literature search performed by the semi-automated literature search computer script. 
From the initial literature search (covering studies published between 2000-August 
2014), a total of 7,978 studies from Medline, HuGE Navigator and EMBASE were 
identified after duplicates were removed. From the 1st stage of screening, where the 
titles and abstracts of the studies were examined, 236 records were deemed to be 
potentially relevant, meaning 7,742 studies were excluded.  The 236 studies brought 
forward for the 2nd stage screening where their full manuscript was analysed to 
determine eligibility for data extraction. Of these, 74 studies were included for the 
systematic review (see thesis bibliography - Studies featured in Systematic Review) 
and the remaining 155 studies were excluded. The follow-up data collection performed 
in August 2015 utilised the semi-automated literature mining computer script. The 
literature search, covering studies published between April 2014 and August 2015, 
yielded 4,969 articles for analysis. The script classified 64 studies as being potentially 
relevant where upon manual analysis of the full manuscripts 11 studies were included. 
Therefore, a total of 85 studies were included for data extraction (74 from the initial 
systematic review and 11 from the semi-automated literature mining script).  
 
All 85 included articles were case-control studies (there were no randomised control 
trials) and reported ADRs with a total of 30 drug therapies (25 of which were named 
drugs), with carbamazepine being the most frequently represented (see Table 2.5). 
There were 1,009 ADR-allele comparisons, of which 190 were associations that 
showed statistical significance, which equates to 73 unique associations 
(compensating for that fact that, for example, there are several independent studies 
that reported that HLA-B*15:02 is associated with carbamazepine hypersensitivity). 
The associations covered 259 distinct alleles (214 high resolution alleles + 45 
serotype/antigens) which represents 7 of the HLA family genes.  
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Figure 2.1: PRISMA flow diagram showing the number of studies being considered 
at each stage of the systematic review along with the additional studies identified 
via the semi-automated literature mining script. 
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Table 2.5: List of drugs that are in current use captured from the systematic review 
and semi-automated literature search as well as the number of studies which 
feature the drug. Some studies investigated more than one drug so there is some 
overlap. 
Drugs Number of studies identified from 
the systematic review featuring drug 
abacavir 8 
allopurinol 10 
amoxicillin-clavulanate 2 
aspirin 3 
bucillamine 1 
carbamazepine 29 
clozapine 2 
co-trimoxazole 1 
dapsone 1 
flucloxacillin 1 
lamotrigine 7 
lapatinib 2 
lumiracoxib 1 
methazolamide  1 
nevirapine 4 
oxcarbazepine 3 
paracetamol 1 
phenobarbital 2 
phenytoin 4 
sulfamethoxazole 2 
sulfasalazine 1 
ticlopidine 1 
valproic acid 1 
1antiepileptic drugs 2 
2antituberculosis drugs 1 
3EGF receptor inhibitors 1 
4NSAID and 'multi-ingredient cold medication' 2 
5oxicam NSAIDs 1 
6statins 1 
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Notes: 
Entries with superscript numbers represent studies where the statistics relating to 
the study participants were not separated by drug. Below are the list of the drugs 
that were featured in the studies. 
1 - Carbamazepine, lamotrigine, oxcarbazepine, phenytoin, phenobarbital, 
topiramate and valproate. 
2 - Combination regimen including isoniazid, rifampin, ethambutol, and 
pyrazinamide. 
3 - cetuximab, panitumumab, erlotinib and gefitinib 
4 - acetaminophen, analgin, aspirin, brufen, diclofenac, diclofenac & paracetamol, 
dipyrone, dipyrone & diclofenac, fenton (cold medicine), ibuprofen, mefenamic 
acid, nimesimide, nimesulide, paracetamol, piroxicam, tylenol (cold medicine), cold 
remedies (unknown), medicine for cold (NSAID), medicine for cold (detail unknown) 
and NSAIDs (drug name unknown) 
5 - Not specified beyond “oxicam-NSAIDs” 
6 - Not specified beyond statins. 
 
2.4. Discussion 
2.4.1. Analysis of data 
The data collected from the systematic review suggests that a greater number of alleles 
that have been associated with ADRs are likely to be found in people of Asian descent 
(discussed in greater detail in Chapter 4). One potential explanation is the possibility 
of case-control study bias. Approximately 65% (56 out of 85) of the included studies 
were conducted in Asia and 20% (17 of 85) were conducted in Europe. Therefore, it 
may be possible that the high number of observed ADR-allele associations found in 
patients of Asian origin are likely to be a result of this case-control study bias. 
Furthermore, it is also worth noting that the drugs carbamazepine, lamotrigine, 
allopurinol, oxcarbazepine and phenytoin are all used in the treatment of epilepsy, 
additionally, phenytoin, carbamazepine and oxcarbazepine are antiepileptic drugs with 
aromatic structures that have ADRs associated with HLA-B*15:02. It is likely a 
similar biochemical mechanism could be involved with these ADRs. These similar 
drugs with similar mechanisms could be artificially increasing the count in the results, 
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making Asians seem more susceptible to ADRs compared to other population groups. 
This may be further compounded by the relative lack of data available from the other 
regions, particularly, South America (1 out of 85) and Africa (2 out of 85) which 
further perpetuates the impression that Asians are more susceptible to ADRs. 
 
Another potential reason could be that the drugs were tested in a European population 
during the drug’s clinical trials. Many of the pharmaceutical companies are based in 
Europe or North America where the population (and therefore the trial participants) is 
largely of European descent. It is likely that the drug clinical trials were conducted in 
the host nations, meaning that any ADRs (although rare) that were observed during 
the trials or shortly after release, during a period of active drug-safety vigilance, may 
have led to drug withdrawal. However, this hypothesis is difficult to verify as 
information regarding the location of the original drug trials is difficult to acquire, 
particularly for drugs that have been on the market for several years/decades.  
 
Another issue faced with the data collected from this systematic review was that there 
was inconsistency in the data reporting. Poor replication with some alleles that are 
reported to be associated in some studies may be reported as not-significant in others. 
Typically, this was due to these studies using relatively small patient-control cohorts 
so information regarding individuals had a relatively larger impact on the final results. 
This issue is very difficult to resolve as ADRs are very rare, therefore the studies were 
constrained by the number of patients available to them, thereby limiting the statistical 
power of the study. The file generated in Chapter 6 highlights the rarity of ADRs by 
listing examples of ADR prevalence for patients receiving each of the included drugs 
(see USB/CD media “chapter_6_decision_support_table.xlsx”). 
 
It was also noted during the analysis of the literature that in terms of study designs 
(see Table 2.2), retrospective studies made up the majority of the studies collected. 
These retrospective case-control study designs are suitable for rare outcomes (as is the 
case for immune-mediated ADRs) as the cohort sizes are usually smaller compared to 
prospective cohort studies. However, the collection of data for retrospective studies 
are observational (occurs afterwards by examining medical records in the case of 
immune-mediated ADRs) meaning that it can sometimes be difficult to go back and 
collect additional data. This limitation introduces issues with data quality. However, 
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retrospective studies are often the only option as prospective cohort studies require 
recruitment of large numbers of patients in order to determine rare ADRs (an incidence 
rate of 1 in 1,000 to 1 in 10,000 individuals exposed to culprit medications experience 
ADRs) and are often prohibitively expensive to carry out. This is a likely explanation 
as to why a large proportion of the studies brought forward in the literature review 
were of a retrospective design. 
 
2.4.2. Script validation 
To assess the performance of the script, the resultant lists (“filtered PMIDs”, 
“forwarded titles” and “rejected”) were analysed. The first two of the analyses were 
performed using two previously conducted literature reviews. [98, 114] In the first 
analysis, the studies in each of these reviews were analysed to see if they were 
determined to be relevant by the script. One of the included studies in each of the 
reviews was not part of the validation test as it featured unpublished data (the 
reviewers had contacted the original authors of the studies to obtain the data). In the 
first review (Yip et al., 2012), all but one of the 21 studies contained an HLA reference 
in the title/abstract. The PMIDs of these studies were therefore found in the “filtered 
PMIDs” list. [98] The remaining paper did not feature an abstract but did contain a key-
phrase and so was placed into the “forwarded titles” list. With regards to the other 
review (Cornejo Castro, 2014), 9 of the 12 included studies were found in the “filtered 
PMIDs” list and 1 paper was found in the “forwarded titles” file (without abstract but 
contained a reference to an HLA allele in the title). [114] The remaining two files were 
rejected by the script. Upon further analysis of the full articles, these two papers would 
have been rejected at the 2nd stage screening since the HLA alleles were only typed to 
serotype level resolution (often referred to as 2 digit resolution). This would be 
considered too low (by the criteria of the protocol) and would not be included for this 
review. 
 
For the second validation test, a sample of 200 PMIDs from the “rejected” list were 
analysed manually to determine if they were indeed studies that would be rejected 
under the conditions of this literature review protocol by the reviewer (i.e. true 
negatives). Upon manual review, all 200 studies were determined to be those that 
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would not be included in this review and therefore, were correctly placed into the 
“rejected” list. 
 
After the systematic review was performed, a third validation test was conducted using 
the 74 studies that were included in the systematic review. These 74 studies were used 
as a reference to compare how the semi-automated script compared to the manually 
performed review – this assumes that the manually performed systematic review was 
free from human error, although this is the current gold standard when performing 
systematic reviews. Only the 74 original studies were included for the comparison as 
the additional 11 studies were identified using the script so performing the analysis 
with the full list of the 85 studies (specifically, with the additional 11 articles) would 
be redundant. Of the 74 studies found manually, 61 were placed into the semi-
automated script’s “filtered PMIDs” list, 6 were placed into the “forwarded titles” list, 
4 were found in the “rejected titles” list and the remaining 3 studies were rejected by 
the script. This means that 91% (67 out of 74) of the studies were determined to be 
potentially relevant by both the manual method and by the script. This assumes that 
the same 67 studies would be included upon manual review of the “filtered PMIDs” 
and “forwarded titles” lists. 
 
Of the 4 studies that the script classified as “rejected titles” (i.e. the script could only 
scan the title of the studies), two studies investigated aspirin-intolerant asthma which 
was not part of the list of ADRs that were being scanned for by the script (refer back 
to Table 2.4Table 2.4). Adjusting the script to include aspirin-intolerant asthma (AIA) 
and the related aspirin-induced urticaria (AIU) would move one of the studies into the 
“forwarded titles” list as the script requires both a reference to an HLA allele (in this 
case the title includes “DPB1*0301”) and an ADR phenotype (that the script 
recognises). [26] The second study would still be rejected as the title does not include a 
reference to the associated HLA allele. [115] Similarly, the other two studies [116, 117]that 
were rejected by the script (through a title only scan) also did not contain references 
to HLA alleles. [116, 117] Adjusting the script to compensate for this would greatly 
increase the number of studies that the script would place into the “forwarded titles” 
list and would require the user to manually review these studies during the 2nd stage 
manual review. This would offer little benefit compared to performing an entirely 
manual 1st stage screening of the literature. 
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The three remaining studies, which include a Medline/PubMed entry title and an 
abstract that the script can scan and that were rejected by the script, also faced similar 
issues. [34, 118, 119] The first of these studies (Mammen et al., 2012) investigated anti-
hydroxymethylglutaryl-coenzyme A reductase induced myopathy that was associated 
with HLA-DRB1*11:01. [119] The script did not include “myopathy” as a recognised 
ADR phenotype (Table 2.4) and so was rejected (there were no other references to a 
generalised term for ADRs – e.g. “adverse drug reaction” or “ADR” etc.), this can be 
compensated for by including myopathy in the script. The other 2 studies did not refer 
to the HLA allele using a standardised reference to the HLA nomenclature due to the 
way they handled the asterisk symbol. Amstutz et al., 2013 [34] omitted the asterisk 
and simply used a space (“HLA-A 31:01”) whilst Kindmark et al., 2008 [118] placed 
the asterisk between brackets, such as “DRB1(*)07”, although this study would still 
have been rejected as the title and abstract implies that the study only typed the patients 
and controls’ HLA-DRB1 gene to antigen level resolution (2-digits). Incidentally, 
during the manual systematic review, one of the reviewers (GG) initially rejected this 
study during the first stage review (analysis of the title and abstract) for the lack of 
allele level resolution with regards to patient/control typing. The second reviewer 
(AA) was already familiar with this study and recommended reassessment, the first 
reviewer evaluated the full manuscript and agreed for the study to be included as a 
small part of the investigation did involve typing the patients to allelic level (4-digit) 
resolution. Therefore it is worth recognising that human error is also an issue during 
the review process. 
 
2.4.3. Discussion of script validation 
Overall, the manually performed first stage systematic review took approximately four 
weeks to assess the titles and abstracts of 7,978 to identify 236 for analysis in the 2nd 
stage of the review. In comparison, there were 459 studies in the “filtered PMIDs” list 
and 344 studies in the “forwarded titles” list. This is a total of 803 studies which the 
script identified as potentially relevant and took approximately 1 hour to compile 
against the same 7,978 titles and abstracts. Potentially, 93% or 69 out of 74 studies 
(67 studies that were included by the script and an additional 2 studies that were 
rejected by the script but could be compensated for) can be identified using this script. 
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Whilst not perfect, it does offer >90% accuracy in identifying the relevant studies in a 
fraction of time allowing the user to conduct a literature review comparatively quicker 
by automating the first stage of the literature screening, and would be useful in 
scenarios where the time is a more crucial factor than absolute accuracy. 
 
The accuracy is greatly improved when used to investigate individual ADRs, the 
ability of the script to correctly identify all the studies that were part of literature 
reviews focusing on individual drugs – for the first validation test: Yip et al., 2012 and 
Cornejo Castro, 2014 focused on carbamazepine and nevirapine hypersensitivity 
reactions respectively. In these cases the accuracy was greater as ADRs involving 
these drugs are fairly well studied so the script could be programmed with all the 
alternative names for the ADRs allowing for a more comprehensive search. This 
means that if the user knows that they are looking for then it can be argued that the 
script functions very well in its task. When the script was utilised for a generalised 
search of all ADRs, the script could not take into account ADRs that the user is 
unaware of (as was the case with anti-hydroxymethylglutaryl-coenzyme A reductase 
induced myopathy). This remains the main limiting factor for using any keyword 
based automated search. 
 
It would therefore be recommended that the automated script be executed regularly 
(e.g. every 1-2 years) and after a few cycles (suggested as every 5 years) that a manual 
review be performed in parallel and therefore allows any studies missed by the semi-
automated script a second chance to be picked up for potential inclusion and also allow 
for additional code flaws to be picked up and amended into the code.  
 
2.4.4. Effectiveness of review 
Interpretation of the data collected from the systematic review largely follows what is 
already known in the literature a few high-profile examples include: HLA-B*57:01 
and abacavir hypersensitivity; HLA-A*31:01 and HLA-B*15:02 for carbamazepine 
hypersensitivity etc. However, there is some loss of granularity in the information, 
namely with regards to allelic linkage and haplotypes. For example, the case of 
carbamazepine hypersensitivity, 29 studies were identified that investigated ADRs in 
association with this drug and from these, 22 HLA alleles were reported to be 
 57 
 
significantly associated (i.e. a p-value < 0.05) when statistically analysed. However, 
the HLA-A*31:01 and HLA-B*15:02 alleles were reported in 11 and 19 studies 
respectively (with some overlap) whereas the remaining alleles were reported to be 
significant in 3 or fewer studies. Many of these 20 alleles, when investigated, were 
found to be in linkage with either HLA-A*31:01 and HLA-B*15:02 indicating that 
these other 20 alleles are likely found to be statistically significant due to their co-
occurring relationship with HLA-A*31:01 or HLA-B*15:02. For carbamazepine, this 
information was readily provided in the studies reporting these alleles and the 
contextual information was lost in this review when collecting the raw data from these 
studies. Therefore, careful interpretation of the collected data is required. 
 
It is very likely that this review was able to identify the majority of available data 
given that all of the studies present in two previous literature reviews (regarding 
carbamazepine and nevirapine) were identified in this review. The high concordance 
with the two prior literature reviews provides a reasonable degree of confidence that 
all of the relevant studies were identified which in turn provides confidence that a 
suitable amount of data was collected to allow the review question to be adequately 
answered. Therefore, there is reasonable assurance to further utilise the data in other 
aspects, such as Chapter 3 – “The HLA-ADR web-database: a centralised location to 
store and provide data relating to immune-mediated adverse drug reactions”. 
 
2.4.5. Potential improvements 
A key area for potential improvement is the ability for the semi-automated literature 
mining script to overcome the limitation of keyword searches that limit its ability to 
pick up associations with previously unreported drugs and clinical phenotypes. One 
method would be to review the titles and abstracts of interest (the studies that were 
included in the literature review) and analyse the language, beyond the specific 
references to drugs, HLA alleles and ADR phenotypes used within the text to 
determine if there is a common pattern with the included studies that could be used as 
a marker to weight the title/abstract it in favour of inclusion. This methodology has 
the potential to allow the identification of published literature which features HLA 
mediated ADRs where the user has not entered specific search terms thereby possibly 
overcoming the limitations of keyword based searches. 
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Chapter 3. The HLA-ADR web-database: a centralised 
location to store and provide data relating to immune-
mediated adverse drug reactions 
 
3.1. Introduction 
The previous chapter describes that the field of immune mediated ADRs is growing 
rapidly with new data released at frequent intervals. It also shows that due to the high 
growth rate of the field, if an investigation regarding ADRs needs to be conducted, 
then the researcher/research group would need to perform an in-depth literature search 
or systematic review for each study. This process is highly inefficient if the 
investigations are exploring similar questions with significant overlap, as multiple 
groups could independently conduct the same search. It is therefore important that a 
centralised database be constructed where users can view relevant studies from which 
to initiate their investigation, and enabling dynamic linkage to other accessible 
information about drugs and immune genes/alleles. 
 
This chapter describes the creation of such a database built upon the information 
collected in Chapter 2 regarding ADRs that have been associated with the carriage of 
particular HLA alleles. As this database is built using HLA-ADR data and that the 
website that overlays the database utilises tools from the Allele Frequency Net 
Database (AFND), http://www.allelefrequencies.net/ it was decided to construct the 
web database as a module within AFND. [120, 121]  
 
3.1.1. AFND Website 
The Allele Frequency Net Database (AFND) was initially developed to store allele, 
haplotype and genotype frequencies of several immune-related genes including HLA, 
Killer-cell immunoglobulin-like receptors (KIR), cytokines and Human MHC class I 
chain related (MIC) genes from diverse worldwide populations although the main 
focus is on genes.  [120, 121] The population data sets are comprised of healthy, unrelated 
individuals (for example, bone marrow registries). As of March 2017, there are HLA 
allele, haplotype and genotype data from 1,086 populations present in the AFND 
representing 10,447,550 individuals. The website is built upon a Microsoft SQL 
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Server with active server pages (ASP classic) delivering the webpages, the various 
database and web development languages are described in Chapter 0. New data from 
researchers can be added via the web-based framework that provides an online 
submission system which is then manually curated by a process of data validation to 
enforce strict accuracy with the results.  
 
3.2. Design of the HLA-ADR database 
3.2.1. Database implementation 
Since the aim of the website is to create a centralised location where the data collected 
from the systematic review can be retrieved, a web database was created. Firstly, a 
relational database was constructed in order to store the information. Although many 
relational database management systems (RDBMS) are available (as described in 
Chapter 1.4.3.1), the HLA-ADR database utilises Microsoft SQL Server as its 
RDBMS. SQL Server is the system that was implemented with the main AFND 
website and therefore, chosen in order to ease integration into the AFND. This setup 
also allows for future interaction/crossover and joint maintenance with the main 
database underlying AFND.  
 
3.2.2. Database schema 
The schema for HLA-ADR database is shown in Figure 3.1 below which shows the 
individual tables as boxes where the connecting lines demonstrate the relationships 
that are enforced by the RDBMS. The database tables have been normalised following 
the guidelines of normalisation as laid out in section 0. However, this was not done to 
fully conform to 3NF as there would be diminished returns with regards to the 
potential benefits that normalising the database would bring. For example, referring to 
Figure 3.1 the HLA-ADR database table “tbl_association_data”, the information for 
the ADR frequency in patients (stored in the column “patient_adr_frequency”), this 
information is dependent on the key (1NF) and the whole key (2NF) but it is not 
dependent on the other fields for its existence, e.g. the type of statistical correction 
only applies to the p-value, which therefore violates the requirements for 3NF. 
However, the information only retains contextual meaning along with the other 
information in the table therefore, it still makes sense to keep these information 
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together as although it is violating the strict sense of 3NF, it is in contextual 3NF. If 
the table was decomposed to separate these fields so that it does conform to the strict 
definition of 3NF, this would require additionally complex joins with the query. It was 
therefore decided that contextual 3NF would be the optimal structure for this database 
schema. The rest of the database follows this contextual 3NF principle 
 
 This contextual 3NF can be seen in Figure 3.1; where each box represents a table 
within the database with the table name in the first row. The first column displays the 
column names for the data contained in the table with the second column presenting 
the data type e.g. “int” refers to integer values; “nvarchar(45)” means that the field 
contains text (character limit within the brackets); “float” refers to floating point 
number (non-integer). Connecting lines represent relationships. In this schema, all 
relationships are one-to-many (infinity symbol) to implement database normalisation 
as described in 1.4.2 Database table normalisation. For example, for the relationship 
between tbl_drugs and tbl_study_details means that one record entry within the 
tbl_drugs table can be referenced by many entries within the tbl_study_details table. 
 
3.2.3. Data curation 
The initial data set was collected in the systematic review as described in Chapter 2. 
However, the database itself is designed to accept new data as it is received and will 
expand as more HLA-ADR association studies are published. Updates to the database 
can be performed via Python scripts which were developed with the primary aim to 
speed up and automate the process of adding additional and new data into the database. 
[104] Additionally, very little training or programming knowledge is actually required 
to run these finalised scripts and therefore, the scripts can be run to update the database 
by curators without knowledge of coding. 
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Figure 3.1: Database Schema for the HLA-ADR database. 
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The update scripts work by reading in the data from the spreadsheet document that is 
used to store and record the data extracted from the systematic review as described in 
Chapter 2.2.4  and converts the information to generate the SQL statements that are 
sent to the server hosting the database. These SQL statements provide instructions to 
add the new data entries. The scripts can be found in the accompanying USB/CD 
media for this thesis in the Chapter 3 folder. The first file, “HLA-
ADR_create_source_files.py” reformats the data so that the spreadsheet document is 
converted into a series of text files that is in the same format that as the database 
schema. The second script “HLA-ADR_update_database.py” will read these text files 
and insert the information into the database. 
 
 
3.2.4. Website organisation 
Webpages were designed to allow users to easily access and visualise the HLA-ADR 
data in a user-friendly manner. These webpages were integrated into the main AFND 
site with the HLA-ADR database directly available with the URL: 
http://www.allelefrequencies.net/hla-adr which links to the HLA-ADR home page. 
All of the webpages are generated using Microsoft’s classic Active Server Pages 
(ASP) with VBScript (based on Visual Basic) as the underlying language, the same as 
the main AFND webserver. The webserver is able to serve out HyperText Markup 
Language (HTML) and Cascading Style Sheets (CSS) thereby allowing the retrieved 
data to be viewed in most common web browsers. 
 
3.3. Results 
3.3.1.1. Homepage 
The home page acts as a gateway for the HLA-ADR website and allows users to access 
the other pages. The homepage can be accessed using the URL: 
http://www.allelefrequencies.net/hla-adr/default.asp (screenshot of the webpage is 
shown below in Figure 3.2). Users are presented with a brief introduction describing 
the purpose of the HLA-ADR database as well as hyperlinks to the Query page, 
Authors submission page, ADR report page and the bibliography page which are 
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detailed below. The users are also presented with basic information pertaining to the 
underlying data, including the unique number of: a) HLA alleles in the database, b) 
drugs which have been investigated for ADRs, c) the total number of association 
records (all reported alleles, both significant and non-significant associations across 
all studies) and d) the total number of studies from which the database is built upon. 
The information pertaining to this underlying data is acquired by directly querying the 
database meaning that the information is always kept up to date. 
 
 
Figure 3.2: Screenshot showing the HLA-ADR website’s homepage.  
Here the users are presenting with a brief introduction for the HLA-ADR database, 
links to the other webpages that are a part of HLA-ADR and also some information 
pertaining to the data stored in the underlying database. 
 
3.3.1.2. Query page 
The query page is the primary method by which users can access the information 
stored in the HLA-ADR database. The user is able to choose and limit the type of data 
they receive from the search by using the dropdown filters as shown in Figure 3.3 
below. These dropdown filters are divided into three sets: in the first set, the user has 
the option to choose a HLA gene, a specific allele or from what the site refers to as 
“non-standard” alleles (e.g. serotype or antigens). These dropdown options within the 
first set are mutually exclusive and therefore only one of these options can be chosen. 
If a user selects from two or more options, then an error message returns indicating 
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that there is a conflict with the chosen options and instructs the user to select a 
maximum of one option. However, options from the first set are not mutually exclusive 
with the other sets and can be selected in combination with options from the second 
and third sets.  
 
The second set of options provide the user to select additional parameters including 
the specific drug investigated in the study, patient-control cohort ethnicity, strength of 
the association (based on the p-value), the country/geographic region where the study 
was conducted and the condition for which the patients were being treated (e.g. 
epilepsy). Unlike with the first set, the options within the second set are not mutually 
exclusive and can be used in any combination with each other (except when the 
country and geographic region options conflict). The third set only contains one 
dropdown bar where the user may select the order in which the results are displayed, 
using one of 3 options: the user can specify that the results from the same study, drug 
or allele are grouped together when the website returns the results of the query. Only 
one of these three options can be selected, with the website defaulting to “study”. 
 
In instances where potential conflicts could occur, e.g. selecting for the “HLA-A” gene 
but the “HLA-B*15:02” allele or contradictory country and geographic region options, 
an error is provided which states the nature of the conflict, e.g. “Error, there is a 
conflict: You have selected values for country and geographic region which do not 
make sense. Please use only one of these parameters”. This provides the user with a 
meaningful error message to help them formulate a query that can be executed. There 
are exceptions to this inbuilt error check feature however, there is no inbuilt check to 
prevent contradictory errors between the options selected for the drug and patient 
disease. This was intentionally left as the relationship between drug and disease can 
potentially be a many-to-many relationship i.e. one drug can be used to treat multiple 
diseases and additionally, one disease can be treated by multiple drugs (e.g. 
antiepileptic drugs). This many-to-many relationship limits the benefit for enforcing a 
check for contradictions and therefore, it has been left for the users to understand and 
deal with any such potential conflicts. 
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Figure 3.3: Screenshot showing the menu options on the HLA-ADR query page.  
The options allow the user to select association records for particular genes/alleles, drugs, patient ethnicity, level of significance (p-value 
thresholds) a particular patient disease, the expressed ADR phenotype and/or the country or geographic region (continent) where the study 
was conducted. The user can also sort the results to group together results which are related by the reporting study, the drug inducing the ADR 
or grouping alleles together
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Once the search options are chosen, the webserver utilises these options and generates 
the SQL query needed to retrieve the requested data from the HLA-ADR database, 
and then executes the query. The data that is retrieved from the query search is 
processed by the webserver to display the results in the table format that the webpage 
is designed to display, see example query search in Figure 3.4 which shows an 
example of a search using “abacavir” as the only criteria with all other options set to 
default (i.e. no specifications on HLA gene/allele, ethnicity, p-value thresholds, 
patient disease, adverse reaction phenotype or location of study). In the example 
search shown in Figure 3.4, the HLA-ADR database returns nine results which have 
been sourced from eight studies, all the studies have reported a HLA-B*57:01 
association with one of these studies (Rauch et al., 2008) also reporting HLA-
DRB1*07:01 to be statistically significant however, the investigation also reported 
that HLA-DRB1*07:01 was in high linkage with HLA-B*57:01. The returned results 
from the query shows information pertaining to each of the records as described in 
Table 3.1.  
 
Not all of the information for the record stored in the database is displayed on the 
results of the query page. Displaying all of the record data would result in the user 
having to scroll along the horizontal axis in order to see all of the information. This 
was deemed to be a sub-optimal visual design, so the More Details page was created 
(see section 3.3.1.3 More Details page) where users can view the entire record, with 
only part of the entire record being displayed on the query page. 
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Figure 3.4: Screenshot of an example query performed on the HLA-ADR website query page. In this example, the only option chosen was to 
search for data pertaining to the drug abacavir. For all other options, the default settings were kept which does not apply any other 
restrictions, e.g. data for all gene/allele associations are displayed, no country restrictions are applied, non-significant and significant 
associations are displayed etc. The only subset of data that are omitted are those pertaining to non-standard alleles (i.e. serotype/antigens). 
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Table 3.1: Description of the information returned when a user performs a search 
using the HLA-ADR database’s query page.   
The description column provides information about the types of data that the query 
page shows. 
Record 
information 
Description 
PubMed Link Hyperlink that directs to the reporting article’s PubMed entry 
Drug Drug that is reported in the association as well as link to the 
HLA-ADR database’s report page (see section 3.3.1.4). 
Allele The allele that has been tested as part of the association, can 
include both statistically significant and non-significant 
associations. Also contains a hyperlink to the main Allele 
Frequencies Net Database’s allele frequency search detailing 
the frequencies for that particular allele in various populations. 
Cohort Ethnicity Information about the ethnicity makeup for the study’s cohort. 
p-value (Pat1 and 
ExpCtrl2) 
The p-value for the association as reported by the investigating 
study (comparing patients against the drug exposed controls) 
p-value (Pat1 and 
Pop3) 
The p-value for the association as reported by the investigating 
study (comparing the patients against the population controls) 
Pat1 allele or 
carrier frequency 
The proportion of patients carrying the tested allele (n) or 
proportion of tested alleles in the patient group against total 
number of alleles (2n) 
ExpCtrl2 allele or 
carrier frequency 
The proportion of drug exposed controls carrying the tested 
allele (n) or proportion of tested alleles in the drug exposed 
control group against total number of alleles (2n) 
Pop3 allele or 
carrier frequency 
The proportion of population controls carrying the tested allele 
(n) or proportion of tested alleles in the population control 
group against total number of alleles (2n) 
More Details Hyperlink to view the complete information for that particular 
record (see section 3.3.1.3) 
Allele distribution Hyperlink to view the Allele Frequencies Net Database’s allele 
frequency distribution page relating to the allele associated 
with the record. 
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3.3.1.3. More Details page 
The More Details page displays the complete information that has been recorded with 
the association into the database. Here, the record’s demographic data (the country and 
geographic region of where the study was conducted and the patient cohort’s ethnicity 
makeup), information about the sample including the drug, the phenotype that the 
patients were being treated for, the allele that was analysed as part of this record, the 
ADR phenotype, the proportion of carriers/alleles (for the patients, drug exposed 
controls and population controls) and the study calculated p-values and odds ratios can 
be seen. The page also displays information about the statistics performed by the study 
investigators such as the type of test performed, whether the statistical calculations 
were performed using the number of carriers (n) or number of alleles (2n), whether 
any statistical corrections was applied as well as any issues/notes that are worth 
highlighting to the user. The page also provides a hyperlink to the PubMed entry for 
the original article that reported the association. For an example, see Figure 3.5. 
 
 
Figure 3.5: Example screenshot of the More Details page of the HLA-ADR website. 
The record displayed in this figure is associated with the first entry that was shown 
in Figure 3.4 (an association between HLA-B*57:01 and abacavir-induced 
hypersensitivity syndrome). [105] 
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3.3.1.4. ADR Report page 
The HLA-ADR database also provides an ADR report page which provides a summary 
of all significant associations with a particular drug as well as additional external tools 
from which users can conduct further research. The user selects a particular drug and 
the webpage returns all HLA-ADR records which are statistically significant for the 
selected drug. The user has the option to include additional filters where they may 
select a particular significance threshold (the default is a p-value of ≤ 0.05; with ≤ 0.01 
and ≤ 0.001 also available) and/or limit the results based on the patient-control cohort’s 
ethnic background. The returned summary of an example search, for the drug abacavir 
is shown in Figure 3.6. The returned summary table of the results page provides the 
user with a link to the original reporting article’s PubMed entry, the allele(s) that have 
been associated with the ADR, a risk/protective colour designation, the odds ratios and 
p-values as well as a link to the More Details page where users can view the entire 
record. The reports page also provides additional information gathered from external 
resources which may also be of benefit for the user. The additional information is 
provided on the reports page in HTML frame objects as shown in the figures described 
below. The frame objects allow the external data to be shown without the user having 
to manually search and refer to the external providers. Firstly, for each allele listed in 
the summary table at the top of the page, a worldwide map showing the allele 
frequency distribution is displayed (see Figure 3.7) which is generated by querying the 
allele from the AFND Allele Frequency Distribution page and the results are returned 
in an embedded window within the reports page. 
 
Secondly, the reports page will display HLA haplotypes/alleles that have been shown 
to co-occur with each of the alleles listed in the summary table (see Figure 3.8). The 
haplotype searches are performed using the main AFND website where HLA-ADR 
performs the search with each of the unique alleles identified in the summary section 
at the top of the reports page. A window for each of the haplotype searches is then 
provided in the reports page so that users may see if the allele has a high co-occurrence 
with another allele that was in the reports page summary. The summary table at the 
top of the page can list out associations with alleles that are found in haplotypes. This 
feature allows users to determine any co-occurring alleles. 
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Figure 3.6: Screenshot of an example search performed on the HLA-ADR reports page.  
In this example, aspirin has been selected with the p-value and patient ethnicity filters kept to their default (p ≤ 0.05 and all ethnicities 
respectively). 
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Figure 3.7: Screenshot of the HLA-ADR reports page’s Allele Frequency Distribution map.  
This is generated by querying each allele on the main AFND Allele Frequency Distribution tool and returning a window of the results into the 
reports page. Each circle on the map represents a population which is then coloured based on the frequency of the allele relative to the 
population represented by the circle. 
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Figure 3.8: Screenshot of the HLA-ADR reports page’s Haplotype frequency search section.  
This example screenshot continues on from Figure 3.6 and Figure 3.7 with a search for aspirin. The screenshot shows the returned AFND 
haplotype search for HLA-DPB1*03:01
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In addition to the resources from the main AFND website, the HLA-ADR reports page 
also provided links to other tools that are provided by the EMBL-EBI’s IMGT/HLA 
resource. [78] The first of these IMGT/HLA tools are multiple sequence alignments 
(MSA), see Figure 3.9, which are performed using the alleles that are featured in the 
summary table at the top of the page. The alleles are grouped by each gene/loci where 
the allele(s) that appear in the summary table along with the 10 most common alleles 
for that loci are passed to the IMGT/HLA MSA. The 10 most common alleles for the 
gene were determined by reviewing the allele frequencies for each gene using the 
Allele Frequencies Net Database and are not specific to a certain population (i.e. this 
list of 10 alleles is based on worldwide frequencies). 
 
3.3.1.5. Author’s submission page 
A systematic review is an effective method for capturing studies which are relevant to 
a task, however, it may not capture all available studies due to limitations such as only 
studies published up to the moment that the systematic review was conducted and are 
available in the chosen publications database such as MEDLINE and EMBASE can 
be analysed. Whilst the HLA-ADR website intends to carryout periodic systematic 
reviews every six months, users of the website can request certain papers to be 
included manually. To achieve this, an authors’ submission page was developed. 
 
The author’s submission page provides users with a tutorial .pdf document to 
download which provides instructions to fill in the spreadsheet document that is also 
available to download on the author’s submission page. The layout of the spreadsheet 
document is similar to spreadsheet that is used to collect data (as described in Chapter 
2.2.4) which therefore makes the transfer of new data from the author’s submission 
spreadsheet relatively straightforward as the data on the author submitted document 
can be copied over to the master document where it can then be entered into the 
database. Once the author fills the spreadsheet form with their data, they can then 
upload the document on the author’s submission page where the HLA-ADR 
administrators are notified of the submission by an automated email. 
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Figure 3.9: Screenshot of the HLA-ADR reports page’s multiple sequence alignment (MSA) section. 
This example screenshot continues on from Figure 3.6, Figure 3.7 and Figure 3.8 with a search for aspirin. The page shows an MSA for each loci 
of the alleles that were in the summary table (as featured in Figure 3.6). A button is provided which links to IMGT/HLA MSA page where the 
MSA uses the alleles identified in the summary table and from the list of the 10 most common alleles for that gene
  
 
7
6 
 
 
Figure 3.10: Screenshot of the first three entries of the HLA-ADR bibliography page. 
From left to right, the table displays a line number so that the users can see the total number of entries in the database at a glance; the PMID 
number which acts as a link so the user can be directed to the study’s abstract hosted on PubMed; the year; title; the publishing journal and 
the volume number for the study. 
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3.3.1.6. Bibliography page 
The HLA-ADR website also provides users with a table displaying the studies from 
which the HLA-ADR database has collected its data from (see Figure 3.10 above). For 
each study the user is able to view the line number, the PubMed ID (PMID) which 
also provides a hyperlink to the abstract page for the study hosted on the NCBI 
PubMed page as well as the year of publication, title, publishing journal and journal 
volume associated with the publication of the study.  
 
3.4. Discussion 
The ADR reports page aims to provide researchers with information from multiple, 
internal and external resources in one report thereby reducing the time taken to conduct 
investigations. The risk/protective colour designation in the table at the top of the 
report is provided as some drug-allele associations that are statistically significant may 
actually show protective markers where more of the control group carry the allele as 
compared to the patient group. From a clinical perspective, the apparent protective 
biomarkers need to be treated differently from risk markers since clinicians can 
administer the drug to carriers of the apparent protective alleles similarly to patients 
carrying alleles that are statistically not-significant for ADR associations. Therefore, 
this distinction between risk and apparent protective alleles is valuable information 
with regards to the report. 
 
Certain trends in the results as reported in Chapter 2.4.1, the presented hypothesis of 
reporting bias - the geographic distributions of investigations reporting ADRs, led to 
the inclusion of the maps displaying the allele frequency distributions so that users 
could investigate if a reported allele was specific to a certain region(s) of the world. 
This was aimed to address such conjecture and is investigated in 0. 
 
In addition to these maps, the haplotypes frequency search frame objects were 
specifically included to allow users to investigate instances where studies report 
multiple alleles which form haplotypes as significant associations although this is 
discussed in detail in Chapter 4. As a demonstration of concept, an example search is 
provided here to illustrate that two alleles, HLA-B*57:01 and HLA-DRB1*07:01, 
reported by Daly et al. as significant, however the study reports that the two alleles 
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are in linkage whereby the study also demonstrated that HLA-DRB1*07:01 was not 
independent of the linkage with HLA-B*57:01. [24] The HLA-ADR reports page’s 
Haplotype Frequency search also supports the co-occurrence of these two alleles (see 
Table 3.2). This haplotype search was conducted using the AFND haplotype 
frequency search tool, after a filter is applied to only display results where the 
population sample size is greater than 1,000. Ten out of the top 22 hits (ordered by 
percentage frequency) were of haplotypes which contained both alleles, although none 
of the hits exclusively contained just HLA-B*57:01 and HLA-DRB1*07:01 thereby 
making an exact quantification difficult. It is worth noting that the study by Daly et al. 
[24] reports HLA-B*57:01 as the primary allele of interest to bring forward for further 
investigation. The co-occurrence of alleles to be significantly associated with certain 
ADRs is reported in the literature (such as Daly et al.) [24] however, it is of potential 
interest to see if this occurs across many independent studies, this is further 
investigated in Chapter 4. 
 
The tools that have been built into the HLA-ADR are in themselves useful and 
powerful to enable users to conduct additional research into immune-mediated ADRs, 
however the practical utility for these tools is only of value as long as the data is kept 
up to date. As mentioned above, the author submission page was developed to assist 
this process. Researchers can submit their own data, both published and unpublished 
or contact the AFND/HLA-ADR administrators to request data be included. It was 
decided that unpublished data would be useful as negative results (i.e. an investigation 
that did not find a significant association) would have greater difficulty in acquiring 
publication of their results, but the data itself is of great importance as it can be made 
available for meta-analysis or possibly refute the findings of other studies. The HLA-
ADR website and the associated publication (see section regarding publications before 
the thesis abstract) specifically mention the intention to capture unpublished data. The 
author’s submission page also allows for researchers who feel that their study was not 
included in the database to be incorporated, this was done specifically to address 
scenarios where the initial data collection conducted in Chapter 2 was incomplete or 
not thorough enough to capture all relevant studies. This situation did in fact arise 
during the HLA-ADR’s associated publication as the reviewers indicated specific 
studies that were not included. The mentioned studies were subsequently examined 
and were included into the HLA-ADR database. 
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Table 3.2: Listing the top 22 haplotypes when HLA-B*57:01 is selected in the AFND Haplotype frequency search tool.  
Only population sample size > 1,000 is shown. The two alleles have been highlighted in bold and underlined. 
Line Haplotype Population 
Frequency 
(%) 
Sample 
Size 
1   A*01:01-B*57:01-DRB1*13:05   Israel Poland Jews  2.47 13,871 
2   A*01:01-B*57:01-DRB1*13:05   Israel USA Jews  2.40 6,058 
3   A*01:01-B*57:01-DRB1*13:05   Israel Argentina Jews  2.18 4,307 
4   A*01:01-B*57:01-C*06:02-DRB1*07:01-DQB1*03:03   USA NMDP South Asian Indian  2.16 185,391 
5   A*01:01-B*57:01-DRB1*13:05   Israel Ashkenazi Jews  2.00 4,625 
6   B*57:01-C*06:02   USA Asian pop 2  1.99 1,772 
7   A*01:01-B*57:01-C*06:02-DRB1*07:01-DQB1*03:03   USA NMDP Southeast Asian  1.49 27,978 
8   A*01:01-B*57:01   USA Asian pop 2  1.41 1,772 
9   A*01:01-B*57:01-DRB1*13:05   Israel USSR Jews  1.37 45,681 
10   A*01:01-B*57:01-C*06:02-DRB1*07:01   Germany DKMS - Austria minority  1.33 1,698 
11   A*01:01-B*57:01-DRB1*07:01   Israel Libya Jews  1.31 3,739 
12   A*01:01-B*57:01-C*06:02-DRB1*07:01   Germany DKMS - United Kingdom minority  1.20 1,043 
13   A*01:01-B*57:01-C*06:02-DRB1*07:01   Germany DKMS - Netherlands minority  1.14 1,374 
14   A*01:01-B*57:01-C*06:02-DRB1*07:01   Germany DKMS - France minority  1.07 1,406 
15   A*01:01-B*57:01-DRB1*04:03   Israel Bukhara Jews  1.04 2,317 
16   A*01:01-B*57:01-DRB1*13:03   Israel Bukhara Jews  0.93 2,317 
17   A*01:01-B*57:01-C*06:02-DRB1*07:01-DQB1*02:01   USA NMDP South Asian Indian  0.92 185,391 
18   A*01:01-B*57:01-C*06:02-DRB1*07:01-DQB1*02:01   USA NMDP Vietnamese  0.87 43,540 
19   B*57:01-C*06:02   USA Hispanic pop 2  0.85 1,999 
20   A*01:01-B*57:01-DRB1*13:03   Israel Iraq Jews  0.85 13,270 
21   A*02:01-B*57:01-C*06:02-DRB1*07:01   Poland DKMS  0.84 20,653 
22   A*01:01-B*57:01-C*06:02-DRB1*07:01-DQB1*03:03   USA NMDP European Caucasian  0.83 1,242,890 
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Provisions have also been made whereby database administrators do not need to be 
knowledgeable and proficient in both immune-mediated ADRs and database 
management in order to keep the database up to date. A researcher into immune-
mediated ADRs who can understand the data can maintain the spreadsheet document 
(mentioned in 2.2.4) relatively easily and then execute the specially designed Python 
script which will automatically read in the data from the spreadsheet and then update 
the database accordingly. This reduces the need to hire a database administrator who 
is proficient in both computation and biological fields or hire two individuals from 
each field in order to maintain the database. For security reasons, the Python script 
should only be accessible to members of the database administration/curation team.  
 
It is envisaged that the database will primarily be used to conduct meta-analyses by 
researchers. HLA-ADR can allow these researchers to perform a quick search about 
their drug(s)/ADR phenotype etc. of choice and have access to the data from the 
published literature and save them from performing an extensive literature search 
themselves. The tools created for the HLA-ADR website and the links to external 
resources will enable these meta-analyses to be performed in a relatively 
straightforward and streamlined approach whereby HLA-ADR is either the singularly, 
or one of few, utilities that are employed or even act as a starting point from which to 
conduct further informatics investigations.  
 
Although the HLA-ADR website has been live for only a relatively short period of 
time, there are already a few examples demonstrating the utility of the website for 
researchers. There are two non-self-citing studies that are accessible and have cited 
HLA-ADR (see 3.6 for the HLA-ADR publication details).  [122, 123] Chapter 4 also 
demonstrates an example of the database being used to support meta-analysis and 
Chapter 6 showcases the data being used with a clinical perspective. The ultimate goal 
for a bioinformatics resource is to aid several studies. 
 
3.5. Conclusion 
Investigating immune-mediated adverse drug reactions requires the lengthy process of 
conducting deep literature reviews in order to collect the necessary data for the 
researchers’ investigation. Over the years, data pertaining to HLA associated ADRs 
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has grown and will likely continue to grow as more drugs are developed and enter the 
market. It is therefore important that the data is digitised and centralised to enable 
clinicians and researchers to be able to access all of the available information in a 
flexible manner without having to conduct a systematic review each time. Therefore, 
it is proposed that this web based HLA-ADR database which provides flexible access 
to relevant data will be of great benefit to the research and clinical communities. 
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Chapter 4. Investigating observed patterns between 
reported HLA associated adverse drug reactions and 
patient ethnicity 
4.1. Introduction 
Following on from the previous chapters, a hypothesis that was posed from the 
analysis of the data from Chapter 2 was the possibility of case-control publication bias 
whereby many of the studies relating to immune-mediated ADRs were published from 
a limited number of countries – predominantly in Asia and Europe. This was proposed 
as a possible reason as to why certain ethnicities are reported to be at higher risk of 
experiencing ADRs when exposed to a drug (as well as the possibility that the 
observations are indicative of a genuine difference in response between the population 
groups). 
 
The relatively high number of studies from Asia has influenced drug labelling advice 
from the regulatory drug bodies (see Table 4.1) where certain antiepileptic drugs are 
contraindicated in patients of Asian origin. The table shows that to date, the United 
States Food and Drug Administration (FDA) and the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) have issued recommendations for the pre-
treatment genetic screening for four drugs including carbamazepine and phenytoin. 
The labels other drugs featured in this thesis did not include any advice with regards 
to screening patients for risk HLA alleles. 
 
As a result of this reported pattern showing differing responses to drugs based on 
patient ethnicity, this chapter includes an investigation carried out using the data 
collected in Chapter 2 and the toolset developed in Chapter 3 to see if this data set 
could show any statistical evidence to support these observations that ethnicity can 
influence risk profiles for a particular ADR. The aim of this chapter is to summarise 
the data present in the HLA-ADR database with particular focus on the variability 
based on patient ethnicity in the reporting of HLA associated ADRs. The findings of 
this chapter have been published and the paper serves a condensed version of this 
chapter. [124]  
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Table 4.1: FDA and CPIC drug labelling advice related to HLA associated adverse 
drug reactions 
Drug FDA advice CPIC advice 
Abacavir 
“Prior to initiating therapy 
with abacavir, screening for 
the HLA-B*5701 allele is 
recommended.” [49]  
“HLA-B*57:01 screening should 
be performed in all abacavir-naive 
individuals before initiation of 
abacavir-containing therapy.” [125] 
Allopurinol 
No information available 
pertaining to HLA mediated 
ADRs. 
No direct recommendation 
regarding pre-screening of patients 
for HLA-B*58:01. However, for 
patients known to carry HLA-
B*58:01: “allopurinol is 
contraindicated.” [126] 
Carbamazepine 
“Patients with ancestry in 
genetically at-risk 
populations [Asia] should be 
screened for the presence of 
HLA-B*1502 prior to 
initiating treatment with 
Tegretol [carbamazepine]. 
Patients testing positive for 
the allele should not be 
treated with Tegretol unless 
the benefit clearly outweighs 
the risk.” [51] 
Directly quotes FDA - “‘patients 
with ancestry in at-risk populations 
should be screened for the 
presence of HLA-B*15:02 allele 
prior to starting carbamazepine’. 
Individuals at highest risk are 
those of Han Chinese descent, 
followed by those in Vietnam, 
Cambodia, the Reunion Islands, 
Thailand, India (specifically 
Hindus), Malaysia, and Hong 
Kong.” [127] 
Phenytoin 
“Consideration should be 
given to avoiding phenytoin 
as an alternative for 
carbamazepine in patients 
positive for HLA-B*1502.  
The use of HLA-B*1502 
genotyping has important 
limitations and must never 
substitute for appropriate 
clinical vigilance and patient 
management.” [53] 
Directly quotes FDA -
“‘Consideration should be given to 
avoiding phenytoin as an 
alternative for carbamazepine in 
patients positive for HLA‐
B*15:02’ due to the increased risk 
of SJS/TEN in patients of Asian 
ancestry.” [128] 
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4.2. Methods 
The alleles that were reported to be statistically significantly associated (defined as p 
< 0.05) from the data within the HLA-ADR database were brought forward for 
analysis in this investigation. The alleles were grouped by the drug, e.g. for the drug 
lapatinib, the alleles HLA-DRB1*07:01, HLA-DQA1*02:01 and DQB1*02:02 were 
reported as significantly associated and therefore analysed together. This was repeated 
for each drug featured in the results section. Alleles were permitted to be part of 
multiple groups e.g. HLA-B*15:02 was part of the groups relating to carbamazepine, 
phenytoin, lamotrigine etc. Next the frequencies for each allele were obtained using 
the Allele Frequency Net Database (AFND) allele frequency search tool using what 
AFND labelled as ‘gold standard’ population data. These ‘gold standard’ populations 
are defined as information for the population that is available at two fields or greater 
for the HLA alleles. [129] Wherever possible, these frequencies were obtained where 
the sample size for each population was greater than or equal to 1,000. In situations 
where populations with sample sizes above or equal to 1,000 were not available, the 
size of the populations are provided in the text. All of the allele prevalences that were 
collected for this investigation are quoted as the frequency of the allele within the 
population as such, the carrier frequencies would be approximately double the allele 
frequency. Individuals that are homozygous across the entire MHC region are 
extremely rare except in situations of consanguineous parentage. Therefore, doubling 
the allele frequency to obtain the carrier frequency provides a good approximation. 
 
In addition to the allelic frequency data, the frequencies for HLA haplotypes with each 
set of the above mentioned grouped alleles were obtained from the AFND haplotype 
search tool. As with the allele frequencies, sample sizes greater than 1,000 were 
preferred for these haplotype frequencies however, this was not always possible. For 
all instances of referring to haplotype data, the sample sizes have been included in the 
results section. For this investigation, when referring to the studies individually, the 
populations are described using the country name or geographic location as used in 
the original study. However, when conducting the meta-analysis, the populations are 
categorised into three major demographic groups: African, Asian and European. It is 
also worth noting that populations represented within AFND are labelled based on the 
ancestry of that group and these are reflected in this investigation, for example 
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populations from the United States where the members of the population sample are 
of Chinese origin are classed as Asian in this meta-analysis. This classification based 
on ancestry allows the analysis to explore the relationship of ADRs with ethnicity 
without having to compensate for population nationality. The primary advantage for 
this simplification of populations into three major groups provides the analysis with a 
higher statistical power, however this is done at the expense of some granularity of the 
information. 
 
For the analysis of all of the data, the information was summarised as a table of 
descriptive statistics with the Mann-Whitney U test (a nonparametric comparison of 
the medians) applied to compare the data pertaining to Asian and Europeans to see if 
certain alleles could be described as having higher frequencies in certain populations 
- the descriptive statistics and the Mann-Whitney U test were performed by EJM 
Santos, co-author of the study that published these findings. To expand on this, a 
Kruskal-Wallis test was applied to perform a three-way comparison of the three ethnic 
super-groups and Bonferroni correction for multiple comparisons was applied (The 
Mann-Whitney U test only makes a pairwise comparisons). The Kruskal-Wallis test 
was performed using the R statistical software package (Version 3.2.2 - R Foundation 
for Statistical Computing, 2015, UK https://cran.r-project.org). The Kruskal-Wallis 
test was performed by the author.  
 
For the data relating to carbamazepine, there was a sufficient number of alleles to 
perform a Spearman’s correlation test to investigate the co-occurrence of the alleles 
reported to be associated with carbamazepine hypersensitivity. The statistical analyses 
were performed independently by two researchers; EJM Santos performed the 
Spearman’s correlation and the analysis using the AFND haplotype searches was 
performed by the author. The AFND haplotype data are recorded from population 
samples, i.e. obtained directly from sample sources. The two analyses were compared 
to measure relative concordance. 
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For the analysis of dapsone, there is reference to the geographic region of Oceania. 
For the context of this thesis, Oceania is defined by the countries listed in Table 4.2.  
 
Table 4.2: Countries classified as ‘Oceania’ in the HLA-ADR database 
Country 
American Samoa 
Australia 
Christmas Island 
Cocos Islands 
Cook Islands 
East Timor 
Federal States of Micronesia 
Fiji 
French Polynesia 
Guam 
Indonesia 
Kiribati 
Marshall Islands 
Nauru 
New Caledonia 
New Zealand 
Niue 
Norfolk Island 
Northern Mariana Islands 
Palau 
Papua New Guinea 
Pitcairn Islands 
Samoa 
Solomon Islands 
Tokelau 
Tonga 
Tuvalu 
Vanuatu 
Wallis and Futuna Islands 
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4.3. Results 
All frequencies referenced in this results section were obtained from the Allele 
Frequencies Net Database [120, 121] (AFND) using the following URLs: the frequencies 
of individual alleles the URL was http://www.allelefrequencies.net/hla6006a.asp and 
the frequencies for HLA haplotypes were obtained using the URL 
http://www.allelefrequencies.net/hla6003a.asp. These URLs were accessed June 
2016. 
 
4.3.1. Antigout drugs 
4.3.1.1. Allopurinol 
Allopurinol is prescribed to patients with gout/hyperuricaemia. Several studies have 
been published which have reported allopurinol hypersensitivity to be associated with 
carriage of HLA-B*58:01 across many populations including Caucasian, [130, 131] Han 
Chinese, [23, 132, 133] Japanese, [133] Korean [133-135] and Thai [136] patients. Another study 
also reported the association with HLA-B*58:01 in a patient-control cohort which has 
been marked as ‘diverse’ as the study did not separate the cohort by ethnicity but did 
state that the cohort consisted of individuals of South Asian, South American, 
European and African ancestries.  
 
As well as HLA-B*58:01, the studies referred to above also reported associations that 
were statistically significant between allopurinol-induced hypersensitivity and HLA-
A*33:03, HLA-C*03:02 and HLA-DRB1*03:01. The HLA-A*33:03 allele has been 
reported to be associated with allopurinol induced hypersensitivity in patients of 
Caucasian, Han Chinese and Korean origin. HLA-B*58:01, HLA-A*33:03 and HLA-
C*03:02 were found to be significantly associated in Han Chinese and Korean 
patients. [133, 135] The AFND HLA haplotype frequency search (URL 
http://www.allelefrequencies.net/hla6003a.asp accessed June 2016) shows that these 
three alleles co-occur with the haplotype relatively commonly in East Asian 
populations where the frequency is as high as 8% of the population. In comparison, 
this haplotype frequency is < 2% in European populations where the frequency of the 
individual alleles is also < 2%. The frequency of the haplotype is not available for 
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African populations. The frequencies for the individual alleles are between 5-6% for 
HLA-A*33:03, 4% for HLA-B*58:01 and 2% for HLA-C*03:02. 
 
The class II allele HLA-DRB1*03:01 has been found with relatively high co-
occurrence with HLA-A*33:03 and HLA-B*58:01 in east and south-east Asian 
populations, specifically, as high as 6.6% co-occurrence for all three alleles in Taiwan 
– from AFND Haplotype Frequency tool (accessed June 2016). Furthermore, the 
haplotype containing all four of the alleles (HLA-A*33:03, HLA-B*58:01, HLA-
C*03:02 and HLA-DRB1*03:01) is reported to have 4.4% frequency in south-west 
China. The haplotype data indicates that the simplest explanation is that not all four 
alleles are independently causative (or are a risk factor), but that the alleles gained 
statistical significance due to high linkage disequilibrium with the actual risk factor 
allele. Given that the association for HLA-B*58:01 carriage and allopurinol induced 
hypersensitivity was replicated by multiple studies and across many ethnic groups, 
HLA-B*58:01 is the strongest candidate as the true risk factor for this ADR. 
 
4.3.2. Antituberculosis drugs 
Tuberculosis (TB) is treated using a combination regimen of multiple drugs (isoniazid, 
rifampicin, ethambutol and pyrazinamide). It is consequently difficult to establish the 
causative agent for anti-TB induced ADRs. A study investigating anti-TB drug-
induced hypersensitivity syndrome (DIHS) in Korean patients who were receiving the 
combination regimen reported HLA-C*04:01 as having statistically significant 
association, p = 0.02, OR = 6.9 (95% CI: 2.2-20.11), based on HLA-C*04:01 allele 
carriage of 7/14 hypersensitive patients, 21 of 166 drug-tolerant controls and 62/485 
population controls. [137] AFND allele frequency search tool reports that this allele is 
found across the world in many populations including 22.8% in a population of 
African ancestry, 19.3% in a Turkish population, 17.5% in Latin Americans and 13.6% 
in South Asians. All of the populations referred to above were of sample size > 1,000. 
 
HLA-associated hepatotoxicity has also been reported in an Indian patient cohort. [138] 
The reporting study presented HLA-DQB1*02:01 as a statistically significant risk 
factor for drug induced liver injury (DILI) where 25/47 DILI patients and 84/256 drug-
exposed controls carried the allele: p ≤ 0.01 (OR = 2.2 and 95% CI: 1.19-4.15). 
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Conversely, the study also reported that carriers of HLA-DQA1*01:02 were 
statistically less likely to experience an ADR based on 3/47 DILI patients and 68/251 
drug exposed controls carrying the allele: p < 0.001 (OR = 0.2 and 95% CI: 0.05-0.61). 
Within the Indian population, HLA-DQB1*02:01 is found at a frequency of 19.9% 
(sample sizes were limited to between 58 and 202). In other populations, HLA-
DQB1*02:01 is observed at frequencies of 59% in Sardinians, 22.8% in a US 
population of European ancestry, 22.3% in population of African origin and 21.8% in 
Latin Americans. In all cases of these referenced populations, sample sizes > 1,000. 
 
4.3.3. Antibiotics 
4.3.3.1. Dapsone 
The antibiotic, dapsone, is used to treat leprosy and has been associated with 
hypersensitivity reactions with Han Chinese patients. [139] The group reporting the 
association presented that carriage of HLA-B*13:01 and HLA-C*03:04 crossed the 
threshold of statistical significance, 𝑝 = 2.04 ×  10−16;  𝑜𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 =
 21.67 (95% 𝐶𝐼: 1.41 − 45.12) and 𝑝 = 1.84 × 10−14; 𝑂𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 =
13.43 (95% 𝐶𝐼: 6.91 − 26.11) respectively. However, when the study adjusted for 
the fact that these two alleles are in linkage, only HLA-B*13:01 remained significantly 
associated – adjusted 𝑝 = 5.16 ×  10−5;  𝑜𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 =  17.92 (95% CI values were 
not provided in the publication).  
 
HLA-B*13:01 is found predominantly in the region of East Asia, South-east Asia and 
Oceania (as defined by AFND and provided in Table 4.2 in this chapter’s Methods 
section). The AFND allele frequency tool reports that HLA-B*13:01 is found at a 
frequency of, 6.4% in a Han Chinese population, 3.9% in Vietnamese and 2.8% in the 
Philippines for samples sizes > 1,000. Higher frequencies are reported in populations 
with smaller sample sizes, approx. 100, in the populations originating from Papua New 
Guinea, Taiwan and Australia (Aborigine) where the allele frequencies were between 
25-28%. 
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4.3.3.2. Amoxicillin-clavulanate 
Amoxicillin is a broad-spectrum antibiotic and can be prescribed as on its own or 
combined with clavulanic acid where it is known as either co-amoxiclav or 
amoxicillin-clavulanate. Adverse reactions with this drug have been reported to be 
associated with HLA-DRB1*15:01, HLA-DRB5*01:01, HLA-DQB1*06:02, HLA-
A*02:01, and HLA-A*30:02 (see Table 4.3). In all four of these studies, the 
patient/control cohorts were of European ancestry, specifically Belgium, Scotland, 
mixed European (north-west European and Spanish subpopulations) and Spain. Of 
these listed alleles, HLA-DRB1*15:01 and HLA-DQB1*06:02 are of particular note 
as they were reported by all four studies for the former allele and three out of four 
studies for the latter. The AFND haplotype search tool reported that co-occurrence of 
the two alleles is > 10% in many diverse populations including Russian, Indian, 
European, East Asian and Australian Aborigine. The two alleles are also found 
together at relatively lower frequencies in many other populations. 
 
Table 4.3: List of alleles that have been reported to be associated with amoxicillin-
clavulanate/co-amoxiclav induced adverse drug reactions along with the reporting 
study and the origin of the studies’ cohorts.  
Allele Reporting study Study cohort 
subpopulation 
HLA-A*02:01 Lucena et al., 2011 [140] mixed European 
HLA-A*30:02 Stephens et al., 2013 [141]  Spain 
HLA-DRB1*15:01 Hautekeete et al., 1999 [25] Belgium 
O'Donohue et al., 2000 [142] Scotland 
Lucena et al., 2011 mixed European 
Stephens et al., 2013 Spain 
HLA-DRB5*01:01 Hautekeete et al., 1999 Belgium 
HLA-DQB1*06:02 Hautekeete et al., 1999 Belgium 
Lucena et al., 2011 mixed European 
Stephens et al., 2013 Spain 
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4.3.3.3. Flucloxacillin 
The β-lactam antibiotic, flucloxacillin is typically used to treat gram-positive bacterial 
infections. The HLA-B*57:01 allele has been associated with flucloxacillin-induced 
DILI. [24] The study also reported that HLA-DRB1*07:01 was also statistically 
significant, however, the focus of the report’s conclusion was to HLA-B*57:01 as this 
allele had the stronger association (𝑝 = 8.97 × 10−19 for HLA-B*57:01 compared 
with 𝑝 =  1.9 × 10−5 for HLA-DRB1*07:01). Based on the strength of the 
associations, HLA-B*57:01 is the more likely candidate to be classed as the true risk 
marker for flucloxacillin-induced hepatotoxicity.  
 
Whilst this study was conducted in the United Kingdom with a patient cohort of 
European ancestry, both of these alleles are found in many diverse populations. HLA-
B*57:01 carriage has been reported by AFND to be in populations of Indian, European 
or East Asian ancestry at frequencies over 1%. HLA-DRB1*07:01 is found at 
frequencies greater than 10% in Indian, European, North African, East Asian, Native 
American and Latin American populations. The study also reported that the two alleles 
co-occur frequently as part of the haplotype which is shown in Table 4.4 below and 
the frequencies for the haplotype which contain all 5 of these alleles were obtained 
from AFND to provide frequency data for the co-occurrence are listed in Table 4.5 
which show the diversity of the haplotype. 
 
 
Table 4.4: List of HLA alleles that are reported by Daly et al. that form a commonly 
occurring haplotype with the two alleles that the study reported to be statistically 
significantly associated with flucloxacillin-induced hepatotoxicity (HLA-B*57:01 and 
HLA-DRB1*07:01).[24]  
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 
A*01:01 B*57:01 C*06:02 DRB1*07:01 DQB1*03:03 
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Table 4.5: Haplotype frequencies obtained from Allele Frequencies Net Database 
for the haplotype containing the alleles from Table 4.4 (HLA-A*01:01–HLA-
B*57:01–HLA-C*06:02–HLA-DRB1*07:01–HLA-DQB1*03:03). 
URL http://www.allelefrequencies.net/hla6003a.asp accessed June 2016. 
Population Haplotype occurrence Sample size 
North African (Tunisia) 9% 100 
South Asian 2.16% 185,391 
South-east Asian 1.49% 27,878 
European 0.83% 1,242,890 
 
4.3.3.4. Sulfamethoxazole 
Sulfamethoxazole is a broad spectrum antibiotic and has been reported to induce 
SJS/TEN in some patients. A study by Kongpan et al. reported that HLA-B*15:02, 
HLA-C*06:02 and HLA-C*08:01 were statistically significantly associated with these 
drug-induced hypersensitivity reactions in a Thai patients. [143] HLA-B*15:02 is found 
at high frequency in East Asian and Southeast Asians and the populations showing the 
highest carriage rate are shown in Table 4.6. The allele frequencies listed in this table 
refer to populations with a sample size greater than 1,000. There were additional, 
smaller populations which showed a larger representation for the HLA-B*15:02 allele. 
There are five subpopulations from various provinces of China (Han Chinese) that 
have HLA-B*15:02 allele frequencies between 14.8-35.8% where the sample sizes 
ranged from 108-153. 
 
HLA-C*06:02 is found in many populations and can be found at frequencies (where 
sample sizes are >1000) of 13.9% in South Asians, between 8 and 11% in many 
European populations, between 3 and 5% in East Asians and around 8% in populations 
of recent African ancestry. HLA-C*08:01 is particularly common in East and South-
East Asian populations where it can be found at frequencies of 16.4% in Vietnamese, 
10% Chinese and 7% in Japanese and Korean populations. It has also been reported in 
North American (Mexican, Native Alaska and Native American) population at a 
frequency between 1 and 3%. 
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Table 4.6: Populations which have the highest frequencies of HLA-B*15:02 carriage. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016 and the 
website was set to show populations where the sample size was greater than 1,000  
Population HLA-B*15:02 Frequency Sample size 
Vietnamese (USA) 13.8% 43,540 
Chinese (Hong Kong) 9.38% 7,595 
Chinese (USA) 6.47% 99,672 
Filipino (USA) 4.21% 50,614 
 
4.3.4. Antiepileptic drugs 
4.3.4.1. Carbamazepine 
The anticonvulsant, carbamazepine is employed in the treatment of epilepsy, 
trigeminal neuralgia and bipolar disorders. It is one of the most studied drugs in terms 
of HLA associated ADRs and is represented in the HLA-ADR database with over 27 
studies investigating carbamazepine induced hypersensitivity reactions. From these 
studies, 22 HLA alleles, at 2 field resolution, have been reported to be statistically 
significantly associated (where 𝑝 < 0.05) for carbamazepine induced ADRs – these 
alleles are shown in Figure 4.1. Of particular note are the HLA-A*31:01 and HLA-
B*15:02 alleles which are reported as significant in 11 and 19 papers respectively. 
Also, shown in Figure 4.1 are that the remaining 20 alleles have not been well 
replicated as they were reported in three or fewer studies. For example, a study by Li 
et al. reported the allele HLA-A*02:01 to be statistically significant associated (𝑝 =
0.033) with carbamazepine induced hypersensitivity in Han Chinese patients. [21] 
However, statistical significance was not achieved in other studies in which the allele 
was part of the patient-control cohort; i.e. these studies observed HLA-A*02:01 in 
their respective cohorts but carriage of the allele was not found in a statistically 
significantly higher proportion of the hypersensitive patients compared to the drug 
exposed controls. This lack of statistical significance for HLA-A*02:01 replication 
includes studies investigating carbamazepine induced ADRs in other Han Chinese 
patients [144, 145] or Japanese and Korean patients. [18, 146] 
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For studies reporting HLA-B*15:02 associations with carbamazepine hypersensitivity 
reactions, 15 of the 19 reporting studies were conducted with a patient-control cohort 
of Han Asian origin, specifically: Han Chinese (n = 10), Thai (n = 3), Malay (n = 1) 
and Indian (n = 1) with the remaining four investigations reported each of their 
associations based on ethnically diverse study cohorts. Referring back to Table 4.6 
which shows the populations where HLA-B*15:02 allele frequency is at its highest, 
this is predominantly in the East and South-East Asian populations, in fact the first 
entry in AFND allele frequency search for a non-East or South-East Asian population 
is an entry for Caucasians (Italy) where the allele was found at 0.1% in a sample of 
1,089. This low allelic frequency in non-Asians is the most probable reason as to why 
no associations have been reported between HLA-B*15*02 and carbamazepine 
induced SJS/TEN in Caucasians. [147, 148] 
 
In contrast, HLA-A*31:01 is a globally occurring allele at a low frequency throughout 
the populations which are shown in Table 4.7. The literature reflects the universality 
of the allele where of the 11 of the reported significant associations for HLA-A*31:01 
carbamazepine hypersensitivity, two studies were conducted with a Japanese patient 
cohort, [18, 117] two of the associations were Korean, [146] three used a Han Chinese 
cohort, [144, 149, 150] two were performed with Europeans [19, 149] and two associations 
were found using an ethnically diverse patient-control cohort. [34] Note that some 
studies reported the association twice (as part of the systematic review in Chapter 2, 
the patient/control groups were separated by ethnicity or ADR phenotype so this 
section may report them separately – e.g. above mention of two Korean associations 
but only one cited study). 
 
A Spearman's correlation analysis (Table 4.8) was performed on the alleles featured 
in Figure 4.1 (i.e. alleles present in HLA-ADR that have been associated with 
carbamazepine ADR). This analysis is a statistical inference of the likelihood that two 
alleles are likely to co-occur. Only alleles which are statistically significant (p < 0.05) 
as reported by the literature sources contained within the HLA–ADR database and 
where more patients carried the allele compared to the control group – that is positive 
statistical significance indicating risk were included for the analysis. Alleles where 
one or more study reported the allele to have an apparent protective effect – statistical 
significance where more controls carried the allele compared to the hypersensitive 
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patients were excluded. The table shows that only two alleles: HLA-A*31:01 and 
HLA-B*39:02 did not display evidence of linkage disequilibrium with the other alleles 
associated with carbamazepine induced ADRs which suggests that these alleles may 
be independently associated with the carbamazepine hypersensitivity. For the 
remaining alleles, a more complex model of linkage disequilibrium exists with varying 
degrees in the strength of the association. For example, HLA-A*02:01 showed weak 
linkage with HLA-DRB1*07:01 (0.05 < 𝑝 > 0.01), whilst HLA-DRB1*12:02 seems 
to be in strong linkage with four of the other alleles associated with carbamazepine 
hypersensitivity (HLA-B*15:02, HLA-B*58:01, HLA-C*03:02 and HLA-C*08:01). 
This correlates with the observed haplotype frequency from AFND whereby HLA-
B*15:02, HLA-C*08:01 and HLA-DRB1*12:02 are known to form a haplotype which 
is common in Asians. The highest frequencies for this haplotype are found in 5.6% of 
Vietnamese people (n = 43 540) and also 2.5% in a Chinese population (n = 99 672). 
 
Table 4.7: Populations where the HLA-A*31:01 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-A*31:01 frequency Sample size 
Japanese (Japan) 8.49% 24,582 
Native American (USA) 7.37 35,791 
Korean (USA) 5.35% 77,584 
Latin American (USA) 5.31% 261,235 
South Asian – Indian (USA) 3.31% 185,391 
Caucasian (Netherlands) 3.30% 1,305 
  
 
Table 4.8: Nonparametric Spearman’s correlation analysis showing the statistically inferred measure of linkage disequilibria between the HLA 
alleles reported to be associated with carbamazepine induced hypersensitivity reactions. 
This analysis was performed across all the ethnicities/populations. Higher positive correlation values signify that the alleles are more likely to 
appear together. Data obtained from URL Allele Frequencies Net Database: URL http://www.allelefrequencies.net/hla6006a.asp accessed June 
2016. 
Allele A*02:01 A*31:01 B*15:02 B*15:11 B*39:02 B*58:01 C*03:02 C*08:01 DRB1*07:01 DRB1*12:02 
A*02:01                     
A*31:01  0.221                   
B*15:02 -0.684 b -0.303                 
B*15:11 -0.333 -0.067  0.071               
B*39:02  0.371 -0.200 -0.400  0.500             
B*58:01 -0.785 b -0.396 a  0.662 b  0.190 -0.257           
C*03:02 -0.812 b -0.215  0.601 a   0.310 -0.800  0.847 b          
C*08:01 -0.793 b -0.004  0.709 b   0.000  0.600  0.667 b   0.714 b       
DRB1*07:01  0.343 a   0.041 -0.200 -0.233 -1.000 b -0.468 b -0.557 b -0.596 b     
DRB1*12:02 -0.776 b  0.026  0.754 b  0.107  0.000  0.713 b   0.749 b   0.881 b  -0.592 b   
DRB1*14:05 -0.200 -0.147 -0.143 0.786 a   0.500  0.050  0.170  0.571 -0.564  0.627 a 
In bold are the significant positive correlations (nonparametric Spearman's correlation). 
a Correlation is significant at the 0.05 level (two-tailed); 
b Correlation is significant at the 0.01 level (two-tailed) 
9
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Figure 4.1: HLA alleles which have been reported in the HLA–ADR database to be significantly associated with carbamazepine-induced adverse 
drug reactions. 
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The black bars (positive y-axis) in Figure 4.1 represent studies that report risk alleles, 
that is with 𝑝 < 0.05 and where allele was found in proportionally more 
hypersensitive patients as compared to the control groups(s). The grey bars (negative 
y-axis) represent studies where the reported allele is suggestive to be protective, that 
is with  𝑝 < 0.05  and where fewer patients exhibiting hypersensitive reactions to 
carbamazepine carried the allele compared to the control group(s). Note there is some 
overlap with the studies – where studies have reported multiple alleles as significant. 
In these cases, the graph shows these as separate entries. 
 
4.3.4.2. Oxcarbazepine 
Oxcarbazepine is a structural derivative of carbamazepine and is also used as an 
anticonvulsant. Several HLA-B alleles have been implicated with oxcarbazepine 
induced hypersensitivity reactions (see Table 4.9). It is worth noting that all three 
studies listed in the table were conducted using Han Chinese patient cohort. However, 
none of the studies demonstrated a statistically significant association between the 
hypersensitive patients and the drug exposed controls. The significant differences are 
with the hypersensitive patients and the population controls (non-drug exposed). It is 
also worth noting that none of the studies was able to replicate an association from one 
of the other studies. 
 
Table 4.9: HLA-B*15:02 alleles that have been reported to be associated with 
oxcarbazepine induced hypersensitivity along with the reference to the reporting 
study. 
HLA-B allele Reporting study Cohort ethnicity in study 
HLA-B*13:02 
He et al., 2012 [151] 
Han Chinese 
HLA-B*15:27 
HLA-B*15:19 
HLA-B*27:09 
HLA-B*48:04 
HLA-B*15:02 Hu et al., 2011 [152] 
HLA-B*38:02 Lv et al., 2013 [153] 
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4.3.4.3. Phenytoin 
Phenytoin is another drug used in the treatment of epilepsy. Of the studies included in 
this review, three reported a significant association between phenytoin-induced 
hypersensitivity and HLA-B*15:02 and HLA-B*15:13 carriage (see Table 4.10).  
Whilst the table does include other alleles reported by Hung et al., it is worth noting 
that these associations are of borderline significance: 𝑝 = 0.0154; 𝑝 = 0.0281; 𝑝 =
0.0128 for HLA-B*13:01, HLA-C*08:01 and HLA-DRB1*16:02 respectively. 
Another study by Manuyakorn et al. investigating phenytoin-induced hypersensitivity 
in Thai patients was unable to find statistical significance for the association with 
HLA-B*15:02. [154] However, all five investigating studies were conducted with 
relatively small patient cohorts ranging between 4 and 26 and therefore it can be 
argued that these studies are underpowered. Recently, a meta-analysis by Bloch et al. 
using the pooled HLA-B*15:02 data from four of the five listed studies (the Chang et 
al investigation was published after Bloch et al) reported a combined odds ratio of 
3.48 (95% 𝐶𝐼: 1.75 − 6.91) which supports the association between HLA-B*15:02 
and phenytoin-induced SJS/TEN. [33]  
 
Table 4.10: Alleles reported to be significantly associated with phenytoin induced 
adverse drug reactions along with patient-control cohort ethnicity and the size of 
the hypersensitive/patient group size. 
HLA allele Reporting study Hypersensitive 
patient group 
size 
Cohort ethnicity 
in study 
HLA-B*15:13 
Chang et al., 2017 [155] 13 Malay 
HLA-B*15:02 
Locharernkul et al., 2008 [156] 4 Thai 
Cheung et al., 2013 [17] 15 
Han Chinese 
Hung et al., 2010 [22] 26 
HLA-B*13:01 
HLA-C*08:01 
HLA-DRB1*16:02 
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4.3.4.4. Lamotrigine 
Two meta-analyses have reported the carriage of HLA-B*15:02 to be a significant risk 
factor for patients being treated with the anticonvulsant lamotrigine. [22, 33] The two 
studies needed to pool data from primary studies to achieve sufficient statistical power 
(see Table 4.11). The number of lamotrigine-induced SJS patients was very small, 
despite this, Hung et al. was able to report borderline significance for the HLA-
B*15:02 association (𝑝 = 0.03 odds ratio = 7.62 (95% 𝐶𝐼: 1.4 − 42.4) and Bloch et 
al. reported a pooled odds ratio of 3.59 (95% 𝐶𝐼: 1.15 − 11.22). 
 
In addition to SJS, lamotrigine-induced maculopapular exanthema (MPE) has been 
reported as an observed ADR phenotype in patients by Li et al., 2013. [21] The study 
reported statistical significance between the ADR and the carriage of HLA-A*30:01 
(𝑝 = 0.013) and HLA-B*13:02 (𝑝 = 0.013). The haplotype frequency of these two 
alleles is listed below in Table 4.12for populations where the co-occurrence is 
proportionally at its highest; in East Asians and the Middle East (Israel). AFND does 
report that the haplotype can be found at lower frequencies (below 1%) in other 
populations including Europeans and South Asians. The study also reported a 
decreased occurrence of HLA-A*33:03 in lamotrigine-induced maculopapular 
exanthema patients compared with the control group (𝑝 = 0.048). 
 
Table 4.11: List of studies from which the meta-analyses (table headings) used to 
conduct their respective investigations. 
The meta-analyses pooled data from the listed studies in order to acquire a 
sufficiently powered dataset. 
Bloch et al., 2014 Hung et al., 2010 
An et al., 2010 [157] 
Hung et al., 2010 [22] 
Shi et al., 2011 [158] 
Cheung et al., 2013 [17] 
Man et al., 2007 [20] 
Self (own primary data) [22] 
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Table 4.12: Populations which show the highest frequencies for haplotypes 
containing the HLA-A*30:01 and HLA-B*13:02 alleles along with the sample sizes 
from which the frequencies were obtained. 
The values were obtained from the Allele Frequencies Net Database haplotype 
search tool (URL http://www.allelefrequencies.net/hla6003a.asp accessed June 
2016) and were limited to sample sizes above 1,000 to reduce the impact of small 
sample sizes skewing the frequencies. 
Population (country) Haplotype frequency 
A*31:01 – B*13:02 
Sample size 
Han Chinese (China) 8.87% 3,238 
Bukhara Jews (Israel) 5.38% 2,317 
Han Chinese (Germany) 4.52% 1,282 
Korean (USA) 2.26% 77,584 
Korean (South Korea) 2.19% 4,128 
Han Chinese (USA) 2.03% 99,672 
Kavkazi Jews (Israel) 1.98% 2,840 
 
4.3.5. Antiretrovirals 
4.3.5.1. Abacavir 
The nucleoside reverse transcriptase inhibitor, abacavir, is used in the treatment of 
HIV. To date, immune mediated ADRs with abacavir have only been reported to be 
statistically significant to the HLA-B*57:01 and HLA-DRB1*07:01 alleles (see Table 
4.13). The latter allele has only reported in one study which also stated that the 
association was stronger with HLA-B*57:01 (𝑝 < 0.001 compared with 𝑝 = 0.01). 
 
Although the studies described in this section investigated abacavir ADRs in 
predominantly Caucasian patient-control cohorts, the HLA-B*57:01 allele is found 
across many ethnic populations which is reflected by the studies reporting the 
associations in non-Caucasian individuals as well. Examples to demonstrate the wide 
distribution of the allele is shown in Table 4.14below. 
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Table 4.13: List of studies present in the HLA-ADR database that have reported 
abacavir induced adverse drug reactions along with the study cohort ethnicity. 
Each instance of the term “predominantly” is defined immediately below the table. 
Allele Reporting study Cohort ethnicity in study 
HLA-
B*57:01 
Mallal et al., 2002 [107] Caucasian (predominantly) a 
Hughes et al., 2004 [15]  Caucasian 
Martin et al., 2004 [16] Caucasian (predominantly) b 
Stekler et al., 2006 [110] Caucasian (predominantly) c 
Rodríguez-Nóvoa et al., 2007 [109] Caucasian 
Almeida et al., 2008 [105] Caucasian (predominantly) d 
Berka et al., 2012 [106] Diverse 
Rauch et al., 2008 [108] Caucasian (predominantly) e HLA-
DRB1*07:01 
a 18/18 abacavir ADR patients; 147/167 drug exposed controls reported as 
Caucasian in the study. b 18/18 abacavir ADR patients; 196/230 drug exposed 
controls reported as of European descent in the study. c 7/9 abacavir ADR patients; 
39/41 drug exposed controls reported as Caucasian in the study. d 11/11 abacavir 
ADR patients; 7/9 drug exposed controls; 8/8 drug naïve controls reported as 
Caucasian in the study. e 138/149 of possible abacavir ADR patients; 1,451/1,728 
drug exposed controls reported as Caucasian in the study - Although only 27 ADR 
patients were brought forward for HLA typing, the ethnicity of these 27 patients is 
not described.  
 
Table 4.14: Populations where the HLA-B*57:01 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. 
URL http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population ethnicity (country) HLA-B*57:01 frequency Sample size 
South Asian – Indian (USA) 6.76% 185,391 
South-east Asian (USA) 4.79% 27,978 
Ashkenazi Jews (Israel) 4.51% 4,625 
Caucasian/European (USA) 4.50% 1,245 
Black/African (USA) 0.71% 416,581 
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4.3.5.2. Nevirapine 
The non-nucleoside reverse transcriptase inhibitor, nevirapine has been associated 
with hypersensitivity reactions, see Table 4.15. No common allele has been reported 
as statistically significantly associated with nevirapine hypersensitivity. However, 
HLA-C*04:01 and HLA-B*35:05 are in linkage that is common to people of East and 
South-East Asian origin. AFND data for the co-occurrence of these two alleles is 
limited; it is found at a rate of 0.97% in a USA based Asian population (sample size 
1,772), 0.13% in a USA based Hispanic population (sample size = 1,999) and 0.10% 
a USA based Black African population (sample size = 2,411). For haplotypes which 
contain these two alleles along with other HLA alleles the data indicates that the co-
occurrence rate is higher (see Table 4.16Table 4.16), particularly so for East and 
South-east Asians. 
 
Whilst Phillips et al. [159] reported many alleles as statistically significant, the p-values 
were not corrected for multiple comparisons. The study performed a multivariate 
analysis which specified that HLA-B*58:01 and HLA-DRB1*01:02 show an 
increased risk for nevirapine induced ADRs (only these alleles have been listed in 
Table 4.15).  The co-occurrence for these two alleles is relatively low; AFND only 
reports frequencies of less than 0.05% in any population included in the database. The 
Phillips et al. multivariate analysis also indicated patients carrying HLA-B*15:01, 
HLA-B*58:02 and HLA-C*02:10 have a decreased risk to nevirapine 
hypersensitivity. Contrary to the Chantarangsu et al. [36] report Phillips et al. did not 
find statistically significant evidence to support HLA-B*35:05 as a risk factor in their 
ethnically diverse patient cohort (𝑝 = 0.81).  
 
Table 4.15: List of studies present in the HLA-ADR database that have reported 
nevirapine induced adverse drug reactions along with the study cohort ethnicity. 
Allele Reporting Study Study cohort ethnicity 
HLA-C*04:01 Carr et al., 2013 [35] Black African (Malawi) 
HLA-B*35:05 Chantarangsu et al., 2009 [36] Thai (Thailand) 
HLA-B*58:01 
Phillips et al., 2013 [159] Diverse 
HLA-DRB1*01:02 
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Table 4.16: Frequencies for haplotypes that include HLA-B*35:05 and HLA-C*04:01 (bold) obtained from Allele Frequencies Net Database 
(AFND). 
The AFND contains limited data for haplotype information for just these two alleles so this table contains haplotypes that also include alleles 
from other genes. The population ethnicity is also included as well as the sample size from which the frequencies were obtained (AFND 
restrictions were applied to only display frequencies where the sample sizes were greater than 1,000). The table is ordered descending for the 
haplotype frequencies with the final entry in the table being that of the first non-Asian entry i.e. the non-Asian population where the 
haplotype has been reported to be at its highest frequency. URL http://www.allelefrequencies.net/hla6003a.asp accessed June 2016. 
Haplotype Population ethnicity (country) Haplotype 
Frequency 
Sample 
Size 
A*24:07-B*35:05-C*04:01-DRB1*12:02-DRB3*03:01-DQB1*03:01  Filipino (USA) 3.98% 50,614 
A*24:07-B*35:05-C*04:01-DRB1*12:02-DRB3*03:01-DQB1*03:01  Vietnamese (USA) 1.18% 43,540 
A*24:07-B*35:05-C*04:01-DRB1*15:02-DRB5*01:01-DQB1*05:02  Filipino (USA) 0.73% 50,614 
A*24:07-B*35:05-C*04:01-DRB1*12:02-DRB3*03:01-DQB1*03:01  South-East Asian (USA) 0.31% 27,978 
A*24:07-B*35:05-C*04:01-DRB1*12:02  Chinese (Hong Kong) 0.14% 7,595 
A*68:01-B*35:05-C*04:01-DRB1*04:11-DQB1*03:02  European (Italy minority in Germany) 0.04% 1,159 
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4.3.6. Antirheumatics and NSAIDs 
4.3.6.1. Aspirin 
Aspirin is a widely used nonsteroidal anti-inflammatory drug (NSAID) and 
antirheumatic, antipyretic and analgesic agent that is available over the counter 
without the need of a prescription. In addition to this, low dose aspirin is often used to 
reduce the likelihood of cardiovascular disease and to prevent pre-eclampsia in 
pregnancy. 
 
There are three studies within the HLA-ADR database which have investigated the 
association between HLA carriage in patients and aspirin-induced urticaria (AIU) and 
aspirin-intolerant asthma (AIA); shown in Table 4.17 below. All three studies were 
conducted with Korean case-control cohorts based in South Korea.  HLA-
DPB1*03:01 was found by two of the three studies. Interestingly, the allele did appear 
in the patient cohort for the Kim et al. study but the association was not significant.  
 
The HLA-DPB1*03:01 allele is not specific to people of Korean descent (or even East 
Asia) and can actually be found in greater frequencies in Europe and North America 
(see Table 4.18) where the population with the highest frequency of HLA-
DPB1*03:01 carriage is 48.5% which is remarkably high for a HLA allele. The three 
alleles reported by Kim et al. [27] were presented as a haplotype in the study. The 
AFND haplotype search tool does not contain information pertaining to these three 
alleles grouped on their own. However, haplotypes containing these three alleles along 
with others are included in Table 4.19 which shows that although the haplotype is not 
exclusive to Koreans, it is found at relatively high frequencies (1-2%) in Koreans 
compared to other populations. 
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Table 4.17: List of studies present in the HLA-ADR database that have reported HLA 
associations with aspirin-induced urticaria (AIU) and aspirin-intolerant asthma 
(AIA). 
Studies featured in the table were conducted using a Korean patient-control cohort. 
HLA allele Study ADR 
phenotype 
Study cohort 
ethnicity 
HLA-DPB1*03:01 
Lee et al., 2009 [115] 
AIU 
AIA 
Korean 
Choi et al., 2004 [26] AIA 
HLA-DRB1*13:02 
Kim et al., 2005 [27] AIU HLA-DQB1*06:09 
HLA-DPB1*02:01 
 
 
Table 4.18: Populations present in the Allele Frequencies Net Database which show 
relatively high frequencies for HLA-DPB1*03:01 carriage. 
Information for populations where sample size is greater than 1,000 was limited so 
this restriction was relaxed to show the frequencies for samples > 100. Data 
obtained from Allele Frequencies Net Database - URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-DPB1*03:01 frequency Sample size 
Caucasian – Sardinian (Italy) 48.50% 1,129 
Caucasian – NW Slavic (Russia) 16.0% 200 
Native American (USA) 13.3% 101 
Caucasian (UK) 12.93% 537 
Korean (South Korea) 3.70% 324 
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Table 4.19: Frequencies for haplotypes that include HLA-DRB1*13:02, HLA-DQB1*06:09 and HLA-DPB1*02:01(bold) obtained from Allele 
Frequencies Net Database (AFND). 
The AFND contains limited data for haplotype information for just these three alleles so this table contains haplotypes that also include alleles 
from other genes. The population ethnicity is also included as well as the sample size from which the frequencies were obtained. URL 
http://www.allelefrequencies.net/hla6003a.asp accessed June 2016. 
Haplotype Population (country) 
Haplotype 
frequency 
Sample 
size 
 DRB1*13:02-DQA1*01:02-DQB1*06:09-DPB1*02:01  Korean (South Korea) 2.10% 149 
 DRB1*13:02-DQA1*01:02-DQB1*06:09-DPB1*02:01  Korean (South Korea) 1.20% 207 
 A*32:01-B*07:02-C*07:02-DRB1*13:02-DQA1*01:02-DQB1*06:09-DPB1*02:01  African (Kenya) 0.50% 100 
 A*66:01-B*58:02-C*06:02-DRB1*13:02-DQA1*01:02-DQB1*06:09-DPB1*02:01  African (Kenya) 0.50% 100 
 A*33:03-B*58:01-C*03:02-DRB1*13:02-DQA1*01:02-DQB1*06:09-DPA1*01:03-DPB1*02:01  Japanese (Japan) 0.13% 3,078 
 A*24:02-B*58:01-C*03:02-DRB1*13:02-DQA1*01:02-DQB1*06:09-DPA1*01:03-DPB1*02:01  Japanese (Japan) 0.03% 3,078 
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4.3.6.2. Bucillamine 
Another antirheumatic agent, bucillamine, has been reported to cause proteinuria in 
Japanese patients. [160] The reporting study found an association between bucillamine 
induced proteinuria and the alleles: HLA-DRB1*08:02 (𝑝 = 1.96 × 10−5; 𝑂𝑅 =
25.17, 95% 𝐶𝐼: 7.98 − 79.38) and HLA-DQB1*04:02 (𝑝 = 2.69 ×  10−4; 𝑂𝑅 =
10.35, 95% 𝐶𝐼: 2.99 − 26.83). The study reported that due to high linkage between 
the two alleles, they were unable to reach the threshold for significance when 
attempting to separate the two alleles during analysis to determine which was the more 
probable allele for being the risk factor for bucillamine induced ADRs. The AFND 
haplotype search tool is able to support the high co-occurrence for the two alleles 
(Table 4.20). The table indicates that that allele is particularly prevalent in indigenous 
North American populations. 
 
Table 4.20: Frequencies for haplotypes within the Allele Frequencies Net Database 
containing the HLA-DRB1*08:02 and HLA-DQB1*04:02 alleles. 
The population ethnicity and the sample sizes are also included. URL 
http://www.allelefrequencies.net/hla6003a.asp accessed June 2016 
Population (country) 
Haplotype frequency 
DRB1*08:02 – DQB1*04:02 
Sample size 
Latin American (Mexico) 21.60% 103 
Latin American (Mexico) 19.02% 234 
Alaska Yupik (USA) 13.30% 252 
Japanese (Japan) 10.00% 50 
Hispanic (USA) 5.61% 1,999 
Caucasian (Sweden) 3.00% 154 
Japanese (Japan) 2.20% 371 
Caucasian (Sweden) 1.20% 130 
Asian1 (USA) 0.53% 1,772 
Caucasian (Italy) 0.16% 975 
1. Presumed to refer to individuals of East Asian origin. 
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4.3.6.3. Lumiracoxib 
One study reported that lumiracoxib, a nonsteroidal anti-inflammatory drug, can cause 
hepatotoxicity associated with a common HLA haplotype: [HLA-DRB1*15:01, HLA-
DQB1*06:02, HLA-DRB5*01:01, HLA-DQA1*01:02]. [161] Interestingly, the study 
noted that this haplotype has also been associated with multiple sclerosis. AFND has 
limited information for HLA-DRB5 as this gene is not routinely typed. AFND only 
has one population group in which the individuals have a haplotype containing these 
alleles. However, they also contain HLA-DPB1 alleles and are listed below in Table 
4.21Table 4.21.  
 
It is also worth noting that the HLA-DRB1*15:01 allele has also been associated as a 
risk factor for amoxicillin-clavulanate as mentioned earlier in this manuscript. 
Amoxicillin-clavulanate and lumiracoxib are different classes of drugs, so it is 
unlikely that the two drugs interact with HLA-DRB1*15:01 protein using the same 
mechanisms. 
 
4.3.6.4. Sulfasalazine 
Inflammatory bowel diseases and rheumatoid arthritis can be treated with 
sulfasalazine. The drug has been reported to induce hypersensitivity reactions in Han 
Chinese patients carrying HLA-B*13:01, HLA-B*15:05 and/or HLA-B*39:01. [162] 
HLA-B*13:01 is a commonly occurring allele in the South-East Asian and 
Australasian region (see Table 4.22). Conversely, HLA-B*15:05 is a very low 
occurring allele, less than 1% for sample sizes greater than 1,000 with AFND reporting 
the East and South Asian populations showing the greatest allele frequency (see Table 
4.23). HLA-B*39:01 has been reported in Japanese, Native Americans, Europeans and 
Han Chinese individuals (see Table 4.24Table 4.24). Greater frequencies are observed 
when sample size restrictions are relaxed with the highest frequency being reported in 
several Taiwanese populations: Saisiat ethnic group at 54.9% and Tsou ethnic group 
at 24.5%. 
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Table 4.21: Frequencies for haplotypes that contain the HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB5*01:01 and HLA-DQA1*01:02 obtained 
from Allele Frequencies Net Database (AFND). 
The AFND haplotype search tool has limited information for this haplotype so the HLA-DPB1 alleles were also included. All entries in this table 
contain HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB5*01:01 and HLA-DQA1*01:02 and only differ by the HLA-DPB1 allele for which the 
frequencies are included. For all haplotypes, the population groups are actually the same group. 
URL http://www.allelefrequencies.net/hla6003a.asp accessed June 2016 
Haplotype Frequency Population Sample Size 
HLA-DRB1 HLA-DRB5 HLA-DQA1 HLA-DQB1 HLA-DPB1 
15:01 01:01 01:02 06:02 
04:01  9.3% 
Caucasian (USA) 220 
02:01  2.1% 
04:02  1.8% 
23:01  1.1% 
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Table 4.22: Frequencies obtained from Allele Frequencies Net Database (AFND) for 
the HLA-B*13:01 allele and the populations where it is found at relatively high 
frequencies. 
The first three entries in the table are for the top entries where the sample size was 
smaller than 1,000 and show that the allele is present in populations outside of East 
Asia. The bottom four entries are the top results from AFND where the sample size 
was greater than 1,000. URL http://www.allelefrequencies.net/hla6006a.asp 
accessed June 2016. 
Population (country) HLA-B*13:01 frequency Sample size 
Melanesian (Papua New Guinea) 28.30% 131 
East Asian (Taiwan) 28.00% 50 
Aborigine (Australia) 27.00% 103 
Han Chinese (Hong Kong) 7.94% 7,595 
Han Chinese (Hong Kong) 7.75% 3,892 
Han Chinese (USA) 6.35% 99,672 
Vietnamese (USA) 3.94% 43,540 
 
Table 4.23: Populations where the HLA-B*15:05 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-B*15:05 frequency Sample size 
South Asian/Indian (USA) 0.45% 185,391 
South-East Asian (USA) 0.33% 27,978 
“Asian” (USA)1 0.28% 1,772 
Han Chinese (Germany) 0.12% 1,282 
Japanese (Japan) 0.10% 1,018 
1. Presumed to refer to East Asian 
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Table 4.24: Populations where the HLA-B*39:01 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-B*39:01 frequency Sample size 
Japanese (Japan) 3.40% 1,018 
Native American (USA) 3.39% 35,791 
Japanese (Japan) 3.32% 18,604 
Japanese (USA) 3.03% 24,582 
Caucasian (Croatia) 2.56% 4,000 
Caucasian (Germany)1 2.24% 1,028 
Han Chinese (USA) 1.93% 99,672 
1. Minority Bosnia and Herzegovina population residing in Germany 
 
4.3.7. Antipsychotics 
4.3.7.1. Clozapine 
Clozapine is an antipsychotic agent used to treat patients with treatment-resistant 
schizophrenia. Clozapine-induced agranulocytosis has been reported in two studies by 
the same group which likely used the same patient and control groups of European 
origin. [116, 163]The initial study limited the investigation to HLA-B, HLA-DRB and 
HLA-DQB typing, whilst the full investigation typed these loci and also the HLA-C, 
HLA-DPB as well as the HLA-DRB1, DRB3, DRB4 and DRB5 loci. The authors 
reported HLA-DQB1*05:02, DRB5*02, HLA-C*07 and HLA-DPB*04:01 were 
associated with clozapine-induced agranulocytosis. However, their reporting of HLA 
was variable as they employed old and current HLA nomenclature as well as a mix of 
high- and low-level resolution typing which limits the ability to incorporate these 
results within a meta-analysis as the allele and resolution data are not comparable with 
data from other studies. 
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The only allele reported as a risk factor for a clozapine-induced adverse response typed 
to two-field resolution was HLA-DQB1*05:02 (𝑝 = 0.006 and 𝑂𝑅 =
15.4, 95% 𝐶𝐼: 1.72 − 138). Table 4.25 shows the allele frequencies for HLA-
DQB1*05:02 in populations where the allele is at its highest prevalence. The other 
significant associations cannot be determined to their specific allele product (two-field 
resolution). A recent GWAS also reported that a SNP that is in strong linkage with 
HLA-DQB1*05:02 is a risk allele for agranulocytosis to clozapine. [164] This study 
also reported that a SNP located in HLA-B played an important role, and the HLA-
B*38, HLA-B*39 and HLA-B*67 alleles were offered as candidates to investigate 
further. 
 
Table 4.25: Populations where the HLA-DQB1*05:02 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-DQB1*05:02 frequency Sample size 
Caucasian (Italy – Sardinia) 10.60% 1,129 
“Asian” (USA)1 7.35% 1,772 
Turkish (Germany) 6.63% 4,856 
Vietnamese (USA) 5.77% 43,540 
Black (USA) 2.73% 2,411 
1. Presumed to refer to East Asians 
 
4.3.8. Antithrombotic drugs 
4.3.8.1. Ticlopidine 
Ticlopidine is a drug which is used for preventing thrombotic stroke in patients who 
are unable to take aspirin, for example the above-mentioned AIU and AIA, or if aspirin 
has previously failed to adequately treat the patient for a stroke. Ticlopidine-induced 
hepatotoxicity has been reported in Japanese patients carrying HLA-A*33:03, HLA-
B*44:03, HLA-C*14:03, HLA-DRB1*13:02 and HLA-DQB1*06:04. [165] The 
haplotype containing all these listed alleles is the second most commonly occurring in 
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the Japanese populations and was present in 10 out of the 14 hypersensitive individuals 
of the reporting study.  
 
4.3.9. Anticoagulants 
4.3.9.1. Ximelagatran 
Ximelagatran is an anticoagulant which was withdrawn from distribution in 2006 due 
to reported elevation of liver enzyme levels and hepatic damage in patients. [166] A 
study by Kindmark et al. found an association between HLA-DRB1*07:01 and HLA-
DQA1*02 with ximelagatran based DILI in a Northern European patient-control 
cohort. The study also reported that HLA-DQB1*02 was associated as 65% of the 
cases which carried the DRB1*07-DQA1*02 haplotype also possessed a DQB1*02 
allele. [118] The AFND haplotype frequency search tool shows that this haplotype can 
be found in many geographic regions including Africa, Asia, Australia (Aborigine) 
Europe and North America; this is likely due to the HLA-DQA1 and HLA-DQB1 
alleles only being resolved to the 1st field so is therefore extremely broad for the search 
tool. 
 
4.3.10. Anticancer drugs 
4.3.10.1. Lapatinib 
Lapatinib is used in the treatment of solid tumours including breast cancer and lung 
cancer. Lapatinib induced hepatotoxicity has been reported in three HLA class II 
alleles: HLA-DQA1*02:01, HLA-DQB1*02:02 and HLA-DRB1*07:01. [28, 167] The 
two reporting studies were each conducted with ethnically diverse patients. The 
distribution of the three alleles follows this pattern as they all have a wide geographic 
distribution which is not specific to a particular region in the world or ethnic group as 
shown in Table 4.26. A recent investigation identified HLA-DRB1*07:01 to be 
strongly associated with lapatinib based DILI and did not find a similar association 
with the other alleles of the above mentioned haplotype. [168] It is also worth noting 
that HLA-DRB1*07:01 and serotypes that HLA-DQA1*02:01 and HLA-
DQB1*02:02 belong to have also been associated with ximelagatran ADRs despite 
the dissimilar structures between the drugs. HLA-DRB1*07:01 is a commonly 
occurring allele not specific to a particular geographic region (see Table 4.27). 
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Table 4.26: Frequencies for haplotypes within the Allele Frequencies Net Database 
containing the HLA-DQA1*02:01, HLA-DQB1*02:02 and HLA-DRB1*07:01 alleles. 
The population ethnicity and the sample sizes are also included. URL 
http://www.allelefrequencies.net/hla6003a.asp accessed June 2016 
Population (country) Haplotype frequency Sample size 
North African (Morocco) 16.70% 98 
Caucasian (USA) 11.08% 1,899 
North African (Tunisia) 10.20% 100 
Caucasian (USA) 8.90% 220 
Korean (South Korea) 6.60% 467 
 
Table 4.27: Populations where the HLA-DRB1*07:01 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. These 
frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-DRB1*07:01 frequency Sample size 
Morocco Jewish (Israel) 23.86% 36,718 
Libya Jewish (Israel) 23.32% 3,739 
Tunisia Jewish (Israel) 17.98% 9,070 
Yemen Jewish (Israel) 17.84% 15,542 
South Asian – Indian (USA) 16.95% 185,391 
Caucasian (Germany)1 15.94% 1,176 
Han Chinese (China) 15.80% 3,238 
1. Portuguese minority residing in Germany 
 
4.3.11. Ocular glaucoma drug 
4.3.11.1. Methazolamide 
The carbonic anhydrase inhibitor, methazolamide is used to treat glaucoma. The drug 
has been reported to be associated with SJS/TEN in Han Chinese patients. [169] The 
study reported the associations to be with the haplotype consisting of HLA-B*59:01 
and HLA-C*01:02. When the study looked at the individual alleles, they reported that 
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the association with HLA-B*59:01 was statistically more significant (𝑝 = 6.3 ×
 10−7; 𝑂𝑅 = 305.0; 95% 𝐶𝐼: 11.3 − 8259.9) compared to HLA-C*01:02 (𝑝 =
1.6 ×  10−2; 𝑂𝑅 = 12.1; 95% 𝐶𝐼: 1.3 − 111.7).  The HLA-C*01:02 allele is 
commonly occurring in Chinese and Japanese populations (see Table 4.28). The allele 
is also found at lower frequencies in Latin American and Europeans (≤ 5.7% where 
sample sizes are greater than 1,000). The HLA-B*59:01 allele is found at much lower 
frequencies as shown in Table 4.29. Although the table itself lists East Asian 
populations, the allele is found at frequencies that approach zero in other populations 
such as Native American, South Asian, Caribbean Black, Latin Americans and 
Europeans. The difference in the significance values between the two alleles can be 
explained as HLA-B*59:01 was reported to be carried by none of the drug-exposed 
controls and HLA-C*01:02 was found in 11 of 30 controls. As such, the study reported 
that HLA-B*59:01 is the most likely candidate for the risk factor for methazolamide-
induced SJS/TEN. 
 
Table 4.28: Populations where the HLA-C*01:02 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-C*01:02  frequency Sample size 
Han Chinese (China) 20.17% 1,098 
Han Chinese (USA) 19.15% 99,672 
Han Chinese (Hong Kong) 18.99% 7,595 
Japanese (Japan) 18.20% 1,018 
Japanese (Japan) 17.60% 18,604 
Korean (USA) 16.77% 77,584 
Vietnamese (USA) 16.73% 43,540 
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Table 4.29: Populations where the HLA-B*59:01 allele is found at relatively high 
frequencies where the sample size of the population was greater than 1,000. 
These frequencies were obtained from the Allele Frequencies Net Database. URL 
http://www.allelefrequencies.net/hla6006a.asp accessed June 2016. 
Population (country) HLA-B*59:01  frequency Sample size 
Japanese (USA) 2.24% 24,582 
Japanese (Japan) 2.04% 18,604 
Korean (South Korea) 1.85% 4,128 
Korean (USA) 1.67% 77,584 
Han Chinese (China) 0.30% 3,238 
Han Chinese (USA) 0.05% 99,672 
 
4.3.12. Analysis of all data 
To investigate whether any observable trends can be determined in responses between 
different ethnic groups, the information was analysed by producing a table of 
descriptive statistics (see USB/CD media file “chapter_4_descriptive_statistics”), a 
Kruskal-Wallis test (Table 4.30) and boxplots (Figure 4.2) of the frequencies for the 
alleles which have been associated with ADRs. A limitation was applied to only 
included strong associations (where 𝑝 ≤ 0.01) and/or have been independently 
replicated in two or more studies were included for this analysis. In these analyses, the 
information has been grouped by the three major ethnic groups (as described in the 
methods section). Across the range of drugs featured in this chapter, there is an 
apparent trend whereby more of the alleles that have been associated with adverse 
events have higher allele frequencies in Asians. The results show that 6 of 33 HLA 
alleles which show significant associations (𝑝 ≤ 0.01) have statistically higher allele 
prevalence in Asians compared to two in Africans and two in Europeans. This is 
particularly noticeable in patients prescribed with antiepileptic drugs where 43% of 
the alleles associated with carbamazepine hypersensitivity, 33% of the alleles 
associated with lamotrigine ADRs and 67% of alleles associated with phenytoin 
ADRS are found in higher frequencies in Asians. For these three drugs, the 
associations with alleles that show strong evidence/well replicated were either 
associated with Asians or were neutral (i.e. not specific to a particular ethnic group). 
None of the alleles can be classed as strongly associated with Europeans or Africans. 
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Figure 4.2: a) Boxplots showing the frequencies for class I HLA alleles that have been reported in this chapter to have a strong association with 
adverse drug reactions (𝑝 < 0.01) and/or have been reported independently by two or more studies. 
 
a) 
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Figure 4.2: b) Boxplots showing the frequencies for class II HLA alleles that have been reported in this chapter to have a strong association with 
adverse drug reactions (𝑝 < 0.01) and/or have been reported independently by two or more studies. 
b) 
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Table 4.30: Kruskal–Wallis test displaying the level of significance for the 
differences in allele frequencies between the three major ethnic groups (Africans, 
Asians and Europeans). 
The selected alleles are those that have been reported in this chapter to be 
significantly associated with an adverse drug reaction. The allele frequencies were 
obtained from Allele Frequencies Net Database (AFND) for various subpopulations 
that belong to the major ethnic groups. The Kruskal–Wallis test was applied using 
the statistical package r version 3.2.2 where Bonferroni correction for multiple 
comparisons was applied. Comparisons that are significant (P < 0.05) after 
correction for multiple testing have been highlighted in the boxplot shown in Figure 
4.1. 
Allele Africans vs Asian African vs European Asian vs European 
A*02:01 1 6.6 × 10−10 8.25 × 10−10 
A*02:06 6.6 × 10−15 1 6.6 × 10−15 
A*30:02 1.716 × 10−09 5.61 × 10−08 0.462 
A*31:01 0.2838 0.1439 0.2319 
A*33:03 0.3036 3.1 × 10−6 9.9 × 10−10 
B*13:01 6.6 × 10−15 0.62 6.6 × 10−15 
B*15:02 6.6 × 10−15 0.36 6.6 × 10−15 
B*44:03 1 1 1 
B*57:01 0.37 0.21 1 
B*58:01 1 2.904 × 10−5 3.0 × 10−5 
B*59:01 0.49 1 0.49 
C*03:02 0.0363 1 0.00396 
C*03:04 1 0.37 1 
C*04:01 8.6 × 10−5 0.14 0.001353 
C*14:03 1 0.97 1 
DPB1*03:01 1 2.2 × 10−5 5.6 × 10−4 
DQA1*01:02 0.00495 0.0132 0.4328 
DQA1*02:01 1 0.1 0.78 
DQA1*03:01 0.93 0.82 1 
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Allele Africans vs Asian African vs European Asian vs European 
DQB1*02:01 1 0.48 0.17 
DQB1*03:03 3.6 × 10−6 0.075 6.9 × 10−5 
DQB1*04:02 0.065 0.255 0.888 
DQB1*05:02 0.066 0.11 0.084 
DQB1*06:02 2.871 × 10−7 0.002343 0.0132 
DQB1*06:04 0.15 1 0.39 
DQB1*06:09 0.09387 7.6 × 10−5 0.01617 
DRB1*03:01 0.4835 1 0.0198 
DRB1*04:02 1 0.429 0.132 
DRB1*07:01 1 0.145 0.825 
DRB1*08:02 0.54 0.86 1 
DRB1*11:01 0.21 1 0.14 
DRB1*12:02 6.6 × 10−15 1 6.6 × 10−15 
DRB1*13:01 0.44979 1 0.01386 
 
4.4. Discussion 
Whilst from a general perspective, there is an abundance of data with regards to the 
reported ethnic response and ADRs, little can be said with absolute certainty. The 
primary reason is that there are inconsistencies in the way the data are reported. Some 
of the reported alleles are not well replicated and appear to be statistically significant 
in some studies whilst non-significant in others - the results section in this chapter 
highlight this where examples can be seen with carbamazepine and nevirapine. A 
likely reason for the inconsistency can be argued by the relatively small patient-control 
cohorts from which the studies are conducted. These small studies are prone to the 
effects where the data from a few patients can greatly influence the statistical analyses 
as a single patient can represent a larger proportion of the available data. The small 
patient-control cohort issue coupled with HLA allele linkage disequilibria as featured 
in this chapter also prevents the risk allele/biomarker from being identified. In these 
cases, only the haplotype can be reported as the risk factor (e.g. in the case of aspirin-
induced urticaria and the haplotype containing the alleles: DRB1*13:02–
DQB1*06:09–DPB1*02:01). [27] However, overcoming this issue of small patient-
control cohort size is easier said than done since specific ADRs are rare and therefore 
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studies have difficulty in obtaining a sufficient number of ADR patients for an 
adequately powered study. 
 
Additionally, there has been few studies published which have demonstrated how the 
drug-allele pairs interact (e.g. the report by Illing et al. showing how abacavir interacts 
with HLA-B*57:01) and the majority of the reported evidence still relies on 
association studies. [46, 170] This not only restricts the understanding for the biological 
mechanisms that cause ADRs, it also forces the majority of investigations to be reliant 
on these association studies. 
 
Looking at specifics, the association between anti-tuberculosis drugs and the carriage 
for HLA-C*04:01 in terms of patient ADRs, the number of ADR patients (n = 14) is 
low and has not been replicated by other groups therefore, any statement with regards 
to the association cannot be made with confidence. In the case with nevirapine, the 
three studies featured in the results section were unable to replicate the findings of 
each other where an allele reported as significantly associated by one study but was 
not found to be significant in another study even when the allele was carried by 
members of the patient-control cohort. With these studies, Carr et al. reported HLA-
C*04:01 as a risk factor however, Chantarangsu et al. reported the risk factor to be 
HLA-B*35:05 and found HLA-C*04:01 to be non-significant after statistical 
correction. [35, 36] Similarly, Phillips et al. found HLA-B*35:05 to be non-significant 
in their study. [159] With all this conflicting evidence, further studies are required to 
investigate the situation for nevirapine induced ADRs. 
 
For the other antiretroviral abacavir, this review only focused on the allele frequencies 
for HLA-B*57:01 and not DRB1*07:01 as it has been demonstrated that abacavir 
directly interacts with the F-pocket located in the antigen-binding cleft of the HLA-
B*57:01 allele and only one of the featured studies reported HLA-DRB1*07:01 as a 
co-occurring allele. [46] In this instance, the evidence is overwhelmingly in favour of 
HLA-B*57:01 as a sole risk factor for abacavir induced ADRs. 
 
In other cases, it is often difficult to pinpoint the exact risk factor as due to the limited 
number of studies available for a particular drug-ADR, in some cases this may be only 
one study. In such reports, as exampled with ticlopidine, the risk factor can only be 
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resolved to a haplotype but not any of the specific alleles. The strong linkage between 
some alleles can create obstacles in research for determining the causative allele. The 
ideal way to overcome this is to conduct a comparable investigation in another 
population where the ADR is observed, but the haplotype is not common. However, 
such scenarios can be rare to achieve. 
 
As showcased in Chapter 2 there are issues with publication bias where these types of 
studies are conducted and are limited with East Asia and Europe representing the 
majority of the data present in the HLA-ADR database, only a handful of publications 
are produced from other regions. This can limit the impact of declaring certain ADRs 
to be more prevalent in patients of particular ethnic groups. For example, to date, 
bucillamine induced ADRs has only been implicated in Japanese patients. However, 
the results of this review indicate that the associated haplotype is also found in other 
populations such as indigenous North Americans where very little information 
regarding immune-mediated ADRs is available. It is possible that these populations 
are at greater risk of experiencing bucillamine related ADR events compared to the 
baseline ADR incidence rate. Conversely, a situation where the haplotype is in lower 
frequency for a population but one of the alleles is present would present a good 
opportunity to conduct a study to isolate the true risk allele. For example, HLA-
DQB1*04:02 is present in many populations of recent African origin but does not co-
occur with HLA-DRB1*08:02 at a high rate (see Table 4.31Table 4.31). If a study is 
conducted using this population, it could help separate the risk allele from the co-
occurring allele.  
 
There are also different responses to similar class drugs. Both nevirapine and abacavir 
are used in the treatment of HIV however, different alleles have been implicated with 
their respective ADRs. However, the difference in response is likely due to the 
difference in chemical structure and method of reverse transcriptase inhibition (one is 
a nucleoside analogue reverse transcriptase inhibitor and the other is a non-nucleoside 
reverse transcriptase inhibitor). The chemical structure also likely explains why many 
of the antiepileptics have HLA-B*15:02 in common as an associated risk factor as 
their chemical structures are similar. This similarity in structure suggests a similar 
mechanism of action which triggers the hypersensitivity reactions with the possibility 
of cross-reactivity between the antiepileptic drugs. [33]
  
 
1
2
4 
Table 4.31: Allele frequencies net database haplotype search where HLA-DQB1*04:02 was selected and “any” for the other HLA genes. 
The search was further restricted to patients of Black/African origin where the sample size was greater than 1,000. The table shows the other 
alleles that co-occur with HLA-DQB1*04:02 and the corresponding haplotype frequency is included. URL 
http://www.allelefrequencies.net/hla6003a.asp accessed June 2016. 
Haplotype Population Haplotype frequency Sample size 
DRB1*03:02-DQB1*04:02  Black (USA) 5.94% 2,411 
A*30:01-B*42:01-C*17:01-DRB1*03:02-DRB3*01:01-DQB1*04:02 Caribbean Black (USA) 1.60% 33,328 
A*30:01-B*42:01-C*17:01-DRB1*03:02-DQB1*04:02  Black (USA) 1.52 2,411 
A*30:01-B*42:01-C*17:01-DRB1*03:02-DRB3*01:01-DQB1*04:02 Black (USA) 1.48 416,581 
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The manifestation of hypersensitivity reactions to antiepileptic drugs has been 
reported to be approximately five times greater in patients who have previously 
exhibited ADRs with a different antiepileptic drug. However, the rate of cross-
reactivity varied between different drugs. [171] The reporting study also recommended 
against prescribing phenytoin, carbamazepine and lamotrigine (two of which have 
ADRs associated with HLA-B*15:02) to patients with a history of antiepileptic-
induced ADRs. All three of these drugs also have ADRs associated with HLA alleles 
that have higher frequencies in Asian populations. High cross-reactivity has been 
reported in Chinese patients that were prescribed carbamazepine, oxcarbazepine, 
phenytoin and lamotrigine. [172, 173] The precise mechanisms which cause cross-
reactivity of antiepileptic drugs are not fully understood therefore, additional 
investigations which look to elucidate the mechanism of action would be required to 
confirm this hypothesis. Whilst the Kruskal–Wallis analysis of population control data 
does show a skewing towards Asians, more data are required to form robust 
conclusions. The observed skewing towards Asians is possible because many drugs 
particularly in the past were likely developed in Europe and/or North America and 
where clinical trials were conducted with participants of European descent. 
 
 
Some of the associations for the drugs featured in this chapter have been reported with 
both class I and class II HLA alleles. However, there is limited haplotype data 
available for alleles covering both class I and class II alleles because most of the 
available data focus on each class type. Of the 91 studies that are featured in systematic 
review of Chapter 2, 56 studies focus only on class I HLA alleles, 18 studies focused 
solely with class II HLA alleles and only 17 studies typed patients across both of these 
classes. These restrictions pose as obstacles for a full understanding of the relationship 
that alleles in high linkage have in the context of ADRs. The solution to this issue 
would be to sequence/type patients across the entire MHC region allowing all of the 
HLA allele data to become available. Recently, there have been techniques that have 
been developed which aim to produce complete phasing of the MHC region but the 
technology is still in its infancy. [174] 
 
The findings of this chapter also suggest that the different prescribing decisions may 
require revaluation for each drug–ADR combination and should take into account the 
 126 
 
patient's ethnicity (a proxy to give an indication as to the likelihood of the patient 
carrying a risk allele). For example, whilst the analysis of all the data indicates that 
both the HLA-A*31:01 and HLA-B*15:02 alleles have been strongly associated with 
carbamazepine hypersensitivity, evidence is stronger to support pre-treatment 
genotyping of patients for HLA-B*15:02 in Asians before prescribing the drug. [175] 
Comparatively, HLA-A*31:01 is an allele that can be found throughout many 
populations across the world at fairly low frequencies.  
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Chapter 5. Validation of a new HLA typing method 
based on a panel of select HLA alleles associated 
with ADRs 
5.1. Introduction 
Historically, HLA typing of samples was performed using a serological based 
approach. However more recently, HLA typing is performed using one of three main 
molecular based methods. These are: sequence-specific primer assay (SSP), sequence-
specific oligonucleotide (SSO) assay and sequence based typing (SBT) which are 
described in Chapter 1.3. One of the biggest challenges faced in HLA typing is the 
difficulty in acquiring the phase of the polymorphisms- that is to say due to the high 
level of heterozygosity and diversity in the MHC region, using the non-next generation 
sequencing techniques mentioned above across the entire HLA locus has poor 
reliability. [176, 177] This is further complicated as the multiple HLA genes within the 
region share some degree of sequence homology which means that attempting to 
overlap the sequence reads in an attempt to determine phase will be near impossible 
to obtain unambiguously. [178]  
 
5.1.1. General principle of the HISTO MATCH typing method 
The HISTO SPOT HLA typing methods that were tested as part of this project 
involved an SSO based system where the assay tests for six HLA gene loci. The six 
HLA loci are: HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1 and HLA-DQB1.  
The test principle of the procedure is shown below in Figure 5.1. The procedure 
involves extracting DNA from the patient sample which is then amplified via PCR 
(PCR protocols are shown in Methods section) – the amplification is locus specific 
(MHC/HLA region). The PCR plate is then placed within the MR SPOT machine 
along with the assay reagents and the reaction wells which contain the SSO probes 
that are fixed at the bottom. The SSO probes are designed to be specific to certain 
sequences for particular HLA alleles. Any amplified DNA that is bound to the SSO 
probes trigger an enzyme mediated colourimetric reaction which appear as dark spots 
at the bottom of the well. The pattern of dark spots is then interpreted by the HISTO 
MATCH software (included with the assay equipment) and if the pattern of probes 
correlates with that of one or more predetermined alleles then these are highlighted as 
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risk alleles to the user in the final report. In this context the risk alleles are defined in 
section 5.1.2.  
 
This chapter features two variants of the MR SPOT kit, the first method which will be 
referred to as a “one well system” and is a test where the risk alleles for all five tested 
genes/loci are tested for in one well. The other variant of the kit is referred to as a “five 
well cartridge system” where the five HLA loci are each tested in separate wells 
contained within one cartridge (see Figure 5.2). The cartridges are actually composed 
of eight wells where the first five wells each correlate to an HLA loci whilst the 
remaining three are left unused but are left available for future expansions to the kit. 
With the one well system, the MR SPOT machine can accommodate 12 × 8 well 
strips (a total of 96 samples can be tested in a single run) whilst the five well cartridges 
system can hold a total of six cartridges so only six patients can be HLA typed in a 
single run. 
 
 
Figure 5.1: Test principle showing work path / procedure steps of the HISTO SPOT 
assay. 
Sourced from MC Diagnostic
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Figure 5.2: Diagrammatic representation to show the SSO probes distribution based 
on HLA loci. 
 
5.1.2. Determination of panel of HLA alleles 
The predetermined alleles are a panel of over 20 HLA alleles which have been reported 
to cause HLA mediated ADRs (see Figure 5.3). [179] The panel was designed around 
alleles that showed significant evidence to be associated with ADRs where the alleles 
were typed to at least 2-field resolution. As part of the data analysis performed in 0, 
the inclusion/exclusion of some of the alleles were re-evaluated and subsequently, the 
panel has since been modified – the details of the changes and reasons are discussed 
in that chapter.  
 
 
Figure 5.3: Panel of 24 alleles which were initially reported by the HISTO MATCH 
software. 
From Pirmohamed et al., 2015. 
 
HLA-A 
HLA-B 
HLA-C 
HLA-DRB1 
HLA-DQ 
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5.1.3. HISTO MATCH software 
5.1.3.1. Worklist creation 
The HISTO MATCH software is provided by the manufacturer to their customers who 
have purchased the lab equipment. It is designed to prepare the initial worklist that 
allows the test to run and also interpret the results (the colourmetric probes pattern) 
from the test assay. The user must first, as a requirement, create a worklist detailing 
the layout of the samples into the software. This can be achieved in two ways: first, 
the user can create a comma separated value (CSV) list whereby the samples are on 
separate lines and the sample ID and program type are separated by a comma. The 
sample ID is for the benefit of the user to refer back to the samples using their own ID 
system that is in place and in the program type allows the HISTO MATCH 
interpretation software gain context for the samples. In the one well system, the 
program type is “ADR” for all samples whilst in the five well cartridge system, the 
program type is the HLA gene locus being tested in the reaction assay (e.g. “A” or “B” 
etc). The order of the samples is important, relative to the PCR plate where the well 
designated as A1 is located at the top left corner, the next sample must refer to the well 
B1, then C1 etc – i.e. the order is top-down, left to right; this ensures that the software 
refers to the correct sample. 
 
Once the CSV file is created, the file can be loaded into the HISTO MATCH software 
where the program will generate the XML worklist file that the MR SPOT equipment 
requires for the assay. The second method to generate an XML worklist is done within 
the MR SPOT software itself where in the absence of an XML document from HISTO 
MATCH, the machine will automatically generate a worklist and preload the sample 
IDs with 1 until the end number of samples that the assay can support (96 for the one 
well assay and 6 samples for the five well assay system) along with the appropriate 
program type. After this has been entered into the machine, the user can complete the 
steps laid out in the Methods section. 
 
5.1.3.2. Results interpretation 
When the reaction assay is complete, the user can export the XML file and a zip folder 
containing images of the reaction wells. The exported XML file is a modified file of 
the original XML worklist and contains the metadata associated with that specific run 
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including the date of the run, machine ID, the lot/batch number of the reagents used in 
the test, the batch number of the assay wells/cartridges and the status of completion 
for each step. This allows the user and/or manufacturer to pinpoint any issues that may 
arise if a test run should fail. The user then imports these XML files and zip folders 
back into the HISTO MATCH software where the results can be analysed for HLA 
typing. The software reads in the XML file to refer to the sample ID and program type 
so that it has context on how to interpret the colourmetric probes pattern (see Figure 
5.4 for the premise of the spots and Figure 5.5 for premise of the software’s gridding 
function). If the intensity of the colourmetric probe reaches the threshold that was 
defined by the manufacturer for that probe then that probe is interpreted as a positive 
hit (Figure 5.6). The pattern of positive and negative hits on the probes will determine 
the allele called.  
 
5.1.4. Premise of project 
The primary aim for the manufacturer is for the equipment to be deployed in clinical 
scenarios where clinicians need a relatively quick answer as to whether a patient 
carries an ADR risk allele for a particular drug they wish to administer to their patient. 
The new method aims to have a very quick turnaround time (approx. 48 hours from 
when the extracted DNA is processed) and be more cost effective compared to current 
methods. This would allow a clinician to predict, prevent and/or diagnose ADRs. For 
this thesis project, the equipment requires validation before being implemented in a 
clinical setting. The HISTO MATCH kit was tested using samples which have been 
previously typed using a currently accepted method and therefore the HLA alleles for 
the samples are already known. As part of the validation process, the samples were 
independently tested twice using two researchers to demonstrate if the kit is both 
accurate and consistent. 
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Control spots: 
Indicates that master mix was added to the PCR run and also act as 
positional probes that enables the software to locate the picture  
 Kit identity 
 Lot identity 
 Batch identity 
 
Check digits:  
Control, if kit, lot and batch identity are correct. If not, something is 
wrong with the gridding  
 Positive specific probes 
 
Positive controls: 
Positive for all alleles and indicates that the PCR was successful  
Basis for defining the reactivity of the other probes in the well 
Figure 5.4: Diagram showing the colourmetric probes pattern within the well and what each of the spots represent.  
Sourced from manufacturer. 
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Figure 5.5: HISTO MATCH software’s gridding function to align colourmetric assays against reference (Figure 5.4). 
a) An example of the raw image file  
b) Shows the grid overlay generated by the HISTO MATCH software. The software automatically performs the gridding, however it is advised 
that users manually check these and adjust if required. 
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Figure 5.6: Screenshot of the HISTO MATCH software analysing the colourmetric probes to determine positive/negative hits for that probe. 
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In addition to validating the assay, the panel of HLA alleles was evaluated in the 
context of this project, allowed changes to be recommended where necessary.  
Additionally, this was the first time that the assay was tested using DNA extracted 
directly from human cells so there was an expectation that the machine would need 
some minor calibration to be able to adapt to the change – the data collected during 
initial runs was to be reviewed and used to formulate the required adjustments. As 
well as the equipment’s primary function of informing clinicians of the carriage of risk 
alleles associated with ADRs, the project was also be complemented with a clinical 
decision support tool (0). The work carried out in that chapter is supportive for the 
development of the project in this chapter and vice versa.  
 
5.2. Materials and Methods 
Table 5.1: List of reagents/consumables that are used with the new HLA typing 
methods investigated in this chapter. 
Protocol step Item(s) Supplier 
PCR amplification 
Mastermix 
Magnesium chloride (MgCl2) 
PCR plates (96 wells) 
PCR seal 
MC Diagnostic 
St Asaph 
Wales 
United Kingdom 
dH2O 
DNA 
 
Mr Spot Assay 
Conjugate  
Block buffer 
Stringent buffer 
Tris-buffered saline (TBS) 
Substrate buffer 
Hybridisation buffer 
MC Diagnostic 
St Asaph 
Wales 
United Kingdom 
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5.2.1. Researchers 
The following people were involved in the project and their roles are defined below: 
 
AA – Principal/supervising investigator 
 
LH – One of the researchers who was conducting the analysis of the HISTO SPOT 
kit. (Departed the project mid-way though) 
 
AO – researcher who took over upon the departure of LH 
 
GG – other researcher who conducted the analysis of HISTO SPOT 
5.2.2. Volunteers / DNA samples 
The DNA samples were obtained from an archive generated from 1,000 healthy 
volunteers which were recruited from the North West region of England. The DNA 
samples were collected prior to this project and were collected in two stages with the 
demographic characteristics of the volunteers listed in the (see Table 5.2) below. In 
the first collection, 400 patients were recruited with 385 of those being brought 
forward – this thesis will refer to these as the first 400 based on the internal ID 
numbering system used. [180] An additional 600 volunteers were recruited in the second 
round. [181] 10mL of venous blood was used where the genomic DNA was extracted 
using Chemagic magnetic separation (Chemagen, Baesweiler, Germany). The samples 
were analysed using sequence based typing by Histogenetics laboratory 
(Histogenetics, New York, USA). The sequencing was performed over exon 2 for class 
II HLA genes and exons 2 and 3 for class I loci – the HLA loci covered were HLA-A, 
HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 and HLA-DQA1. The DNA 
concentrations were determined using Nanodrop spectrophotometer and picogreen 
measurements and the samples were normalised to 50 ng/μL concentrations. The HLA 
typing information for these samples were performed prior to this project. [180, 181] 
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Table 5.2: Demographic information of volunteers’ DNA samples. 
Characteristic Archive samples 
1-400 401-1000 
Median age (standard dev.) 29 (± 10 years) 31.5 (± 10.6 years) 
Sex, female : male 0.64 : 0.36 0.66 : 0.34 
Ethnic diversity 
Caucasian 
South Asian 
Chinese 
Black 
Other / Mixed 
 
77.4% 
7.3% 
3.9% 
1.3% 
10.1% 
 
90.2% 
2.8% 
1.5% 
1.2% 
3.8% 
 
During initial assay runs to test and calibrate the HISTO SPOT equipment, samples 
with ID 1-1000 (the whole sample range) were used. However, several rounds of 
testing and equipment adjustments were required, more than originally envisioned, so 
samples with tube ID 1-400 were close to the point of depletion. Consequently, a 
decision was made to conserve the samples and not use samples 1-400 in the final 
results. Therefore, the results section only displays the allelic calls for samples in the 
range of 401-1000. The one well assay method shows the results for samples 401-804 
– a decision was made to stop at this sample and not continue with samples 805-1,000 
as it became apparently clear that the one well assay method would not come anywhere 
close to 100% accuracy for HLA typing. Priority was given to conserve the DNA for 
further analysis (both relating to this project and for other studies) – similarly as to 
why samples 1-400 were not included.  
 
The HISTO MATCH software was adjusted with the data collected from the 
interpretation of samples 401-804. It was decided that the samples that were not 
included (805-1,000), could be used for the five well cartridge system as these samples 
are unknown to the HISTO MATCH software meaning that the software would be 
making the allele calls without the manufacturers programming the software to 
automatically recognise the samples’ HISTO SPOT profiles.  This is similar to the 
concept of training data in bioinformatics and statistical analysis which is used as a 
means to prevent overfitting of the data. Since the five well cartridge system requires 
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using five times the quantity of sample DNA, it was apparent that there were 
insufficient quantities of samples 805-901 therefore, the five well cartridge assays 
were performed using 96 samples from tube ID range 902-999. 
 
5.2.3. One well assay method 
The first stage of the procedure was to amplify the DNA in the samples that were 
provided in the project. The samples were previously diluted from the original stock 
solutions to have a standardised concentration of 50 ng/μL. The HISTO SPOT 
protocol requires that the DNA samples be at a concentration of 15 ng/μL. Therefore 
for this project, the DNA was diluted down to 15 ng/μL for the procedure using Tris-
EDTA (TE) buffer. The PCR amplification reagents are prepared as shown below: 
 
Table 5.3: Quantities of reagents required for mastermix solution for one well assay 
method. 
Reagent 
Quantity 
Per Sample 96 well plate (x110) 
Mastermix 10µL 1100µL 
MgCl2 5µL 550µL 
 
In 2mL microcentrifuge tube: 
 Add the mastermix and MgCl2 together and vortex 
 
In PCR plate: 
 Add 15μL of mastermix and MgCl2 solution into each well 
 Add 5μL of DNA – one patient sample per well 
 Cover plate using PCR seal 
 Centrifuge PCR plate for 60 seconds at 500rpm 
 Transfer to thermal cycler for amplification as described in Table 5.4 
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Table 5.4: PCR thermal cycler program for the one well assay method as provided 
by the manufacturer. 
Program Step Time (mm:ss) Temperature Number of cycles 
1st Denature 03:00 95˚C X1 
Denature 00:15 95˚C 
X35 Annealing 00:30 65˚C 
Extension 02:00 68˚C 
Final extension 10:00 68˚C X1 
Hold Program end 22˚C  
 
5.2.4. Five well cartridge assay method 
The procedure for the five well cartridge assay is similar to that of the one well method 
with the main difference being that five times as much sample DNA is required as the 
HLA loci have been separated into individual wells of the cartridge. The mastermix 
and MgCl2 solution is mixed as below: 
 
Table 5.5: Quantities of reagents required for mastermix solution for five well 
cartridge assay method. 
Reagent 
Quantity 
Per Sample 6x five well cartridges (x35) 
Mastermix 10µL 350µL 
MgCl2 5µL 175µL 
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In microcentrifuge tube: 
 Add the mastermix and MgCl2 together and vortex 
 
In PCR plate: 
 Add 15μL of mastermix and MgCl2 solution into each well 
 Add 5μL of DNA in each well of cartridge (25μL of DNA over 5 wells) 
 Cover plate using PCR seal 
 Centrifuge PCR plate for 60 seconds at 500rpm 
 
Transfer to thermal cycler for amplification as described in Table 5.6 
 
Table 5.6: PCR thermal cycler program for the five well cartridge assay method as 
provided by the manufacturer. 
Program Step Time (mm:ss) Temperature Number of cycles 
1st Denature 02:00 96˚C X1 
Denature 00:15 96˚C 
X10 
Annealing + Extension 01:00 65˚C 
Denature 00:10 96˚C 
X20 Annealing 00:50 61˚C 
Extension 00:30 72˚C 
Hold ∞ 22˚C  
 
5.2.5. Loading of automated HLA-typing machine 
After the PCR amplification step, the samples can be loaded onto the MR SPOT 
machine which will carry out the SSO probe based colourmetric reaction that allows 
the HISTO MATCH software to analyse the assay and call the patient’s HLA allele 
status. The steps are described below. 
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 Warm the hybridisation buffer and stringent wash in 30˚C water bath. 
 Load the XML work sheet onto the MR SPOT machine via USB flash drive 
 Follow the on-screen instructions to prepare the machine, which are: 
o Clear the tips disposal and waste liquid troughs 
o Re-rack the 200μL and 1,000μL pipette tips 
o Fill the water bottle with distilled H2O 
o Add the reaction strips/wells to the machine 
o Add the reagents to the labelled wells (see below) 
o Run the program 
o Once run is complete, export results to USB flash drive for 
interpretation on HISTO MATCH software. 
The reagents are proportional to the number of samples being tested. The quantities 
are provided by the MR SPOT machine as the samples have been declared in the XML 
worklist so the machine is able to calculate the required reagent amounts. 
 
5.2.6. Protocol for MR SPOT typing assay 
Whilst the SSO assay is running, the MR SPOT instrument runs through the following 
steps for both the one well system and five well cartridge system (performed 
automatically without user intervention): 
1. Add block buffer into typing wells and leave for 5 minutes 
2. Denature the samples for 5 minutes 
3. Aspirate the blocking buffer 
4. Add hybridisation buffer to the samples 
5. Transfer samples to corresponding typing wells 
6. Hybridise at 50˚C for 15 minutes 
7. Perform 3x washes with stringency buffer 
8. Add conjugate to typing wells and incubate for 15 minutes 
9. Perform 3x washes with buffer 
10. Add substrate and incubate for 15 minutes 
11. Wash with H2O 
12. Dry for 5 minutes 
13. Internal camera takes images of wells’ colourmetric probes 
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14. User transfers images to external PC with HISTO MATCH software for 
analysis 
 
5.2.7. Comparison of HISTO SPOT assay and sequence based 
typing 
This section refers to project researchers using the codes explained in 5.2.1. The final 
reports of the HISTO SPOT assay were collected in a spreadsheet document so that 
they could be compared with the results of the (reference) sequence based typing 
method. In order to minimise potential of bias, the two researchers (GG and AO) who 
performed the HISTO SPOT assay were not told of the HLA status for the samples 
until after the results were collected. Additionally, for reasons of confidentiality, only 
the supervising researcher (AA - who did not perform the HISTO SPOT assays) had 
access to the data that details the samples’ HLA status as derived from the sequence 
based typing method. Researcher AA only provided data stripped of any potentially 
identifying information that was not relevant to the project. The sample ID number 
(with the study code stripped) containing only the sample’s tube number and the HLA 
allele status for that sample were provided for the comparison. The results were then 
analysed and marked to determine the percentage of correct calling of the HLA alleles 
using the SBT derived alleles as the reference. 
 
5.2.8. HISTO SPOT known ambiguities 
The HISTO SPOT assay had ambiguities in calling HLA alleles that are known to the 
manufacturer but could not be resolved. For the one well assay method the ambiguities 
are as follows:  
 HLA-A*33:03:01 could not be uniquely identified in the presence of HLA-
A*31:01:02:01 allele 
 
 HLA-B*13:01 was ambiguous with HLA-B*44:01 
 
 HLA-B*58:01 could not be uniquely identified in the presence of HLA-
B*58:02 
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 HLA-DRB1*15:01 identification is ambiguous with HLA-DRB1*15:03 and 
HLA-DRB1*15:06 
 
 The HISTO MATCH software reported an ambiguity with HLA-
A*68:01:01:01 and HLA-A*68:01:02:01 although this is not treated as an 
ambiguity in this thesis as both alleles produce identical proteins through 
synonymous polymorphisms. 
 
 HLA-DQB1*02:01 and HLA-DQB1*02:02 can be ambiguous due to the 
method of typing. The original Histogenetics sequencing only sequenced class 
II alleles at exon 2 whilst the HISTO SPOT method types using exons 2 and 3 
– the two alleles are identical in exon 2 so the Histogenetics typing method 
cannot distinguish between the two alleles. The HISTO MATCH software was 
subsequently modified so that, for this experiment, the allele calls for HLA-
DQB1*02:02 are reported as ambiguous to allow the comparison using the 
Histogenetics typing can be made. 
 
With the exception of the HLA-DQB1*02:01 and HLA-DQB1*02:02 issue, the other 
known ambiguities do not affect the five well cartridge assay method and is able to 
discriminate between the alleles. 
 
5.3. Results 
The HISTO MATCH software will only display, to the user, the risk alleles that are 
part of the 23 alleles that make up biomarker panel. Alleles from outside this panel are 
not included. The Histogenetics sequencing does include the calls for all the results, 
however, these are not relevant to this project so only the risk alleles are included in 
the results. The results were collected in a spreadsheet document and listed in groups 
of three. The first row of the group is the sample’s HLA status as determined using 
the alleles called using Histogenetics SBT method. Next, is the alleles called using the 
HISTO SPOT biomarker panel carried out by researcher AO and the third row is the 
HISTO SPOT biomarker panel carried out by researcher GG. The results from HISTO 
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SPOT biomarker panel are colour coded depending on whether the allele called is 
correct relative to the sequence data obtained from the Histogenetics typing. A green 
cell within the table means that the allele(s) for that HLA loci called by the biomarker 
panel agrees with that of sequenced data, a red cell reflects the HISTO MATCH 
software assigning a value does not agree with the sequence data and yellow denotes 
an allele is one of the known ambiguities as described in the section above.  
 
Samples shaded black are samples which were not utilised as part of this study with 
the reason being that these samples were already depleted before this investigation 
started. Table 5.7 shows an example of three results. The full table consisting of 
samples 401-804 – the entire run for the one well assay method can be found on the 
attached USB flash disk/compact disk that accompanies the thesis as the spreadsheet 
file “chapter_5_HISTO_SPOT_one_well.xlsx”.  
 
If a sample contained two risk alleles that were called for that HLA loci, then the 
colour code denoting the least favourable outcome was recorded to provide high level 
of stringency. For example in Table 5.7, for sample 447, the biomarker panel for both 
researchers called HLA-DQB1*03:03:02:01 which is a correct call as it matches with 
the sequence data. However, the HISTO MATCH software did not call the HLA-
DQB1*02:01 allele – this is an allele that is known to be ambiguous so the cell could 
be shaded either green or yellow, since the ambiguous result is the least favourable, 
the cell is shaded yellow. 
 
Table 5.8 shows the values that each of the risk alleles were called correctly. A correct 
call is described when the HISTO MATCH biomarker panel result agrees with the 
result for the sequence data obtained by Histogenetics’ HLA typing. Table 5.9 shows 
the percentage of samples where the HLA calls agreed with the sequence data for the 
sample as a whole – e.g. in the examples shown in Table 5.7 sample 401 was called 
correctly across all HLA loci so this sample is registered as correct in Table 5.9Table 
5.9 whilst for sample 405, the HISTO MATCH biomarker panel for researcher AO 
there were two alleles called that did not match with the sequence data, this is classed 
as incorrect in Table 5.9. 
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5.3.1. One well assay method 
 
Table 5.7: Example of results from the one well HISTO SPOT assay. 
Tester 
Tube 
ID HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DQA1 
Sequence data 401  57:01  07:01 03:03 02:01 
biomarker panel AO 401   57:01:01   07:01:01:01 03:03:02:01 02:01:01:01 
biomarker panel GG 401   57:01:01   07:01:01:01 03:03:02:01 02:01:01:01 
        
Sequence data 405       
biomarker panel AO 405     08:01:01   03:03:02:01   
biomarker panel GG 405             
        
Sequence data 447  57:01  07:01 02:01/ 03:03 02:01 
biomarker panel AO 447         03:03:02:01 02:01:01:01 
biomarker panel GG 447       07:01:01:01 03:03:02:01 02:01:01:01 
 
Legend 
Green HISTO SPOT assay called sample allele correctly (relative to sequenced based typing method) 
Yellow Known ambiguities as defined in section 5.2.7 (e.g. HLA-DQB1*02:01) 
Red HISTO SPOT assay called sample allele incorrectly 
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Table 5.8: a) Statistical results measuring the performance of the one well HISTO SPOT assay method relative to the sequence data for each 
allele. Results obtained from test carried out by researcher AO 
Samples 401-804 
Allele 
True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative Sensitivity Specificity 
Positive 
Predictive Value 
Negative 
Predictive Value 
A*31:01 19 371 1 4 0.826 0.997 0.950 0.989 
A*33:03 8 375 11 1 0.889 0.972 0.421 0.997 
A*68:01 17 373 5 0 1.000 0.987 0.773 1.000 
B*13:01 0 384 11 0 N/A 0.972 0.000 1.000 
B*15:02 1 390 2 2 0.333 0.995 0.333 0.995 
B*35:05 1 391 3 0 1.000 0.992 0.250 1.000 
B*56:02 0 394 1 0 N/A 0.997 0.000 1.000 
B*57:01 27 359 1 8 0.771 0.997 0.964 0.978 
B*58:01 4 385 1 5 0.444 0.997 0.800 0.987 
C*04:01 47 299 36 13 0.783 0.893 0.566 0.958 
C*08:01 3 352 39 1 0.750 0.900 0.071 0.997 
DRB1*07:01 84 291 2 18 0.824 0.993 0.977 0.942 
DRB1*11:01 25 364 0 6 0.806 1.000 1.000 0.984 
DRB1*13:02 11 371 5 8 0.579 0.987 0.688 0.979 
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DRB1*15:01 88 276 7 24 0.786 0.975 0.926 0.920 
DQB1*02:01 111 195 4 85 0.566 0.980 0.965 0.696 
DQB1*03:03 36 344 8 7 0.837 0.977 0.818 0.980 
DQB1*05:02 7 372 13 3 0.700 0.966 0.350 0.992 
DQB1*06:02 106 275 7 7 0.938 0.975 0.938 0.975 
DQB1*06:04 9 376 7 3 0.750 0.982 0.563 0.992 
DQB1*06:09 3 384 3 5 0.375 0.992 0.500 0.987 
DQA1*01:02 133 248 2 12 0.917 0.992 0.985 0.954 
DQA1*02:01 94 289 3 9 0.913 0.990 0.969 0.970 
 
 
Table 5.8: b) Statistical results measuring the performance of the one well HISTO SPOT assay method relative to the sequence data for each 
allele. Results obtained from test carried out by researcher GG 
Samples 401-804 
Allele 
True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative Sensitivity Specificity 
Positive 
Predictive Value 
Negative 
Predictive Value 
A*31:01 19 366 6 4 0.826 0.984 0.760 0.989 
A*33:03 9 372 14 0 1.000 0.964 0.391 1.000 
A*68:01 17 372 6 0 1.000 0.984 0.739 1.000 
B*13:01 0 383 12 0 N/A 0.970 0.000 1.000 
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B*15:02 3 392 0 0 1.000 1.000 1.000 1.000 
B*35:05 1 381 13 0 1.000 0.967 0.071 1.000 
B*56:02 0 393 2 0 N/A 0.995 0.000 1.000 
B*57:01 14 360 0 21 0.400 1.000 1.000 0.945 
B*58:01 5 386 0 4 0.556 1.000 1.000 0.990 
C*04:01 42 222 113 18 0.700 0.663 0.271 0.925 
C*08:01 4 276 115 0 1.000 0.706 0.034 1.000 
DRB1*07:01 79 291 2 23 0.775 0.993 0.975 0.927 
DRB1*11:01 20 363 1 11 0.645 0.997 0.952 0.971 
DRB1*13:02 8 368 8 11 0.421 0.979 0.500 0.971 
DRB1*15:01 84 274 9 28 0.750 0.968 0.903 0.907 
DQB1*02:01 74 195 4 122 0.378 0.980 0.949 0.615 
DQB1*03:03 31 343 9 12 0.721 0.974 0.775 0.966 
DQB1*05:02 5 373 12 5 0.500 0.969 0.294 0.987 
DQB1*06:02 99 275 7 14 0.876 0.975 0.934 0.952 
DQB1*06:04 1 368 15 11 0.083 0.961 0.063 0.971 
DQB1*06:09 1 387 0 7 0.125 1.000 1.000 0.982 
DQA1*01:02 123 248 2 22 0.848 0.992 0.984 0.919 
DQA1*02:01 92 290 2 11 0.893 0.993 0.979 0.963 
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Table 5.9: Overall concordance value for the one well HISTO SPOT assay method 
relative to the sequence data across samples 401-804 
Percentage of samples called correctly 
researcher AO 50.91 
researcher GG 23.24 
 
5.3.2. Five well cartridge assay method 
 Table 5.10 shows examples of the results from the five well cartridge method. This 
table uses a same colour code for the results in Table 5.7; green for results that agree 
with the Histogenetics sequenced data and black for samples that could not be assayed 
(insufficient sample quantity). For the known ambiguity for HLA-DQB1*02:01 (and 
02:02), these were classed as correct calls if the biomarker panel HISTO MATCH 
software called HLA-DQB1*02:02 when the sequenced data value is HLA-
DQB1*02:01. These instances were agreed to be more precise due to the nature of the 
typing method which have previously been validated as the manufacturer already 
provides services to type the HLA-DQB1 alleles using the technique that has been 
implemented in this five well cartridge assay.  
 
The full table consisting of samples 902-999; the entire run for the five well cartridge 
assay method can be found on the attached USB flash disk/compact disk that 
accompanies the thesis as the spreadsheet file 
“chapter_5_HISTO_SPOT_five_well.xlsx”.  Table 5.11 shows the percentage that 
each of the risk alleles were called correctly. A correct call is described when the 
HISTO MATCH biomarker panel result agrees with the result for the sequence data 
obtained by Histogenetics’ HLA typing. Table 5.12 shows the percentage of samples 
where the HLA calls agreed with the sequence data for the sample across all six loci.
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Table 5.10: Example of results from the five well cartridge HISTO SPOT assay. 
Tester Tube ID HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DQA1 
Sequenced data 944  57:01     
biomarker panel AO 944   57:01:01         
biomarker panel GG 944   57:01:01         
        
Sequenced data 945     02:01/ 03:03  
biomarker panel AO 945         02:02:01/ 03:03:02:01   
biomarker panel GG 945         02:02:01/ 03:03:02:01   
 
Legend 
Green HISTO SPOT assay called sample allele correctly (relative to sequenced based typing method) 
Yellow Known ambiguities as defined in section 5.2.7 (e.g. HLA-DQB1*02:01) 
Red HISTO SPOT assay called sample allele incorrectly 
Black Insufficient DNA sample to carry out HISTO SPOT typing 
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Table 5.11: a) Statistical results showing the performance of the five well cartridge HISTO SPOT assay method relative to the sequence data for 
each allele in the biomarker panel. Results obtained from test carried out by researcher AO. 
 
 
Samples 901-999 
Allele True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
Sensitivity Specificity Positive 
Predictive Value 
Negative 
Predictive Value 
A*31:01 2 190 0 0 1 1 1 1 
A*33:03 1 191 0 0 1 1 1 1 
A*68:01 6 186 0 0 1 1 1 1 
B*13:01 0 192 0 0 N/A 1 N/A 1 
B*15:02 0 192 0 0 N/A 1 N/A 1 
B*35:05 0 192 0 0 N/A 1 N/A 1 
B*56:02 0 192 0 0 N/A 1 N/A 1 
B*57:01 8 184 0 0 1 1 1 1 
B*58:01 3 189 0 0 1 1 1 1 
C*04:01 19 173 0 0 1 1 1 1 
C*08:01 1 191 0 0 1 1 1 1 
DRB1*07:01 27 157 0 0 1 1 1 1 
DRB1*11:01 8 178 0 0 1 1 1 1 
DRB1*13:02 6 180 0 0 1 1 1 1 
DRB1*15:01 33 153 0 0 1 1 1 1 
DQB1*02:01 24 158 0 0 1 1 1 1 
DQB1*03:03 12 170 0 0 1 1 1 1 
DQB1*05:02 2 180 0 0 1 1 1 1 
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DQB1*06:02 30 152 0 0 1 1 1 1 
DQB1*06:04 3 179 0 0 1 1 1 1 
DQB1*06:09 3 179 0 0 1 1 1 1 
DQA1*01:02 39 143 0 0 1 1 1 1 
DQA1*02:01 27 155 0 0 1 1 1 1 
 
 
 
 
 
Table 5.11: b) Statistical results showing the performance of the five well cartridge HISTO SPOT assay method relative to the sequence data for 
each allele in the biomarker panel. Results obtained from test carried out by researcher GG. 
Samples 901-999 
Allele True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
Sensitivity Specificity Positive 
Predictive Value 
Negative 
Predictive Value 
A*31:01 2 188 0 0 1 1 1 1 
A*33:03 1 189 0 0 1 1 1 1 
A*68:01 6 184 0 0 1 1 1 1 
B*13:01 0 190 0 0 N/A 1 N/A 1 
B*15:02 0 190 0 0 N/A 1 N/A 1 
B*35:05 0 190 0 0 N/A 1 N/A 1 
B*56:02 0 190 0 0 N/A 1 N/A 1 
B*57:01 8 182 0 0 1 1 1 1 
B*58:01 3 187 0 0 1 1 1 1 
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C*04:01 18 150 0 0 1 1 1 1 
C*08:01 1 167 0 0 1 1 1 1 
DRB1*07:01 27 157 0 0 1 1 1 1 
DRB1*11:01 8 178 0 0 1 1 1 1 
DRB1*13:02 6 180 0 0 1 1 1 1 
DRB1*15:01 33 153 0 0 1 1 1 1 
DQB1*02:01 24 158 0 0 1 1 1 1 
DQB1*03:03 12 170 0 0 1 1 1 1 
DQB1*05:02 2 180 0 0 1 1 1 1 
DQB1*06:02 30 152 0 0 1 1 1 1 
DQB1*06:04 3 179 0 0 1 1 1 1 
DQB1*06:09 3 179 0 0 1 1 1 1 
DQA1*01:02 39 143 0 0 1 1 1 1 
DQA1*02:01 27 155 0 0 1 1 1 1 
 
 
 
Table 5.12: Overall concordance value for the five well cartridge HISTO SPOT assay method relative to the sequence data across samples 902-
999. 
Percentage of samples called correctly 
researcher AO 100.00 
researcher GG 100.00 
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5.4. Discussion 
5.4.1. Limitations of the HISTO SPOT assay 
The one well assay method proved to be unreliable when tested with samples that were 
extracted from human volunteers, where the system called 51% and 23% (performed 
by researcher AO and researcher GG respectively) of the volunteers samples’ HLA 
status correctly relative to the sequence based typing method used as the reference. 
This was the final result after several rounds of calibration and improvements were 
conducted with the method. During the calibration stages, the performance was very 
poor – but adjustments were expected to be performed as this was the first live test 
with unseen human samples. Researchers AO, GG and LH (who was heavily involved 
during the calibration stages) collaborated with the manufacturer to discuss 
improvements during which several factors were discovered to be influential. Firstly, 
it was noted that relative to a standard PCR program, there was an extremely long 
DNA polymerase extension cycle. This was done by the manufacturer as the HLA 
region is notoriously difficult region for PCR techniques and so the multiple probes 
covering the many HLA loci were extremely sensitive to slight perturbations. 
Consequently, the PCR machine used by LH and GG was adjusted to decrease the 
ramp rate (the rate of temperature change). This showed noticeable improvement but 
performance was still poor (results not included). A different PCR thermal cycler 
machine that matched with the manufacturer’s recommended model was later used 
which again showed improvement. 
 
After the changes to the PCR program, there were several rounds of HISTO MATCH 
probe thresholds as certain alleles showed extremely poor reliability as the 
concordance percentage against the reference was very low – alleles HLA-
DQB1*06:04 (61.9% for AO and 5.0% for GG for the final run for the single well 
assay) and HLA-DQB1*06:09 (33.3% for AO and 14.3% for GG). When analysed in 
the full results, the biomarker panel would often give false positives for these alleles 
which indicated that there were possibly some issues with the threshold of the HISTO 
MATCH software when measuring the probe/spot relating to these alleles. The 
manufacturer also raised concern with the method with which the DNA was extracted 
from the volunteers’ blood – they have only validated the technique using Qiagen 
DNA extraction columns (Qiagen, Manchester, United Kingdom). There were also 
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problems with gathering consistent results between the two researchers where the 
allele calls from the assay performed by researcher GG was considerably lower than 
that of researcher AO. Observation of GG’s laboratory technique (e.g. pipetting) did 
not reveal any poor technique or other obvious signs of human error. The results from 
Table 5.8 did not show constancy – some alleles AO performed better and other alleles 
GG performed better. The most likely explanation appears to be statistical chance. 
 
After the several rounds of calibration and very poor final results, it was agreed that 
many of the issues that were subsequently controlled for were unrealistic to expect 
when making full product deployment as many labs use different methods for DNA 
extraction and different PCR thermal cyclers so limiting to one approved method and 
equipment machines was unrealistic to expect in practice. The inability to gather 
consistent results (differences between the results when carried out by researchers AO 
and GG) meant that the reliability could not be trusted. Consequently, it was decided 
that the probes for the HLA loci be separated into different wells as part of a cartridge 
system – the downside to this approach was the reduction in turnaround as the only 
six cartridges could be accommodated by the HISTO SPOT automated machine. 
However, the chief investigator of the project has extensive clinical expertise in a 
hospital scenario around ADRs and informed the group that based on his experience, 
it was unlikely that a clinical laboratory would be required to test that many patients 
in a day (personal correspondence with Pirmohamed M., 2017). 
 
The five well cartridge system allowed more probes per locus to be included in each 
reaction well allowing for probe redundancy that greatly aids in robustness and 
reliability. This method involved adapting reaction wells that the company already 
supplies commercially. The method proved to be reliable where both AO and GG 
obtained 100% concordance with the reference sequence data when testing 96 samples 
that were previously unknown to the technique (in either one well or five well cartridge 
assays).  
 
5.4.2. Cost-effectiveness for the HISTO SPOT assay 
It has been difficult to obtain costs/prices for the current procedures as the various 
laboratories supplying the service often negotiate the prices for each individual 
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customer based on several factors. However, the NHS Blood and Transplant Service 
is charged approximately £90 for a single test for HLA-A*31:01 and personal 
communications with the members of this project during progress meetings suggests 
that the cost to type a patient’s DNA sample for an individual HLA loci somewhere 
between £50 and £200. [182] The new HISTO MATCH process aims to test for the 
carriage of the >20 HLA alleles across all five of the tested HLA loci at a lower price 
(still to be set). That is to say HISTO MATCH will type >20 alleles at a cost lower 
than or competitive with an individual HLA loci using currently available methods. 
 
The benefits of a clinical decision support tool will vary depending on the specific 
drug-allele combination. A review describing the cost effectiveness of the HLA panel 
from Figure 5.3 reported that there is evidence to support the cost effectiveness for the 
testing of HLA-B*57:01 (abacavir screening), HLA-A*31:01 and HLA-B*15:02 
(prior to carbamazepine treatment) and HLA-B*58:01 (prior to allopurinol treatment). 
[183] These drug-allele combinations already have relevant warnings pertaining to HLA 
mediated ADRs – most likely due to the relatively high amount of studies published 
for these specific drugs/alleles. Given that the screening test using the HISTO SPOT 
kit costs less than or competitive with testing for an individual allele using already 
available services (> £50) then the potential benefits particularly for the alleles 
mentioned in this paragraph are clear. 
 
The cost-benefit of the other alleles in the panel varies depending on the scenario, 
some of these cost-benefit analysis are implemented in the clinical decision support 
tool in 0. For example, the benefit to screening patients before the treatment of 
flucloxacillin is very low. Despite the data in 0 showing that the negative predictive 
value approaches 1.00, the positive predictive value is very low (0.001) meaning that 
it is not cost-beneficial to screen patients beforehand, but in the (very rare) event that 
a patient experiences DILI whilst on the drug, a negative result for HLA-B*57:01, 
using HISTO SPOT, with the patient experiencing liver injury may help in excluding 
flucloxacillin as a cause. Additionally some alleles do not show strong enough 
evidence to warrant the discontinuation of the drug if the patient carries the risk allele 
or the alternative treatment (if any) does not meet favourable cost-benefit ratio. In such 
cases, the clinician and patient can be informed of the potential risk and be monitored 
more closely. This has already been recommended for carbamazepine in patients 
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carrying HLA-A*31:01. [184] Given the mixed utility for pre-emptive screening of 
patients prior to a particular treatment, it is highly recommended that the cost-
effectiveness also be included in the clinical decision of drug administrating, as such 
the clinical decision support tool in 0 must be mindful of the value for each drug-allele 
combination. 
 
The patient’s HLA information can be included into the patient record allowing it to 
be reviewed for future use if the patient needs to be treated with the same or different 
drug. For example, the cost-effectiveness is difficult to predict. However, since the 
information is already on the patient’s health record, if pre-emptive screening is not 
cost-beneficial but the HLA status is already on file then the clinician can take 
advantage of this when devising the treatment for the patient.  
 
This also links directly with time savings that HISTO-SPOT offers compared to 
current typing methods. The typical turnaround time for current typing methods is 
around two weeks which is often unacceptable for clinicians wanting to make a 
decision regarding a particular treatment/drug they wish to prescribe. The HISTO 
SPOT methodology offers a typical turnaround of 24 to 48 hours to produce a report 
describing the sample’s HLA typing profile. The faster reporting of HLA type is 
patently advantageous to the quicker informed clinical decision making. The time 
savings are further improved using the previous paragraph’s example of the 
information already on patient health records due to previous testing for another of the 
>20 HLA alleles. 
 
5.4.3. Future work 
The five well cartridge system has one further benefit over the one well system, due 
to the added probes in each well, the resulting robustness allows the system to adapt 
to changes in the biomarker panel. If in the future a new allele needs to be added to 
the biomarker panel, it is likely that the existing probes are already present to allow 
the allele to be identified meaning only an update to the HISTO MATCH software is 
required – the probes cover a relatively large area of exons 2 and 3 of each loci. This 
means that the five well cartridge system is very flexible and adaptable to future 
discoveries.  
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The spare wells in the 5-well cartridge (3 unused wells) can also be used to cover 
additional loci such as the cytochrome P450 gene superfamily. These are non-HLA 
genes/alleles that have been implicated in other forms of ADRs that are not covered 
in this thesis. However as an example, the CYP2C19 biomarker was shown to be cost-
effective for pharmacogenetic screening. [183] meaning that there is potential that the 
currently unused wells can be utilised by detecting other biomarkers beyond the HLA 
gene family.  
 
The HISTO SPOT assay’s major limitation is that it relies on a SSO based 
methodology for HLA typing. The assay is only able to type using probes designed to 
detect polymorphisms in exons 2 and 3. As discussed in Chapter 1.3.6 there is a 
possibility that for each of the alleles in the panel, there are other alleles from the same 
gene that have identical sequences inside exons 2 and 3. To HISTO SPOT, such alleles 
would appear identical. To investigate this, it would be worthwhile to see which alleles 
share sequence similarity with the risk alleles from the panel. The frequencies for these 
alleles can be compared within a particular population (e.g. the United Kingdom). 
 
The HISTO MATCH software in its current form (at the time writing) requires 
updating. One key change needed is that the final report is not user friendly. The 
HISTO MATCH software produces a spreadsheet document where each loci is 
reported separately for each patient meaning that the user needs some processing 
before being interpreted. For this project an in house Python script was written to 
format the information so that it reflected the sample (the format observed in the 
results). This has been communicated to the manufacturer and will be included in a 
future update. Additionally for certain circumstances e.g. if a sample is reported to 
carry HLA-DRB1*06:02:01 and HLA-DRB1*06:09:01, the end report shows this as 
“DRB1*06:02 /09:01” which is a common practice in HLA research field but not in 
medicine (the end user) so has the risk of creating confusion in clinicians who are not 
well versed in HLA nomenclature practices/common shorthand. 
 
There is also a desire by the researcher team and manufacturer for the HISTO MATCH 
software directly form links with the clinical decision support software that is 
described about in the next chapter. This would allow the end user to receive the 
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HISTO SPOT report and be taken directly to the relevant page on the clinical decision 
support tool. This can be achieved with little effort as the clinical decision support tool 
is built upon open HTML standards. This would allow the user to seamlessly transition 
from the patient’s HLA status to the support tool’s recommendation allowing for 
streamline clinical decision making.  
 
5.5. Conclusion 
The ADR biomarker panel aims to create an assay able to identify 23 HLA alleles 
which will aid clinicians in predicting, preventing and/or diagnosing serious immune-
mediated ADRs. Initially, the project looked to develop an SSO based typing assay 
with all 23 HLA alleles, covering both class I and class II HLA alleles in a single test 
well that could be processed in an automated machine where the SSO probe profile 
can be interpreted by the manufacturers HISTO MATCH software to identify the 23 
alleles at 2 field resolution or higher. However, after considerable assay development, 
it was determined that the assay required five wells to achieve sufficient robustness 
that can be deemed reliable enough to be deployed in a clinical setting. The 
accompanying HISTO MATCH software which produces the final report only informs 
the user of the alleles that make up the biomarker panel – the other, non-risk alleles 
are superfluous to the end user clinician and therefore not reported. The cost-
effectiveness for the biomarker panel varies depending on the specific drug-allele 
combination but the wider literature reports on the demand and benefit for clinicians 
to be able to pre-empt, prevent and diagnose patients for immune-mediated ADRs. 
When this assay is combined with the clinical decision support tool featured in the 
next chapter, the system has great potential to aid with clinical decision making for 
drugs that are known to cause immune mediated ADRs. 
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Chapter 6. The implementation of a clinical decision 
support tool to aid clinicians with prescribing 
medication known to cause immune mediated adverse 
drug reactions 
6.1. Introduction 
As mentioned in Chapter 2, there is a great amount of literature for clinicians and 
researchers to keep track of. So whilst the results from Mr Spot are informative, they 
may require interpretation of the results depending on the clinician’s background 
knowledge of immune-mediated ADRs. Therefore, a means to support this clinical 
decision is needed to allow clinicians to make an informed decision when it comes to 
the best treatment they can provide to their patients. Therefore, to complement Mr 
Spot (Chapter 5), a clinical decision support tool was developed to help achieve this 
goal of equipping clinicians with relevant knowledge as to whether a particular drug 
they wish to prescribe carries above baseline risks of developing ADRs. 
 
6.1.1. Software specification  
To aid with the development of any software solution, it is recommended that the 
specifications be laid out so that it is clear to the developer and people who 
commission any piece of software as to what the final product will be able to perform. 
Whilst this section is not a formal software specification, it provides the necessary 
information to describe the aims of the clinical decision support tool.  
 
The tool is required to be easily accessible, for this reason a website was chosen as 
opposed to installing it as standalone, installable software. This method of deployment 
has advantages over packing the tool in a standalone program including a lower barrier 
to entry/access. With the aim of the software to aid clinicians, it is important that the 
clinicians have relative ease of access, a standalone program can be accessible in 
offline scenarios (e.g. non-networked computers) whereas with a website, the client 
computer must be connected to the web in order to access the information. However, 
some IT management systems specifically restrict the installation of additional 
software, as a general security precaution, which would potentially limit the outreach 
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of the software. Since all that is required for the website is a web browser which are 
either already installed with the computer’s operating system or a common item to be 
installed by IT management systems (or requested from them), a web based approach 
has the broadest reach to as many clinicians as possible. An additional benefit to web 
browsers are the underlying information can be stored on a database which can be kept 
up to date for all users and limits the possibility that users neglect or are otherwise 
prevented form updating standalone software packages so end up using outdated 
information. 
 
In reference to keeping the information up to date, the clinical decision support tool 
requires that the database be relatively easy to update. This is to allow a team of 
immune-mediated ADR experts who understand the data to be able to update the 
information without requiring knowledge of database administration. Similar to the 
setup described in Chapter 3, a spreadsheet document serves as the primary collection 
point for the information. Spreadsheets also allow for easy manipulation of the data so 
that information from different sources can be reformatted to be included in a uniform 
structure. Once the spreadsheet data is set and ready for deployment, a computer script 
can be written to extract the data and convert it to the relevant database language code 
which can then be executed to update the database from which the website will draw 
its information from. 
 
The database can also be changed in response to the literature, new data can be added 
and current data can also be edited or deleted if required. This is achieved by first 
making the relevant additions/edits with the spreadsheet document and then applying 
the computer script which proceeds to empty the tables in the database and then fill in 
the information from the spreadsheet. Although, this methods is not as quick to execute 
as the individual tasks (e.g. only inserting new data as a opposed to 
emptying/truncating the entire database’s tables and then inserting all of the 
information from the spreadsheet document back in), employing only one method for 
database changes simplifies the process for administration team and reduces the need 
for a dedicated, formally trained database manager. The downside to this approach is 
the time to conduct a database update increases as the number of SQL commands is 
always the maximum needed to update the database rather than the minimum. 
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6.1.2. Functional requirements 
The clinical decision support tool had specific requirements in terms of functionality 
which are listed here. A basic username and password credentials system will be 
required by all users to access the tool (this includes an ability to create new user 
credentials). The tool will then present users with a list of both the drugs and HLA 
alleles that are present in the database from which to conduct a search. The selection 
must also allow the user to select multiple alleles as humans are diploid and multiple 
HLA genes from those that have been included in the underlying data. Once a user has 
selected a drug-allele combination, the user will then be presented with the information 
pertaining to the ADR(s) associated with that particular drug-allele combination.  This 
presented information must draw from the provided data (which will be developed by 
ADR/clinical experts). The reports section of the tool will also provide the current 
guidelines from a selection of drug regulatory bodies (e.g. FDA, EMA etc. guidelines) 
along with hyperlinks to the studies that have reported the association. The tool will 
also perform calculations to determine certain clinically applied statistical values 
including the sensitivity/specificity, negative/positive predictive values, pre and post-
test probabilities and the number of screenings needed to prevent 1 ADR case. 
 
6.2. Materials and methods 
6.2.1. Underlying dataset 
The initial dataset that has generated the panel of HLA alleles that have been 
associated with ADRs was pre-selected and sourced from a previously published 
article (see Figure 6.1). [179] However, it is worth noting that the study itself describes 
the figure as not an “exhaustive list”. So whilst the figure was used as the initial 
underlying database build, the database will eventually be built using a curated set of 
published literature, - the manuscript for this dataset is in development for publication. 
Since there is considerable overlap with the data from the HLA-ADR database, data 
from HLA-ADR was used to aid in the construction of the clinical decision support 
tool as the clinical decision support tool was in development in parallel with the data 
collection. The data that will eventually go into the clinical decision support tool has 
been sourced independently of HLA-ADR but will effectively appear to be a curated 
subset of the HLA-ADR data. The HLA-ADR was used as a source for relevant 
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literature for the clinical decision support tool. A spreadsheet document was used to 
collect the information and a Python script was developed to transfer the information 
from the spreadsheet document to the RDBMS – similar to the process in Chapter 3. 
 
 
Figure 6.1: Panel of 24 HLA alleles and corresponding drugs that were used as the 
basis for the underlying ADR data for the clinical decision support tool. 
 
6.2.2. Calculations from the underlying data 
The data present in the underlying database was analysed from the original spreadsheet 
document. The spreadsheet contains the base information (the information sourced 
from the original study reporting the drug-allele associated ADR and the prevalence 
of the ADR). From this information calculations are performed to calculate that this 
chapter has described as the clinical statistics (see Figure 6.2). The website actually 
performs these calculations as it retrieves the information, however, these calculations 
are also performed by the spreadsheet document so that the data could be analysed in 
this project to aid with the eventual clinical recommendations which the clinical 
decision support tool displays, see USB/CD media file 
“chapter_6_decision_support_table.xlsx”. A full view of this table can be found in the 
accompanying USB/CD media in the file “chapter_6_decision_support_table.xlsx”. 
The condensed version of the table displays the base information collected from the 
original study along with the number of screenings needed to prevent one ADR case 
but excludes the other values calculated using the formulae below.  
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Figure 6.2: Formulae used to calculate the clinical statistics which are utilised in the 
clinical decision support tool. 
 
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑐𝑎𝑠𝑒𝑠 𝑐𝑎𝑟𝑟𝑦𝑖𝑛𝑔 𝑎𝑙𝑙𝑒𝑙𝑒
𝑐𝑎𝑠𝑒𝑠 𝑐𝑎𝑟𝑟𝑦𝑖𝑛𝑔 𝑎𝑙𝑙𝑒𝑙𝑒 +  𝑐𝑎𝑠𝑒𝑠 𝑛𝑜𝑡 𝑐𝑎𝑟𝑟𝑦𝑖𝑛𝑔 𝑎𝑙𝑙𝑒𝑙𝑒 
 
 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =  
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑛𝑜𝑡 𝑐𝑎𝑟𝑟𝑦𝑖𝑛𝑔 𝑎𝑙𝑙𝑒𝑙𝑒
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑛𝑜𝑡 𝑐𝑎𝑟𝑟𝑦𝑖𝑛𝑔 𝑎𝑙𝑙𝑒𝑙𝑒 +  𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑐𝑎𝑟𝑟𝑦𝑖𝑛𝑔 𝑎𝑙𝑙𝑒𝑙𝑒
 
 
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜 (𝐿𝑅+) =  
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
 
𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜 (𝐿𝑅−) =  
1 − 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
 
𝑝𝑟𝑒 𝑡𝑒𝑠𝑡 𝑜𝑑𝑑𝑠 =  
𝐴𝐷𝑅 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒
1 − 𝐴𝐷𝑅 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒
 
 
𝑝𝑜𝑠𝑡 𝑡𝑒𝑠𝑡 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦+  =   
𝑝𝑟𝑒 𝑡𝑒𝑠𝑡 𝑜𝑑𝑑𝑠 × 𝐿𝑅+
((𝑝𝑟𝑒 𝑡𝑒𝑠𝑡 𝑜𝑑𝑑𝑠 × 𝐿𝑅+) + 1)
 
 
𝑝𝑜𝑠𝑡 𝑡𝑒𝑠𝑡 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦− =
𝑝𝑟𝑒 𝑡𝑒𝑠𝑡 𝑜𝑑𝑑𝑠 × 𝐿𝑅−
((𝑝𝑟𝑒 𝑡𝑒𝑠𝑡 𝑜𝑑𝑑𝑠 × 𝐿𝑅−) + 1)
  
 
𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛
=  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐴𝐷𝑅𝑠 𝑝𝑒𝑟 100,000 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
− 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 𝑖𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑎𝑙𝑙𝑒𝑙𝑒 (𝑝𝑒𝑟 100,000)
×  𝑝𝑜𝑠𝑡 𝑡𝑒𝑠𝑡 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦−) 
 
𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔𝑠 𝑛𝑒𝑒𝑑𝑒𝑑 𝑡𝑜 𝑝𝑟𝑒𝑣𝑒𝑛𝑡 𝑜𝑛𝑒 𝐴𝐷𝑅 𝑐𝑎𝑠𝑒 =  
100,000
𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛
 
 
 165 
 
6.2.3. Implementation 
6.2.3.1. Database schema 
The database for the clinical decision support tool followed a contextual 3rd normal 
form as described in Chapter 3.2.2 whereby the information in the database was 
decomposed into tables that always followed 1NF and 2NF but only followed the 
conditions of 3NF if it made contextual sense and only required a reasonable/limited 
number of table joins. The diagram schema is shown in Figure 6.3. The database itself 
was developed within the MariaDB RDBMS which allows it to be compatible with 
other MySQL based languages when it comes to rolling the web database for 
full/public deployment.  
 
 
6.2.3.2. Website construction 
The webpages that act as the interface for the user to access the information contained 
in the database were constructed using PHP 5.4 due to the greater market support for 
the language as mentioned in Chapter 1..5 – the language itself is more than capable 
of providing the desired functionality for the website include inbuilt support for 
accessing the commonly available RBDMS including MySQL. As well as PHP, 
additional functions are provided using JavaScript which is able to provide client-side 
functions (PHP is only server-side). These client-side only functions include the site’s 
main page’s ability to only allow the user to select a maximum of two alleles per HLA 
gene and for the site’s results page to collapse the information card into a condensed 
version which can then be expanded - the user first sees the clinical decision support 
tool’s recommendation and then can choose to expand the cards to view the supporting 
information such as the drug body guidelines, calculated statistics and links to the 
supporting evidence. 
 
  
 
1
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Figure 6.3: Database schema diagram for the clinical decision support tool.
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The colour scheme was also carefully selected. Namely, the base colour scheme was 
kept with a simple white background and black text/objects as the general scheme. 
This was to provide a very minimalistic and clean look where the main focus of the 
site was the selection buttons and information cards which are the only areas of the 
site that are coloured. These selection buttons required a colour scheme which were 
distinguishable for people with common colour perception deficiencies (sometimes 
referred as “colour blindness”). As such, colours that are close to each other on the 
colour spectrum were avoided (e.g. blue and green on the same page were avoided). 
For the drug selection page, the blue colour was chosen for drug selection buttons and 
orange was chosen for the allele selection buttons. Green was chosen for the 
information cards. 
 
6.2.4. Consultation for feedback 
At the time of writing this thesis, the clinical decision support tool has not yet been 
fully deployed. One key task before deployment that is planned is the stage of external 
feedback. Currently, the tool has only been reviewed internally by those who have 
been directly involved with the project. MC Diagnostics (manufacturers of the Mr 
Spot machines) have made arrangements with a group of researchers to test the Mr 
Spot machine and have been provided with user credentials to access the clinical 
decision support tool. Feedback has not been provided as of yet. Additional testing has 
also been planned to gain feedback from clinicians. The feedback consultation is 
intended to provide a constructive critique for both the user experience (e.g. the user 
interface) as well as the information displayed to the end user. The feedback will be 
assessed by the members involved with development to decide what will be 
implemented. 
 
As part of the initial feedback by the development team, the first design draft that was 
presented (shown in section 6.3.1), the drug-allele selection page the default HTML 
radio button layout was described as confusing, clunky and uninspiring. To address 
this, a layout similar to that of the figure (shown in Figure 6.1) from the previously 
published article depicting the 24 plus alleles that have been associated with HLA 
mediated ADRs was then used as a basis to design the buttons that eventually appeared 
in the final version – although the drugs and alleles were separated to allow for a 
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customisable search. Additionally, for the recommendation page, the table layout also 
received similarly negative remarks with regards to the user experience. 
 
Only two people with colour perception deficiencies have viewed the website, both of 
whom have red-green colour vision deficiency. They both reported that the blue and 
orange colour scheme was easily distinguishable allowing the drug selection buttons 
to be discerned from the allele selection buttons. 
 
6.3. Results 
6.3.1. Initial design drafts 
Before the website was constructed, rough design sketches were made for the project 
members to view, critique and vote upon. These sketches specifically relate to the 
graphical user interface (GUI) that end users will eventually interact with. The website 
design sketches are shown below. In these design sketches, the grey boxes represent 
the web elements that the user will be able to see and the black text next to these boxes 
provide a very short description to describe the type of HTML element that will be 
needed to achieve the web element. 
 
6.3.1.1. Design drafts for drug-allele selection page 
Two design drafts were created for the drug-allele selection page; a version where the 
user must select their drug and/or allele options using a dropdown menu (Figure 6.4) 
and the second version of the page where the user must select their options using radio 
buttons/checkboxes (Figure 6.5). 
 
6.3.1.2. Design drafts for recommendation page 
For the recommendation page, the information is proposed to be displayed in tables 
with the two supplied variants only differing in that the first variant (Figure 6.6) will 
display the alleles horizontally with the information below and the second variant 
displaying the same information in a vertical format. The second variant supplies the 
same information as the first but the tables are constructed in a vertically rendered 
alleles approach (Figure 6.7). 
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Figure 6.4: Design draft of drug-allele selection page number 1 – dropdown version. 
 
 
 
Figure 6.5: Design draft of drug-allele selection page number 2 – radio buttons 
version.  
1. Drug selection radio buttons  
2. Allele selection radio buttons 
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Figure 6.6: Design draft of recommendation page number 1 – horizontal table 
headers version in drug view.  
Example search using carbamazepine option where 1 and 2 show the two returned 
alleles along with the relevant information. 
 
 
Figure 6.7: Design draft of recommendation page number 2 – vertical table headers 
version in drug view.  
 
 
  
 171 
 
6.3.2. Skeletal design of website 
From the proposed design drafts, drug-allele selection page variation 2 and 
recommendation page variation 1 were chosen to be created for the clinical decision 
support tool’s beta version. These were constructed as described in the materials and 
methods section of this chapter and are shown in Figure 6.8 and Figure 6.9 
respectively. As mentioned in section 6.2.4, regarding feedback, the layouts were 
modified and improved and shown later in section 6.3.3 – the version current as of 
writing this thesis.  
 
 
Figure 6.8: Drug-allele selection page – version 1 with radio buttons. 
 
 
Figure 6.9: Recommendation page – version 1 results rendered in table with 
horizontally aligned alleles. 
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6.3.3. Website organisation 
The webpages were designed to allow users to easily access and visualise the clinical 
decision support tool data in a user-friendly manner. The support tool is available with 
the URL: http://pgb.liv.ac.uk/~gurpreet/register_form which links to the support tool 
registration page where users can gain credentials to access the tool. Note that this is 
a link to the development server and is not designed for mainstream/high web traffic 
use scenarios. All of the webpages are generated using PHP which serves out 
HyperText Markup Language (HTML) and Cascading Style Sheets (CSS) thereby 
allowing the retrieved data to be viewed in most common web browsers. The CSS 
style sheets have been enhanced using CSS Bootstrap which enables a responsive web 
design whereby the webpage to adjust itself based on the screen dimensions (measured 
in pixels) and display the Bootstrap objects appropriate for the screen, i.e. the layout 
of the website will be different when viewed with a large screen desktop computer vs 
a laptop screen vs a smartphone screen etc. [185] 
 
6.3.3.1. Drug-allele selection page 
After logging into the site the user is presented with the drug-allele selection page 
(Figure 6.10) which from a web development point of perspective acts as the 
home/index page. Here the user can select the allele(s) of interest which in the 
projected use case scenario would be the results from the Mr Spot machine. On the 
website, depicted in the figures below, the selection buttons for the alleles are coloured 
orange. The user can also select a drug (blue selection buttons) – the use case scenario 
for this is for a clinician to select the drug that they wish to prescribe to their patient. 
 
Figure 6.10 shows the drug-allele selection page as rendered on a large desktop screen. 
The website is capable of being viewed on other devices where the website reorganises 
itself appropriately due to the above mentioned responsive design features of CSS 
Bootstrap. The responsive design of the website can be viewed in Figure 6.11 whereby 
the drug and allele selection buttons have arranged themselves to better fit the smaller 
dimensions of the screen that was used to view it. Instead of a 4 × 𝑛 grid for the drug 
selection buttons and a  4 × 𝑛 grid for the allele selection buttons, each set of buttons 
are displayed in a  2 × 𝑛 grid. On a smartphone, the selection buttons will also display 
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in a  2 × 𝑛 grid but the allele buttons will be displayed below the drug selection 
buttons. 
 
 
Figure 6.10: Screenshot of the clinical decision support tool’s home page or drug-
allele selection page. 
 
6.3.3.2. Recommendation page 
Once the user selects their drug and/or allele(s) of choice, they will then be presented 
with information cards that are relevant to the search criteria. In the example 
screenshot shown in Figure 6.12 below, where “carbamazepine” was selected for the 
drug option and “HLA-B*15:02” for the allele option, the recommendation page has 
rendered an information card where the relevant information stored in the underlying 
database has been retrieved in a similar manner as described in Chapter 3. The viewing 
format of these information cards varies depending on the options selected and is 
described later in section 6.3.3.3. 
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Figure 6.11: Screenshot of the clinical decision support tool’s drug-allele selection 
page as viewed on a smaller screen compared to that of Figure 6.10.  
Here, the drugs and allele selection buttons are arranged in a grid that is two 
buttons wide (as opposed to four buttons wide seen in Figure 6.10). 
 
The information card is collapsed by default to only show the clinical decision support 
tool recommendation as depicted in Figure 6.12. If the user requires, the additional 
information can be viewed by clicking on the “show supporting information” button 
located at the bottom of the information card. Once clicked the card will expand and 
the user will also be able to view the available drug-allele guidelines which have been 
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set out by the regulatory drug bodies including: the USA’s Food and Drug 
Administration (FDA); Clinical Pharmacogenetics Implementation Consortium 
(CPIC); the European Union’s European Medicines Agency (EMA); the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada / Santé 
Canada (HC-SC) – hyperlinks to the original source page are also included.  
 
The expanded information card also displays the reported risk ADR phenotypes (e.g. 
SJS/TEN or DILI etc.) for that drug-allele combination; clinical statistics calculation 
for the number of screenings required to prevent one ADR case and hyperlinks to the 
studies that have reported the ADR. An example of the expanded information card 
using the example search where the drug is carbamazepine and the allele is HLA-
B*15:02 is shown in Figure 6.13.  
 
6.3.3.3. Recommendation page display mode 
The website also changes its display mode depending on what the user selected on the 
drug-allele selection page. This causes a subtle change with the displaying of the 
information cards. If a user selects only a drug option or a drug and allele(s) option 
then the recommendation page will present the information in “drug” display mode. 
Alternatively, if the user only selects an allele(s) then the information cards are 
presented in “allele” display mode. 
 
In drug display mode, the cards are formatted around the drug. The information cards 
are separated by allele based on either the user selection or if no allele was selected, 
the alleles that have known associations with the user selected drug. Figure 6.12above 
is an example of the results page presenting the information in the drug display mode. 
If no allele is selected then the example figure would show information cards for both 
the HLA-A*31:01 and HLA-B*15:02 alleles that have been associated with 
carbamazepine hypersensitivity. Figure 6.14 shows the slight variation in the allele 
display mode. In this view, the recommendations are separated by allele. This two 
display mode feature is a requirement to display information based on user input as 
the information cannot be displayed uniformly if the user selects a drug; a drug and 
allele or just an allele.  
  
 
1
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Figure 6.12: Screenshot of the clinical decision support tool’s results page or recommendation page. 
In this screenshot an example search for “carbamazepine” and “HLA-B*15:02” were chosen for the drug and allele selection respectively in the 
drug-allele selection page which has rendered the page display mode to the “drug” view. 
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Figure 6.13: Screenshot of the recommendation page with the information card 
fully expanded (example selection of “carbamazepine” and “HLA-B*15:02”. 
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Figure 6.14: Screenshot of the clinical decision support tool’s or recommendation 
page. 
In this screenshot an example search of “HLA-A*31:01” and “HLA-B*15:02” were 
chosen for the allele selection respectively in the drug-allele selection page which 
has rendered the page display mode to the “allele” view. 
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6.4. Discussion 
6.4.1. Effectiveness and limitations of presenting relevant 
information 
Whilst the process of provided feedback by external testers has not been carried out, 
initial feedback from the members of the internal project team about the presentation 
of relevant information has been positive. Of particular note was the aesthetic layout 
which made the presentation of the information easier/intuitive for reading compared 
to the earlier builds of the website.  
 
In addition to the aesthetics, feedback was provided for the content contained in the 
information card; the level of information provided by the recommendation, the drug 
body guidelines and references to the reporting literature, with hyperlinks to the 
PubMed/MEDLINE abstract were received positively. There were comments that the 
provided clinical statistics were limited – the tool currently only shows the range for 
the numbers needed to screen to prevent one ADR. The website itself does calculate 
the other clinical statistics from the data as described in section 6.2.2 however, 
displaying all the information would make the information card far too large and 
would potentially bombard the user with too much data. Creating an additional page 
that displays the entirety of the clinical statistics calculations would resolve this issue 
– this solution has been noted as a future update. 
 
One major limitation that was noted when analysing the underlying dataset was the 
quality of some of the data. It was observed that in some instances the sensitivity, 
specificity, positive/negative predictive values were a perfect 1.00 and that the most 
likely reason behind this was the fact that the results were skewed/heavily influenced 
by small sample sizes. Table 6.1 shows such examples of small sample skewing which 
lead to clinical stats artificially indicating high usefulness of the tests. In the first row, 
with carbamazepine, all five patients carried the risk HLA-B*15:02 allele with only 
10% of the controls doing so. Whilst the association itself has been repeatedly 
demonstrated the phenomenon has greater impact with associations with fewer studies 
supporting the link – this is demonstrated in the second row where the association with 
lamotrigine and the HLA-A*68:01 allele for SJS/TEN. The risk allele was only found 
in a small percentage of patients and none of the controls. As a result of this, the 
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eventual recommendation that is provided by the clinical decision support tool reads 
as “There may be an increased risk of lamotrigine-induced hypersensitivity syndrome 
in individuals positive for HLA-A*68:01, but at this stage no recommendation can be 
made regards screening.” Situations such as this greatly highlights the need to 
manually curate the data rather than creating an algorithm to come up with the 
suggestion. The algorithm was initially considered with the design of the clinical 
decision support tool but this was rejected due to other limitations discussed later in 
section 6.4.2.2. The example of HLA-A*68:01 and lamotrigine is not as widely 
reported as the example with HLA-B*15:02 and carbamazepine induced 
hypersensitivity so the interpretation of results become less reliable as fewer studies 
are available for review into the overall analysis. The statistics derived from other 
studies reporting the HLA-B*15:02 and carbamazepine can be used to provide context 
as to the impact of the study shown in the example table, however the same is not 
applicable for lamotrigine and HLA-A*68:01. 
 
Another limitation for this clinical decision support tool will be that the 
recommendations will need to be population specific. As discussed in 0, some alleles 
are more prevalent in specific populations and as such the recommendations will need 
to reflect this. This information was taken into account when devising the current 
recommendations e.g. the recommendation relating to carbamazepine only 
recommends screening patients for the  HLA-B*15:02  allele if they are of Asian 
ancestry. For this reason it is therefore imperative that future updates to the database 
continue to factor in population differences. 
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Table 6.1: Examples of data within the clinical decision support tool where the sensitivity, specificity and positive/negative predictive values 
(PPV/NPV) were calculated to be 1.00. 
Reference Drug Risk 
HLA 
Allele 
ADR Patient 
Ethnicity 
Patients 
with risk 
allele 
Controls 
with risk 
allele 
ADR 
prevalence 
Sensitivity Specificity PPV NPV 
Chong  
et al. 2014 
carbamazepine B*15:02 SJS/TEN Diverse 5 / 5 1 / 10 0.0001 1 0.9 0.001 1 
Kazeem 
et al. 2009 
lamotrigine A*68:01 SJS/TEN, 
DIHS 
Caucasian 4 / 44 0 / 86 0.001 0.091 1 1 0.999 
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Since the clinical decision support tool aims to provide interpretation of the results 
from Mr Spot, the cost effectiveness from a clinical perspective for the clinical 
decision support tool is directly tied to the cost effectiveness of the Mr Spot assay test 
and is therefore already discussed in Chapter 5. However, the overall effectiveness, is 
a little more difficult to discuss without the external feedback/testing that is pending. 
Whilst not being able to fully address this point of effectiveness of the tool, a small 
feasibility study which tested a medication decision support system with a panel 
consisting of HLA-B*58:01 and 32 non HLA genes implicated with drug-induced 
ADRs reported successful outcome of the study goals. [186] However, this study does 
not go into great detail as to the feedback relating to the decision support system but 
the study does report relatively high usage of the software indicating that the clinical 
utility was high although the full context of the usage is not discussed in the study so 
whilst interpretation of this point is positive on a surface level, it requires more detail 
for conclusive interpretation. 
 
Additionally, individual tests that are already recommended in primary care (e.g. 
screening for HLA-B*57:01 prior to abacavir treatment) indicates that uptake and 
desire for such screening/testing has potential and that the relative cost benefits and 
expansion of available alleles will likely further drive demand. Since the regulatory 
drug bodies are relatively slow to enforce alterations to the drug labels, high scrutiny 
of the available data is likely to be of benefit in order to reduce falsely demonising a 
treatment option, this can leave clinicians from missing out on relevant knowledge for 
other drug-allele combinations. This is showcased in that only a few of the drug-allele 
combinations known to cause ADRs have led to label modifications to include 
warnings (For FDA controlled drug labels, only abacavir, carbamazepine, lapatinib, 
oxcarbazepine and phenytoin have such warnings and this is the regulatory body with 
the most amount of enforced label warnings relating to HLA mediated ADRs). The 
database for the clinical decision support tool can be updated quicker as the data is 
analysed by experts in clinical pharmacogenetics who are already familiar with the 
field and are actively looking for newly published literature affording them with up to 
date information. 
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6.4.2. Future work 
6.4.2.1. Database maintenance 
The clinical decision support tool was specifically designed from the ground up for 
expansion/updating in mind. The database was deliberately over normalised relative 
to the data that was going in at construction but the computational benefits of this 
normalisation process would be seen once more data is inputted. The website’s drug-
allele selection page also renders the selection buttons by pulling the data from the 
database rather than being manually constructed. Individually created buttons would 
be faster to load for the end user, however, each new drug and allele would need to be 
manually created as they are added. The method that is employed by the website 
actually allows the clinical decision support tool’s development team to only change 
the database and the website will automatically reflect these changes. This system 
makes sure that the website is easier to maintain as specific changes can be reflected 
by all aspects of the database with relatively little input by the development team. New 
drug-allele associations can be added which are already expected. The chief 
investigator of this project has indicated that since the time of the website’s 
construction, new drug-allele associations have been published or are pending 
publication and will need to be considered for inclusion.  
 
The system was also designed so that the clinical experts can comfortably add any 
such new data (or make alterations to existing data) using a familiar data storage 
package (spreadsheets) and pass on the file to the database administrators where they 
can execute a pre-existing script to commit the changes to the MySQL database. This 
allows the database to be maintained with greater flexibility as it does not require an 
expert in both HLA mediated ADRs and database management in order to make the 
changes as these tasks have been deliberately separated. An example of this has 
already been realised, since the original proposal consisting of 24 alleles two alleles 
were removed as further evaluation of the data indicated that there was little evidence 
and clinical utility for these particular alleles to be included. The removal of the alleles 
from the spreadsheet database was the only manual input required where it cascaded 
and was automatically reflected in the removal from the database and the website. 
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6.4.2.2. Role of artificial intelligence 
Earlier in this discussion, it was briefly mentioned about the initial prospect of an 
algorithm to formulate the recommendations as part of the clinical decision support 
tool. However, at this current time there are limitations regarding the introduction that 
would render this consideration to be rejected. The largest issues for artificial 
intelligence are with public trust and the legality, in 2017 there were news reports of 
a partnership between the NHS and Google’s DeepMind project that intended to 
identify patients that were at risk of developing kidney disease – the deal was 
subsequently regarded as illegal. [187] As well as the legal issues, the news article 
featured a quote stating about the public mistrust with sharing data with Google. A lot 
of the problems faced in this project can possibly be attributed to the concept of 
allowing artificial intelligence to diagnose patients being a very new technology. As 
such there is no point of reference/comparison to assess the potential impact from all 
aspects (societal, ethical, legal liability as well as the direct clinical impact). Due to 
the relative infancy of implementing artificial intelligence that has direct public 
interaction beyond low impact functions; Google’s DeepMind was previously 
involved in a project for playing recreational games so was removed of major societal, 
ethical and legal liability hurdles; more time is needed to allow artificial intelligence 
to develop and incorporate itself in other, low impact aspects of public interaction 
before it can be accepted for use in clinical practice. If such a time is reached, then the 
concept of developing algorithms in clinical scenarios can be revisited as it would 
make a very interesting avenue to pursue. 
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Chapter 7. Final discussion 
Adverse drug reactions (ADRs) contribute to between 6 and 12% of all hospital 
admissions in the United Kingdom. [1, 2] ADRs also lead to the withdrawal of 3-5% of 
all drugs that were newly approved between 2002-2011 and 1990-2009 in Europe and 
North America respectively where hepatotoxicity was the second most commonly 
reported reason. [3, 4] This thesis has focused on “Type B” ADRs also referred to as 
immune-mediated ADRs where the carriage of certain human leucocyte antigens 
(HLA) have been associated as a risk factor. [19, 24, 27, 34-36] These reactions represent 
approximately 20% of all ADRs. [31] The clinical manifestations of these ADRs can 
range from simple skin rashes which can be tolerated but can also lead to severe 
morbidity and possible even death for the patient. [9, 11] As a result, ADRs represent a 
major challenge for clinicians and pharmaceutical companies. The mechanisms by 
which and ADRs occur is not fully understood although the leading hypotheses 
involve the drug (or metabolite) interfering with how the T-cell interacts with antigen 
(HLA) molecule and therefore disrupts how the immune system recognises between 
self and non-self cells. [10, 38, 40, 43, 44, 46] In the case of abacavir, while there is published 
evidence that the drug interacts noncovalently with HLA-B*57:01, it has also been 
demonstrated that abacavir can form hapten type interactions with human serum 
albumin. [46, 188] Abacavir’s ability to form both covalent and noncovalent interactions 
indicates that there is potential that the mechanism of action for ADRs may not follow 
one exclusive pathway and instead are complementary. 
 
7.1.1. Evaluation of literature review 
The findings from Chapter 2 shows a significant proportion of the published literature, 
65%, emanated from studies conducted using a patient-control cohort of Asian 
ancestry. The chapter discusses the possibility of publication bias as there is a 
noticeable shortage of studies conducted using patients of South American or African 
origin (1 and 2 respectively out of 85 studies). In addition to this, a hypothesis was 
proposed that since the major pharmaceutical companies are based in Europe and/or 
North America, then the drugs’ clinical trials were conducted on cohorts of 
predominantly European origin. Admittedly, this is difficult to test and/or verify due 
 186 
 
to the information regarding the locations of the original drug trials being difficult to 
locate.  
 
In addition to the literature review performed in Chapter 2, a semi-automated literature 
mining script was developed to speed up the process of performing future data 
collections from the literature. The dramatic decrease in time taken to collect data 
allows for regular updates for the HLA-ADR database that was developed for Chapter 
3 and the database for the clinical decision support tool of Chapter 6. The script 
implemented a keyword search of the titles and abstracts of searches performed in 
Medline/Pubmed. The performance of the script was compared against searches 
performed manually within the chapter as well as against the literature reviews of 
colleagues who performed similar searches where the premise significantly 
overlapped. [98, 114] It is worth reiterating that this script would only substitute the first 
stage of the review process (analysis of the title and abstracts only) and is not capable 
of performing the second stage of the review process (analysis of the complete article). 
The analysis of the script’s performance revealed that with knowledge of the specific 
ADR (drug, allele and ADR phenotypes) that the script is capable of highlighting 
virtually all relevant studies. The script’s general performance was measured to be 
>90% in terms of forwarding relevant studies for the user to review manually for the 
second stage of the review. Therefore, it was determined that in circumstances where 
absolute accuracy was not required relative to time taken to perform the review, then 
the script offers a very appealing alternative to manual review. For the literature search 
in Chapter 2, the first stage of the manual review took four weeks to complete vs one 
hour for the semi-automated literature mining script. Whilst the semi-automated 
literature mining script shows great promise for utility, there is still a case to be argued 
for performing literature reviews manually. This is the current arrangement for the 
HLA-ADR tool (Chapter 3) is for the semi-automated literature mining script be 
executed regularly and a manual review on a semi-regular basis (currently set to be 1 
year and 3-5 years respectively). 
 
7.1.2. Evaluation of HLA-ADR 
A web database (HLA-ADR) was created to allow relatively easy access to the data 
collected in Chapter 2. [189] The overall aim of this website is to reduce the time and 
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effort required to investigate adverse drug reactions by researchers. The website also 
links out to information from the Allele Frequency Net Database (AFND) where the 
website allows users to access stored allele, haplotype and genotype frequencies of 
several immune related genes including HLAs. [120, 121] As a result of this overlap it 
was decided to make the HLA-ADR database as a module within AFND. 
 
The Query page allows users to interact with the information held in the database by 
forming customised queries using the dropdown menus provided on the page. The 
ADR reports page provides a summary of all significant associations for a particular 
drug and also links out to external resources (e.g. the main AFND website and 
IMGT/HLA site). [78] The site also enables researchers to submit their own data via 
the authors’ submission page.  
 
The centralised nature of the web database allows it to achieve its primary aim of 
allowing researchers accessing information (regarding immune mediated ADRs) that 
is spread across the literature.  Whilst the website has been active for a relatively short 
period of time its use has been reported in very recent (non-self-citing) literature and 
the web database was used to aid in the investigations carried out in Chapter 4 of this 
thesis and as the basis for the underlying data in Chapter 6. [122, 123] The ultimate goal 
for any bioinformatical tool is to aid in the research of many studies.  
 
In addition to the direct usage of HLA-ADR to assist other researchers with their 
investigations into immune-mediated ADRs, the HLA-ADR database has been 
referenced as an available tool to aid in the study of ADRs. [190] The review makes 
reference to another database that provides data for HLA allele associations with 
ADRs – HLADR. [191] This database has a larger available dataset to choose from as 
the authors chose to implement less stringent inclusion criteria (e.g. 1st field resolution 
typing). The database also shows information pertaining to the drug, HLA allele, ADR 
phenotype, ethnicity of patient-control cohort etc. HLADR provides additional 
information from that of HLA-ADR as it is capable of calculating the odds ratios, 
sensitivity, specificity, PPV and NPV. However, compared to HLA-ADR the ability 
to customise a search is limited. A user may narrow down the drug or HLA allele or 
ADR phenotype, but not a combination of two or more of these. There is also no 
evidence that the database has been updated since release (three years from the point 
 188 
 
of this thesis) despite the authors’ promise of updates every three months. Like HLA-
ADR this database also has two citations. [192, 193] 
 
7.1.3. Ethnicity review 
The analysis of Chapter 4 also showed an unexpectedly high number of studies that 
originated in East Asia, the HLA-ADR web database was utilised to investigate the 
possibility that Asians are at greater risk of developing immune-mediated ADRs. The 
hypothesis is reported in individual instances where for example, carbamazepine 
hypersensitivity is reported to be more prevalent in patients of Asian origin to the point 
where the major drug/medicines regulatory bodies recommend pre-emptive screening 
of HLA-B*15:02 for patients of Asians decent (as mentioned at the start of this 
chapter). [155, 175, 194]  
 
In this analysis, only alleles that showed a statistically significant association (p < 
0.05) were selected and the alleles were analysed on a per drug basis. The frequencies 
of each allele was obtained using AFND. The haplotype information was also recorded 
to determine reported alleles were likely to co-occur along with the population/ethnic 
information. Analysis of this data indicated that where a particular drug had more than 
one reported HLA allele that has been associated as a risk factor, the alleles in question 
were likely to be in linkage in the reporting studies’ populations groups. For example, 
in the case of allopurinol, the alleles HLA-B*58:01, HLA-A*33:03, HLA-C*03:02 
and DRB1*03:01 have been reported to be risk factors. Of these alleles: HLA-
B*58:01, HLA-A*33:03 and HLA-C*03:02 were found to be significantly associated 
in Han Chinese and Korean patients and the analysis conducted in Chapter 4 
demonstrated that these three alleles co-occur at a relatively high frequency in East 
Asian populations (up to 8%). [133, 135] The analysis also revealed that the co-
occurrence of HLA-A*33:03, HLA-B*58:01 and HLA-DRB1*03:01 can be found at 
relatively high frequency (up to 6.6%) in a Taiwanese population and that all four 
alleles can be found as a haplotype in south-west China at a frequency of 4.4%. [120, 
124] This pattern of co-occurring risk factor alleles was found in many other drugs 
within Chapter 4 indicating that some of the co-occurring alleles were reported as risk 
factors due to the linkage disequilibrium existing between the allele in question and 
the true risk factor allele.  
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This phenomenon of co-occurring false positive alleles can be seen most evidently in 
carbamazepine where 11 alleles have been reported to be associated with 
carbamazepine induced hypersensitivity. After performing a Spearman’s correlation 
analysis, only 2 of the 11 alleles (HLA-A*31:01 and HLA-B*39:02) were found to be 
statistically independent of any linkage disequilibrium of the other alleles. This was 
manually confirmed using AFND haplotype search. It is likely that in the case of the 
9 out of 11 alleles showing linkage disequilibrium, the true risk factor is likely to be 
HLA-B*15:02 as this allele was reported in 19 independent studies with the other 
alleles from this group being reported only a maximum of twice. [17, 34, 144, 145, 149, 150, 
156, 172, 194-205]  
 
Additionally, an observation was made that the literature showed an over 
representation of studies conducted in patients of Asian or European origin (based on 
the findings of Chapter 2). The Kruskal-Wallis test performed in the chapter indicates 
that of the 33 HLA alleles that were analysed (where the reported drug-allele ADR 
association has p ≤ 0.01 and/or independently replicated in two or more studies), only 
six alleles could be described as showing a higher allele frequency in Asian 
populations compared to two in African and two in Europeans. Of particular interest 
was the antiepileptic drugs where 43%, 33% and 67% of the alleles associated with 
carbamazepine, lamotrigine and phenytoin respectively can be found in higher 
frequencies in Asians. For these drugs, none of the remaining alleles could be only be 
described as “neutral” i.e. no significant association with European or African 
population.  
 
This analysis shows inconclusive evidence to support the hypothesis that Asians are 
at greater risk for ADRs as the majority (23 out of 33) HLA alleles that show strong 
evidence of immune mediated ADR associations are classed as “neutral” – where there 
is no population that shows significantly greater prevalence for the risk factor HLA 
allele. However there are 10 drug-allele combinations where the patient’s ethnicity 
may need to be taken into account for clinical decision making (as is already the case 
for HLA-B*15:02 and carbamazepine and other related antiepileptic drugs). This 
indicates that the general literature should not focus on patient ethnicity when 
investigating the wider picture for immune mediated ADRs even though it cannot be 
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ignored in individual examples of drug-allele combinations. This is evident in that 
whilst HLA-B*15:02 has a large focus with regards to patients of Asian origin, the 
allele has been reported in the relatively smaller Spanish Romani population. [206] 
 
The analysis in this chapter again highlighted the inconstancy in reporting immune 
mediated ADR associations as many drug-allele associations were not well replicated 
and some alleles appearing to be significant in one study and nonsignificant in another 
(e.g. HLA-C*04:01 is reported to be significant and nonsignificant in different studies 
[35, 36] and similarly HLA-B*35:05 [36, 159] also for nevirapine). This limitation in the 
data makes it difficult to say with confidence as to whether an allele is a true risk 
factor. The relatively small sized patient-control cohorts found in many of the studies 
likely contributed as each individual patient/alleles had a larger impact on the final 
result and thereby disproportionately increasing the significance for a certain drug-
allele association. Due to the relative rarity of ADRs (see USB/CD media file 
“chapter_6_decision_support_table.xlsx” for ADR prevalence values) the problem of 
the patient-control cohort sizes may be impractical to overcome. 
 
7.1.4. HISTO SPOT HLA typing and the clinical decision 
support system 
The medicines/drug regulatory bodies for the United States, Canada and Europe only 
recommend screening for HLA-B*57:01 in patients who are about to receive abacavir 
[49, 50] and for HLA-B*15:02 in patients of Asian ancestry when prescribing 
carbamazepine, oxcarbazepine or phenytoin. [51, 52] The other drug allele combinations 
that have been discussed in this thesis do not have any recommendations for pre-
emptive screening; e.g. for allopurinol and HLA-B*58:01 – the European medicines 
agency does not advocate screening but if the patient is already known to be a carrier 
for HLA-B*58:01 then it does recommend the additional risk be taken into account 
when making the clinical decision. [52] There has been evidence recently published that 
states pre-emptive screening for HLA-A*31:01 (for carbamazepine) and HLA-
B*58:01 for allopurinol would be a cost effective policy to implement in addition to 
the drug-allele combinations previously mentioned in this paragraph. [182, 183] 
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Conversely, the example of flucloxacillin induced DILI in relation to HLA-B*57:01 
carriage, the cost-effectiveness for pre-emptive screening is weaker. Although, the 
negative predictive value (NPV) is 0.9999 (calculated using Daly et al., 2009 data for 
the clinical decision support tool in Chapter 6), the positive predictive value (PPV) is 
0.0011. [24] This difference in NPV and PPV indicates that patients who experience 
DILI are likely to carry the HLA-B*57:01 allele, however this still only represents a 
small fraction of flucloxacillin taking patients that carry HLA-B*57:01. In other 
words, carriage of HLA-B*57:01 is alone not enough to predict DILI. This only goes 
to highlight that the exact mechanism for ADRs is not fully understood and more 
research is still needed. 
 
Computerised clinical decision support systems (CDS) have been implemented in 
many forms across many aspects of health care that are integrated into electronic 
health records. For example, there have been CDS systems that have been trialled for 
management of familial cancer risk, identifying patients at risk of developing diabetic 
foot complications, prescription management for patients with reduced renal function 
etc. [207-209] These examples show that there is both a need and demand for such tools. 
Multiple reviews have presented the benefits that CDS systems in the context of 
clinical decision making, although they also recommend exercising caution as CDS 
systems are still in their relative infancy and has not yet met widespread adoption.[210-
214]  
 
The clinical decision support system that was developed in this thesis was designed to 
complement the new HISTO SPOT HLA typing kit (Chapters 6 and 5 respectively). 
The combination of the two technologies aims to aid clinicians in predicting, pre-
empting, preventing and diagnosing immune mediated ADRs. The clinical decision 
support tool reports current guidelines from various drugs and medicines regulatory 
bodies (United States FDA, Canada’s HC-SC, the Japanese PMDA, the European 
Medicines Agency and the Clinical Pharmacogenetics Implementation Consortium. 
However, as discussed earlier in this chapter, these guidelines are not comprehensive.  
HISTO SPOT and the associated clinical decision support tool looks to expand on this 
information by providing its own recommendation based for a relatively larger panel 
of drugs and alleles. The information provided by the clinical decision support tool is 
relatively simplistic (deliberately so) to enable only the necessary information to be 
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conveyed. The provided recommendations are only designed to enable clinicians to 
make an informed decision. Given that, as discussed earlier in the chapter, the HLA 
carriage status alone is not enough to induce an ADR, it is important that the clinical 
decision support tool not be used for decision making and that the clinician assesses 
other relevant clinical factors for each patient.  
 
Whilst the HISTO SPOT HLA typing assay and the associated clinical decision 
support tool have not yet been released, the growth in technologies for HLA typing, 
as shown in the various methods discussed in the general introduction (Chapter 1.3), 
there is clearly a desire for cost effective methods with a very fast turnaround. This 
assay has the capability to achieve this as the 48 hour turnaround, accurate HLA 
calling and with a single test for over 20 alleles is cheaper than currently available 
HLA typing methods places it in a good position to achieve this goal of clinical 
adoption. 
 
7.2. Future directions 
7.2.1. Future directions from this thesis 
The semi-automated literature mining script has a lot of potential to be expanded upon. 
The benefits for time saving whilst still maintaining a relatively high level of 
performance accuracy has demonstrated its value. One area that the script can develop 
on is the ability to identify adverse drug reactions that have not been pre-programmed 
in. For example, the script was initially not able to identify anti-
hydroxymethylglutaryl-coenzyme A reductase induced myopathy. An aspect of deep 
learning in the form of natural language processing is an area of interest to help 
identify such papers by analysing the text of the title/abstract and noting the similarity 
with other included studies – i.e. the way a drug induced ADR is referenced in general 
rather than exact keyword based criteria. [215] However, the implementation of natural 
language processing and other forms of deep learning in clinical data is still in its 
infancy, considerably more research is still required. 
 
It is also imperative that the HLA-ADR database continue to be maintained. More 
HLA associations with ADRs are being reported in the literature meaning the database 
needs to be updated to include this new data for the tool to continue to be of use to 
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researchers. This will also apply to the clinical decision support tool once that is 
publically released. There are also conversations taking place to expand the clinical 
decision support tool to include some of the currently hidden clinical calculations such 
as the sensitivity, specificity, PPV and NPV etc. A method is required to display this 
data without overwhelming the user with large amounts of information. 
 
Another area of future development is to investigate the return of the single well 
HISTO SPOT assay. If it is possible to perform the assay within a single well, this will 
greatly increase the turnaround and capacity for the test. However, as evidenced by 
the performance issues seen during this thesis, there will be a great many challenges 
to overcome which may ultimately become impractical due to the rapid advancement 
of competing techniques (e.g. next generation sequencing) or if/when complete 
genomic data becomes part of patient electronic health records. [216] 
 
 
7.2.2. The future of the pharmacogenomics field 
The literature review in this thesis highlights the need to independently replicate 
findings to strengthen the validity of a specific drug-allele combination. The examples 
of HLA-A*31:01 and HLA-*15:02 where there are multiple confirming studies was 
able to resolve issues of the linkage disequilibrium phenomenon The issue comes with 
other associations that lack replicated findings – for example nevirapine where 
reported associations are found to be inconclusive in other studies. This would be 
greatly aided with the inclusion of trans-ethnic studies as this can also address the issue 
of haplotypes/co-occurring alleles as evidenced in Chapter 4. 
 
Additionally, the advances in next-generation sequencing (NGS) typing that utilises 
massive parallelisation so that a single sequence is cloned and millions of strands are 
simultaneously sequenced will provide four-field level resolution (all coding and non-
coding regions of the gene). [89] This will likely prove to be more informative 
compared to current mainstream usage of sequence-specific oligonucleotide and 
sequence-specific primer typing methods which only sequence exons 2 and 3 for class 
I genes and exon 2 for class II genes as this is where most of the known functional 
variability for HLA genes resides.  
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With NGS advances, it will be possible to obtain phasing of the whole gene and/or 
MHC region and will facilitate a broader understanding and further investigations into 
the relationship between HLA alleles in phased haplotypes and patient ethnicity. The 
advances will also allow for HLA sequencing to be cost-effective for larger volunteer 
cohorts – with more available data the field as a whole will benefit. 
 
As well as improvements into the collection of the genetic data, it is clear that simply 
carrying a particular HLA allele is not enough to trigger an ADR. It will be valuable 
to continue researching into the other components that contribute to ADRs. A logical 
place to investigate is to look at performing a multivariate analysis with other clinical 
factors such as the age, gender, ethnicity, blood protein levels, protein levels from the 
ADR affected organ, red/white blood cell counts, co-morbidities etc. This will likely 
be a huge undertaking in terms of collaborative organisation, patient recruitment, 
ethical approval and patient sample collection and analysis, especially in the 
recruitment of enough patients and controls that will be sufficient to achieve statistical 
power. However, such an analysis could reveal other co-risk factors/biomarkers and 
thereby increase understanding of ADRs. 
 
7.3. Concluding remarks 
The era of personalised medicine is rapidly approaching, already patient’s genomic 
information is now being taken into account when it comes to clinical decision 
making. However, the number of genetic biomarkers that are recommended for 
clinical screening is still very limited. It is clear that as the field expands, additional 
HLA alleles will become biomarkers for consideration when making clinical 
decisions. The bioinformatical and diagnostic resources discussed in this thesis 
provide a framework to potentially aid in this endeavour. 
 
The HLA-ADR database provides a centralised searchable resource for information 
pertaining to immune-mediated ADRs to enable researchers to conduct investigations. 
The ethnicity review of Chapter 4 provides an example of such usage of HLA-ADR 
and highlights some interesting findings in relation to the reporting of co-occurring 
alleles in the literature as well as the role that population diversity has in relation to 
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HLA allele carriage in the context of ADRs. The HISTO SPOT and the associated 
clinical decision support tool aims to give clinicians a means to arm themselves with 
accessible expert knowledge and allow for an informed decision be taken. The work 
undertaken for this thesis encompasses many disciplines, starting with literature/data 
synthesis which has been used for the development of computational tools that will 
aid further research. Additionally, lab based experimentation supplemented by a 
clinical decision support tool will be implemented into clinical practice.  
 
 
Figure 7.1: Overview of the work undertaken during this PhD thesis 
 
This thesis also emphasises that further research is needed to investigate a 
multifactorial problem of immune mediated ADRs where only one piece of the puzzle 
is known (the genetic component). Even then, that single piece is not entirely in focus 
as the difficulties highlighted in this thesis with poor replication of studies further 
highlights the need for a better understanding which will hopefully improve drug 
safety and lead clinical practice into an era of personalised medicine. 
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